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Abstract 
Optimum therapeutic outcomes require not only proper drug selection but also effective 
drug delivery and monitoring. The aim of this thesis was to A) study drug delivery 
through the skin with a liquid formulated to promote absorption, B) develop and validate 
methods to analyze the drug in the samples obtained, C) assess appropriate methods to 
measure the transdermal delivery of drug, and D) apply to pharmacodynamics. 
The stability of a rectal formulation of diazepam, Diastat®, and a quality control of a 
topical form, TDS® diazepam, were studied using high performance liquid 
chromatography (HPLC) with ultraviolet absorption detection (UV). It was found that 
diazepam at 10 mg/mL was stable in solution at various temperatures for at least 4 weeks. 
A pharmacokinetic study of diazepam delivery from the TDS® delivery system was 
compared with delivery of the drug following rectal administration of Diastat® in 12 
healthy volunteers. The TDS® diazepam was evaluated for safety and no adverse effects 
or events were observed. The preparation was found to be able to deliver diazepam 
systemically in humans, the confidence interval (CI) of the ratios for Cmax and AUC of 
diazepam from the two formulations A (TDS®): B (rectal) were not contained within the 
bioequivalence limit 80–125%, Cmax (0–72h): 7.3–14% and AUC0-72h: 20–38%. In 
addition, the 90% CI of desmethyldiazepam (A:B) ratio were not contained within the 
bioequivalence limit, Cmax (0–72h): 38–54% and AUC0-72h: 33–58%. Although not 
bioequivalent to Diastat® these finding suggest that skin may be an alternative method of 
diazepam delivery but further developments and studies would be required. 
The development and validation of fast, high throughput methods to evaluate tetracaine 
from skin tape samples was another challenge. Sensitive and reliable capillary 
electrophoresis with UV and HPLC-UV methods were developed and validated to 
measure tetracaine in skin using tape samples from volunteers given 1 mL Ametop gel 
(4% w/w of tetracaine) to support a pharmacokinetic drug delivery study of Ametop. The 
results from these validation studies demonstrated an equal ability of the two methods to 
measure tetracaine concentrations reproducibly and accurately. The Bland Altman test 
was in a range of ± 1.96 SD from the mean (SD = ± 8.02, Mean = 2.23), and percentage 
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error (± 20%.), which show an acceptable difference. The assays were found to possess 
both the sensitivity and specificity necessary to measure the analyte in the skin tape 
stripping at the concentrations range in these tapes.  
Finally, observation of appropriate methods to measure the transdermal drug in vivo 
techniques, such as microdialysis (MD) and tape stripping (TS) have been employed by 
plotting a concentration time profile to investigate the capability of measuring tetracaine 
(pharmacokinetics) in local tissue, instead of measuring tetracaine by conventional 
systemic measurements. The results showed that the tetracaine Cmax concentration was 
higher in the stratum corneum compared with the major metabolites of tetracaine, 4-
butylaminobenzoic acid (BABA) by 3 and 10 times in MD and plasma, respectively. TS 
samples reached the maximum concentration quicker than BABA in dialysate and plasma 
samples (p = 0.002). The median tmax was higher in plasma (IQR -53minutes, 95% CI: -
30– -105) compared with tape samples. The AUC and Cmax for tetracaine were higher in 
TS compared with BABA in MD and plasma (Mean AUC0-4h: 88582, 55594 and 13208 
nM.min: Mean Cmax (0–4h), 850, 459, 110 nM, respectively). 
In addition, the AUC and Cmax values demonstrated that data from the TS study showed 
less variability compared with the data from plasma. The most variable data were for MD 
(CV%; AUC0-4h, 24, 63, and 85%: Cmax (0–4h), 42, 60, 80%, respectively). AUC and 
Cmax (Bartlett’s test, p = 0.004 for AUC; and Levene’s test, p = 0.042, and 0.028, 
respectively) 
This thesis has demonstrated that 1) diazepam was successfully delivered through the 
skin into the systemic circulation by the TDS® system, 2) novel methods have been 
developed for the measurement of tetracaine and its metabolite, and 3) the methods have 
been successfully applied to three different sample types employed in pharmacokinetic 
studies. 
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Chapter 1 Introduction 
1.1 The human skin 
The skin (integumentum commune) or cutaneous membrane is the largest organ in the 
human body, providing approximately 10% of body mass, covering an average area of 
1.8–2 m2 of an average adult person. The skin acts as an important barrier between an 
organism’s internal and external environment.  
It has proved to be an efficient and complicated tissue with metabolic, immunologic, and 
sensory functions. Several fundamental processes are maintained by the skin including 
body temperature, excretion, preservation of body fluids and tissues, maintenance and 
control of fluid and electrolyte balance within the body. It also acts as a defence barrier, 
and mechanical functions include mechanical and chemical protection; protection against 
ultraviolet radiation (UV), protection against organisms such as fungi, bacteria, virus, and 
sensory perception (e.g. pain, heat, sexual sensation), and vitamin D and B synthesis. In 
addition, the skin may include metabolic functions related to other endogenous and 
exogenous substrates. 
In addition to protection and defence, the skin is also an important pathway for the entry 
of drugs and other substances (Schuplein and Blank, 1971, Katz and Poulsen, 1971, 
Kligman, 1983). Certain types of substances have the capability to penetrate the layers of 
the skin, which gives an alternative therapeutic route of drug administration in humans. 
This is known as transdermal drug delivery (through the skin), an alternative to 
traditional routes including oral, intravascular, intramuscular, subcutaneous, and 
sublingual. For this kind of delivery, and in order to recognize how drugs permeate the 
skin, a basic knowledge of the structure of the skin is important.  
The structure of human skin is composed of three main layers. Going from outside to 
inside the body there are the epidermis, the dermis, and the hypodermis (subcutaneous 
adipose tissue or underlying subdermal tissue). Figure 1.1 shows the skin’s three main 
layers. 
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Figure 1.1 Cross section diagram of human skin showing the three main layers  
(modified from Barts medical image library at Queen Mary) 
1.1.1 Epidermis 
The epidermis: Greek epi = upon (above, or top), and derm = skin, hence, epidermis is 
the outermost layer of the skin, consisting of a complex proliferation layer membrane. 
This layer varies in thickness from approximately 0.06 mm on the eyelids to about 0.8 
mm on the palms of the hand and the soles of the feet. The epidermis does not contain 
blood vessels. However nutrients and waste compounds must penetrate through the 
dermal and epidermal layer, in order to maintain the health and integrity of the skin. 
Similarly, molecules permeating through the epidermis may penetrate through the dermal 
and epidermal layer, and finally into the systemic circulation. Throughout adult life, 
proliferation persists. There are four physiological separate layers which, from the inside 
to outside the body, are: 1) the stratum germinativum, 2) the stratum spinosum, 3) the 
stratum granulosum, and 4) the stratum corneum. A fifth layer, the stratum lucidum 
(Figure 1.2), is sometimes described but is usually considered to be part of the lower 
layer of the stratum corneum. 
Epidermis 
Dermis 
Subcutaneous 
tissues 
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Figure 1.2 Cross section diagram of epidermis from human skin showing the five main 
layers (modified from Barts medical image library at Queen Mary). 
1) The stratum germinativum  
The stratum germinativum is also known as the basal stratum or, more commonly, the 
basal layer. The cells of the basal layer are like the cells of other tissues in the body; they 
contain the typical organelles such as mitochondria and ribosomes, and the cells are 
metabolically active. The basal layer is the only layer that contains cells known as 
keratinocytes. These cells which produce keratin, hence their name, also undergo cell 
division in the epidermis. After the cell reproduces via mitosis, one of these cells is 
retained in the basal layer whereas the second cell migrates to the surface, through the 
epidermis and onto the skin surface. The keratinocytes of the basal layer are connected to 
the basilar membrane, known as dermal and epidermal membrane, by hemidesmosomes. 
These act as protein basis for the lower layer cell. A defect in the bond between the basal 
cells and the basic membrane results in dissociation of the skin, such as in some 
blistering conditions. Within the basal stratum and the next cell layer the stratum 
spinosum, keratinocytes are connected through desmosomes, which are a particular 
protein involved in cell connection.  
In addition to the keratinocytes, the basal stratum contains other specific cell types called 
melanocytes. This cell type synthesises melanin which originates from tyrosine. The 
melanin is responsible for the pigmentation of the skin. Melanin can be found in two 
forms, as eumelanin, the more abundant, which is brown or black colour, while the less 
abundant is phaeomelanin which is red or yellow. Melanin granule synthesis in the 
Stratum cornuem 
Stratum lucidum 
Stratum granulosum 
 
Stratum spinosum 
 
 
 
Stratum germinativum 
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melanocytes, tend to be a mixture of both forms. Melanocytes create a contact with 
neighbour keratinocytes through dendritic connections, and this permits the melanin 
granules to cross through the melanocytes to the keratinocytes. The melanocytes are 
arranged in the body and appear to be in different amounts depending on the area 
exposed to the light. Chronic exposure such as in the face results in more melanocytes 
than in the less exposed areas such as the chest. Melanin affords a protection within the 
skin against dangerous light, such as UV radiation, and free radicals. Thus every human 
except albinos have an equivalent melanocyte quantity regardless of skin colour. 
However people with darker skin have more active and efficient melanocytes. 
Langerhans cells also originate within the basal stratum. They were discovered and 
named by P. Langerhans (Kobayashi and Hoshino, 1979) in 1868 in gold chloride stained 
preparations of skin (Kobayashi and Hoshino, 1979, Norikatsu and Akira, 2004). Their 
lineage or function remained unknown until the 1960s when the markers were 
discovered. These include surface I-A molecules, membrane associated enzymatic 
activities to hydrolyze extracellular ATP, intracellular organelles, and more specific 
markers, such as CD1a, E-cadherin, and langerin. Langerhans cells are dendritic and can 
attach and connect to keratinocytes. Langerhans cells originate from bone marrow and 
are the most important antigen present in the cell surface of the skin. Although, 
Langerhans cells are unable to phagocytose, they have the antigens on the surface. 
Nevertheless the possibly contact of skin with many different antigens, results in allergic 
reactions, inflammation and itching, which is the mechanism of defence by the 
Langerhans cells. 
Another important and functional cell in the skin is called the Merkel cell, which is one 
of the dedicated cell types that can be found within the basal layer. The cells can be found 
in numerous numbers in the more touch sensitive sites of the body, such as fingertips, 
lips, and nipple. This is due to the nerve endings which have a sensational characteristic 
when in contact with another body. 
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2) The stratum spinosum 
The spinous layer, or prickle cell layer are other names for the stratum spinosum, the 
cells that originate on the top of the basal layer. Basal stratum and spinosum layers 
together form the malpighian layers. The stratum spinosum consists of keratinocytes that 
are modified in structure from monolateral to multilateral cells. Additionally, in the 
spinous layer the keratinocytes start to differentiate and synthesise keratins that combine 
to form tonofilaments. 
Similarly, desmosomes, connecting the cell membranes to the next keratinocytes, which 
are formed from combined keratins called tonofilaments, have another function of 
keeping a distance between the cells. 
3) The stratum granulosum 
The stratum granulosum is the next layer to the spinous layer, hence referred to as the 
granular layer. In this layer the keratinocytes persist in the synthesis of keratin and 
differentiate, but begin to flatten. The layer thickness of stratum granulosum contains 
fewer cells. Additionally the cell components such as the nucleic acids, and organelles 
(e.g. mitochondria, etc), begin to be nonviable due to enzymatic degradation in the 
stratum granulosum. 
The keratin established inside the cell by keratohyalin granules is composed of cysteine-
rich proteins, loricrin, and profillagrin. Additionally, a membrane covering the granules is 
produced, most likely in the endoplasmic reticulum and Golgi apparatus. The membrane 
has the originator of the intercellular lipid lamellae in the stratum corneum. 
Consequently, the production of the lamellar granules from the cells into the intercellular 
spaces results in the movement of the cells into the top layer of the stratum granulosum. 
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4) The stratum corneum 
The stratum corneum (or horny layer) is the upper (outside) part of the epidermis, which 
is frequently used as a separate part in transdermal drug delivery studies. Stratum 
corneum forms the finishing cell product after cell differentiation in the epidermal. This 
horny layer consist of 10 to 15 cell layers, with a total thickness of 20–40 µm, around 10 
µm thick when dry, although it may swell to several times this thickness when wet. The 
stratum corneum varies in thickness depending on the physiological function of the 
organ; the thickness is greatest on the palms of the hand, and also in the soles of the feet, 
while it is thinner on the lips. The stratum corneum is composed of dead, non nucleate 
keratinized cells implanted in a lipid media. The stratum corneum plays an important role 
in the regulation and protection of functions within the body. The regulatory function is 
focused mainly on water and electrolyte balance in the body, by excreting sweat. The 
protecting mechanism is focused mainly in the stratum corneum, preventing of the 
entrance of dangerous material, including germs to the body. The stratum corneum has 
been portrayed as the ‘brick and mortar’ model (Thomas and Paul, 1995, Barry and 
Williams, 1995), the keratinized cells, “the bricks”, are embedded in a mortar of lipid 
bilayer (Michaels et al., 1975, Elias, 1981, Thomas and Paul, 1995, Barry and Williams, 
1995). The keratinocytes (coenocytes) are multilateral. It takes 14 days for a daughter cell 
in the basal layer to differentiate into the stratum corneum, and further 14 days to remain 
in the stratum corneum before it is separated. The nature of the stratum corneum 
protection is dependent upon its unique components; 5% lipid and protein in the cell 
membrane, 10% lipid, protein, and mucopolysaccharides in the intracellular layer, and 
85% lipid, fibrous and non fibrous proteins. These are primarily cellular with only 
approximately 10% of the components being extracellular (Wilkes et al., 1973). 
Furthermore, under normal conditions (e.g. normal humidity), the water content of the 
stratum corneum is between 15–20% of dry weight (Roberts and Walker, 1993). Water 
has a significant role in maintaining the integrity of the stratum corneum barrier, and 
facilitates the activity of some enzymes for hydrolysis within the stratum corneum, while 
the humidity in the atmosphere can influence the activities of enzymes involved in the 
exfoliation process. Furthermore, water in keratinocytes controls the enzyme which is 
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responsible for the production of the natural moisturising factor (NMF). Additionally 
water enables the stratum corneum to be smooth and elastic, avoiding break down by 
involuntary and physical attack. Hydration of the stratum corneum resulted in an increase 
in its permeability to several solutes (Roberts and Walker, 1993). 
The stratum corneum is composed of a particular lipid combination. These lipid 
components of the multiple layers are important in the regulation of most drug 
permeation through the tissue. Thus, much work has been dedicated to establishing the 
lipid composition of the intercellular space (Elias, 1981, Elias, 1983, Wertz et al., 1985). 
The amount of the lipid matter in the stratum corneum obviously differs from individual 
to individual and also within the body area (Lampe et al., 1983), and particularly between 
genders. The lipid matter is arranged in multiple bilayers which are composed of fatty 
acids, cholesterol, cholesterol sulphate, and ceramides. 
5) The stratum lucidum 
The stratum lucidum is the lower layer from the stratum corneum. In this layer the 
nucleus is fragmented, resulting in an increase in keratin within the cell, followed by 
structural changes which have flattened cells. The stratum lucidum is most likely to be 
seen visibly in the comparatively thick skin area of the body, such as the palms of the 
hand and the soles of the feet. Often transdermal studies tend to view the stratum lucidum 
as part of the stratum corneum and combine it in one layer. 
1.1.2 Dermis 
The dermis, also known as corium, is normally 3–5 mm thick and is the most important 
constituent of human skin. Corium consists of a complex network of connective tissue, 
containing collagen, reticulin fibres to offer tensile strength and elastin fibre to offer 
elasticity of the tissue, and is embedded in a complex matrix of polysaccharide , proteins, 
enzymes, and other substances (Wilkes et al., 1973). In most elderly people the elasticity 
and flexibility of the skin disappears resulting in skin wrinkling.  
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The dermis contains water, thus a lower barrier can be observed in the dermis layer rather 
than the epidermis layer. For instance most polar transdermal drugs can be delivered 
easily through this layer, whereas highly lipophilic drugs can barely be delivered. In 
addition, the dermis contains blood vessels, lymph nodes, nerve endings, pilosebaceous 
components (hair follicles and sebaceous glands), and sweat glands (eccrine and 
apocrine).  
Water is a liquid media that is superior for transport in the presence of an extensive blood 
supply. Blood vessels are vital for delivering oxygen, nutrition, other molecules to the 
cells and tissue, the removal of waste and toxic products, and the regulation of body 
temperature. In addition blood is crucial in stopping the bleeding of a wound, due the 
presence of platelets, which breakdown and aggregate, and is also necessary for the 
healing and repairing of wounds. However, high blood flow is critical in bleeding, easy 
for transport such as for transdermal drug delivery to maintain the concentration of 
compound between applied drug on the skin and the tissue. Hence the permeation of 
transdermal drug is dependent on the concentration of the substance in the tissue. The 
driving force follows Fick's law (Michaels et al., 1975, Barry and Williams, 1995), from 
high concentration to low concentration, and may be expressed mathematically by 
Equation 1.1: 
 
ݍ ൌ ܦ ܣ݄ ܭ ሺܥ0െܥ݅ሻ 
 
 
Equation 1.1 Passive diffusion. 
Where q is the flux of the substance (µg/cm2/h), D the diffusion coefficient (cm2/h), A the 
area (cm2), h the thickness of the stratum corneum (cm), K the partition coefficient, C0 
the concentration of substance in the first layer of the membrane at the skin surface, and 
Ci the concentration of the substance inside the skin (µg/cm3). 
In the dermis the body has a unique defensive system (lymphatic systems) that may reach 
the epidermis layer. The lymphatic mechanism is involved in immunological and 
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regulatory effects, defender and eliminator against microbes and toxic materials. 
Additionally, it may remove substances that have permeated through the skin layer into 
the dermis. Thus, it may help in drug delivery, and the regulation of interstitial pressure. 
In the dermis blood flow is involved in the elimination of small molecules such as 
tetracaine and lidocaine. While the lymphatic system is involved in the elimination of 
large molecules such as interferon (Cross and Roberts, 1999).  
Moreover, the dermis also contains hair follicles, sebaceous glands, and sweat glands. 
These can be seen on the surface of the human skin, and have been described in detail 
(Katz and Poulsen, 1971). Hair follicles are normally found on the entire surface of the 
human skin except the lips, palm of the hand, and the soles of the feet. The hair density is 
varied between adult, children, and genders. Hair is linked with the secretion of sebum 
from sebaceous glands which are found mainly in the face, chest, and shoulder of human 
skin. This oily substance (free fatty acids, triglycerides, waxes) is required to lubricate 
and maintain the hair and skin surface at approximately pH 5. Human skin with a pH 
under 5 is beneficial and has a greater barrier function in comparison with skin at a pH 
above 5 (Lambers et al., 2006). Ebling has described sebaceous glands in detail (Ebling, 
1977). Sweat glands (eccrine glands and apocrine glands) are also found in the dermis 
and secrete sweat when stimulated by heat, fever, stress, in order to regulate the body 
temperature. Eccrine glands can be found everywhere on the surface of human body, with 
most located in the forehead, palms of the hands, and soles of the feet. Apocrine glands 
are developed and activated at puberty and are limited to a particular part of the body 
such as armpits, nipples, and genital regions.  
Hair follicles and sweat glands offer a possible route of delivery for transdermal drugs, 
secluded from the stratum corneum barrier. The route can be described as transapendages 
or through appendages, which may help large polar molecules to cross more easily to the 
stratum corneum. Nevertheless, most drugs permeate through these appendages in low 
amounts, while the main pathway of transport is through the rigid barrier of the stratum 
corneum in the skin surface. The potential pathways of this route are discussed in detail, 
section 1.4 transport pathways (page 54). 
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1.1.3 Subcutaneous 
The subcutaneous fat tissue, or hypodermis, is the bottom layer of human skin. This layer 
is the partition layer between the epidermal-dermal layers and the fundamental body 
components. This fatty layer varies in order of thickness in the human body, and is 
lacking in areas such as eyelids.  
The fatty tissue in this layer mostly provides a protective mechanism against physical 
shock, and in the retention of body heat. The adipose tissue layer carries blood vessels 
and nerves to the skin, and also keeps polar molecules in the skin for longer time, acting 
as a reservoir and supplier.  
1.2 Drug delivery 
Drug delivery is an important field for researchers, pharmaceutical companies, and 
clinical practice. It has recently attracted research interest. Traditionally, once a drug is 
released from its dosage form, it must pass through several barriers before it arrives at the 
site of action. This entire barrier consists of membranes, varying in thickness. Permeation 
or trans-membrane movement, is the process called diffusion, with the rate of diffusion 
depending essentially on the size of the concentration gradient across the membrane, the 
nature of the membrane surface through which the dissolved molecules must pass, and 
the thickness of the membrane (Heilmann, 1984). This can be affected by many factors; 
physiological mechanisms, such as cellular organisation, efflux, and/or chemical and 
enzymatic degradation such as the first pass effect, physicochemical properties of the 
drug molecule itself such as polarity, hydrophilicity, pH, stability, pathological 
mechanism e.g. disease state, as well as the patient himself. Indeed the diverse forms of 
drug delivery routes help us in the following: 
1) Deliver drug to a specific site of action to provide a more safe (minimize the area 
of the site of action) and effective drug (specific site), e.g. chemotherapy. 
2) Avoid factors affecting drug bioavailability including:  
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a) Disease states such as; ulcer, epilepsy. 
b) Chemical degradation such as; stomach acidity. 
c) Enzymatic degradation such as; first pass metabolism, e.g. propranolol is 
affected by the liver “first pass effect”. 
3) Increase patient compliance. by: 
a) Avoiding the complexity of the drug regimen that is related to the 
frequency of administration, which may result in missing doses especially 
in elderly people. An excellent example of avoiding the complexity of 
dose is by using patches e.g. nicotine patch 7 mg/24 hours is better than 
taking a sublingual tablet 2mg/hour (Silagy et al., 2000). Another example 
is clonidine, available as a tablet taken by mouth and also as a patch 
applied to the skin. The tablet usually is taken two or three times a day at 
evenly spaced intervals, but the patch is applied to the skin every 7 days 
(Martindale, 1996d). 
b) Choosing a convenient available route of administration e.g. oral is better 
than IV in people with injection phobia. 
c) Administer the drug to its specific site of action which may prevent or 
minimize the unwanted effects, and may enable a reduction in the length 
of treatment required. 
4) Minimize contamination, diseases, infections, and other possible health hazards 
that may have potentiated/happened by the injection route, e.g. IV, IM, etc. 
5) Helpful with narrow therapeutic index drugs, e.g. digoxin in the treatment of 
congestive heart failure, or warfarin to prevent blood clotting. 
6) Pharmacoeconomic benefits, involve controlling the cost of drug by choosing the 
right dosage form for the right disease or administering the drug directly to the 
Introduction 
Page 45 of 334 
 
site of action to minimize side effects or adverse events which may need another 
treatment. 
Routes of administration can broadly be divided into: 
o Enteral; oral, gastric feeding tube, rectal, etc. 
o Parenteral; intravenous bolus or infusion, intramuscular, subcutaneous implant, 
etc.  
o Topical/transdermal; inhalation, buccal mucosa, intranasal, epicutaneous (on the 
skin), vaginal (female), etc. 
These three major routes of drug administration are the ways in which a drug can be 
delivered to the site of action dependant on its physicochemical properties and/or 
physiological and chemical factors.  
1.2.1 Enteral drug delivery 
From the above three major routes, the enteral route, especially the oral route, is the most 
common, least invasive, easiest, and most convenient for the patient. Once the drug 
enters the alimentary tract, it can be absorbed from the oral cavity, sublingual, stomach, 
small intestine, and large intestine. With regards to the others sections the small intestine 
is the most important part in the alimentary tract. The epithelial coating of the small 
intestine consists of a mono layer of cells known as enterocytes. This layer contains many 
villi and microvilli attached together by a network of blood and lymphatic vessels 
enabling the absorption of digested food, drugs, etc. The villi of the upper intestine have 
a large surface area (~ 200 m²) to enhance absorption of substances. The absorption 
occurs mainly in the upper part of small intestine (in the proximal jejunum), and so the 
speed of gastric emptying determines the speed at which the drug reaches its site of 
absorption. However, some patients cannot swallow tablets and/or capsules, including the 
elderly and the very young person. Other factors, such as malabsorption of a drug, may 
occur due to disease in the gastro intestinal tract (GIT), or be a result of the patient’s age.  
In contrast, the physicochemical properties of the drug play an important role in the 
absorption from the GIT. Thus, in the presence of food, drug absorption may be delayed 
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or reduced. Drugs such as tetracycline, which are highly ionized, can form a complex 
with Ca2+ ions in the membrane, and Ca2+ ions present in food e.g. milk leading to a 
reduction in their rate of absorption. As food can reduce or delay absorption it can also 
increase drug absorption because the splanchnic blood flow is increases during eating. 
Furthermore, drug metabolism changes the bioavailability of drug. It can be defined as 
the chemical alteration of the drug or compound by the metabolic pathway in the body, 
yielding a drug metabolite which may be inactive, active, or a toxic compound in relation 
to the parent compound. Drug metabolism occurs in the gut lumen, gut wall, liver, the 
lung and some happens elsewhere. In the gut lumen, benzylpenicillin (BNF, 2009), and 
insulin (Kenny, 1960), are both almost completely inactivated by gastric acid and 
proteolytic enzymes, respectively. Drugs such as amoxicillin are partially inactivated. In 
the gut wall isoprenaline is sulphated (Back and Rogers, 1987), and many drugs are 
metabolized by enzymes such as monoamine oxidase, and CYP3A4. However, the liver 
is the main site of drug pre-systemic metabolism or first pass effect, which converts 
propranolol to 4-hydroxypropranolol, a pharmacologically inactive metabolite, thus 
explaining the large difference between effective oral and intravenous doses of 
propranolol. This can be overcome by using an oral dose higher than the effective dose 
administered by the intravenous route, which may be useful, but can also enhance the 
possibility of side effects occurring. In some cases, e.g. lidocaine and insulin, metabolism 
is so extensive that it renders oral therapy impossible with conventional oral 
formulations. In such cases the drug must be given by other routes. 
The rectal route with drainage via the inferior rectal veins directly into the systemic 
circulation, offers a comparable alternative route. However, it is not common in the 
United Kingdom (UK), least preferred by some patients (Kogan et al., 2002), and is only 
used for certain types of drugs when the other alternative routes are not available, for 
example to control seizure, anxiolytic, analgesia (Pannuti et al., 1982, Beebe et al., 1992, 
Kogan et al., 2002). In children, this route is used more commonly to achieve a topical 
effect on the rectum and colon, such as a prednisolone enema to treat ulcerative colitis, or 
to minimize adverse effects occurring in the upper gut by indomethacin, which is more 
likely to cause gastric ulceration if given orally. Others such as Fleet Enema (Sodium 
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biphosphate, Sodium phosphate), are used as a laxative for the relief of constipation, and 
to clean the bowel before surgery.  
Other routes such as a gastric feeding tube can be given only if the patient is admitted to 
the hospital and in an appropriate condition. In these cases, drugs must be administered 
by alternative means including injection, inhalation, and transportation through the skin. 
1.2.2 Parenteral drug delivery 
Injection is usually a patient’s least favoured route of drug administration. Drug delivery 
by injection is affects the whole body, rather than reaching a specified site of action. This 
may result in an ineffective dose and possible side effects/events to other organs in the 
body. Also there is a need to avoid needle delivery risks, such as infectious diseases of 
microbials, viruses, and other contamination. Inconvenience and even pain are 
additionally a problem. While it may be a minor problem in adults, young people 
especially children, experience a far greater pain which can develop into “needle phobia”, 
an intense fear of needles that triggers immediate anxiety. This also affects some adults. 
However local anaesthetics are normally used to reduce the pain by inducing a loss of 
feeling (numbness) in skin and mucous membranes. Many researchers have searched for 
a local anaesthetic method that is needleless and pain free via topical application, e.g. 
EMLA (Eutectic Mixture of Local Anaesthetics containing 2.5% each of 
lidocaine/prilocaine) cream and Ametop (4% w/w tetracaine base). But unfortunately the 
slow onset times (EMLA, 1 hour, Ametop, 30 – 45 minutes) remain a deterrent to 
widespread acceptance with the need to organise clinic, ward and operating theatre 
routines accordingly. Additionally, these methods are of little benefit in acute situations. 
Other examples to get a painless injection include the needleless injection and micro-
needle, but due to its difficult use, improper handling of the system, leading to the loss of 
drugs entering the body, it is more complicated, and requires a trained administrator 
which increases the cost.  
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1.2.3  Which drug delivery is appropriate? 
The individuals most opposed to intravenous treatment generally are children. This 
produces several challenges for clinician as children often are unwilling to swallow 
tablets and/or capsules, they refuse injection therapy, and they do not like the taste of 
some medicines (Harold, 2007). 
A good example for children is cited in this recent case study: a nine year old boy was 
complaining of headache, back pain and generalized arthralgia/myalgia. The boy had 
severe bone pain on his forearms, wrists and both hands. He received continuous 
subcutaneous or transdermal fentanyl at 75µg/hour, hydromorphone 3 mg and lorazepam 
when required, gabapentin and naproxen as analgesic, ondansetron and nabilone for 
nausea, polyethylene glycol and docusate as laxative. The treatment reduced all pain 
except for the bone pain in the arms. Clinical teams then attempted to choose a 
bisphosphonate category drug for this untreated pain. However the selection of an IV 
route was opposed by the boy, claiming he was uncomfortable because of his awful 
history in hospital. An oral route was then chosen, but due to his previous gastric outlet 
obstruction, this was not a suitable method. Additionally, he refused the rectal route. 
Hence clinical teams then decided to use the subcutaneous route, which was an 
acceptable and useful treatment for him (Harold, 2007). 
1.2.4 Transdermal drug delivery 
Optimum therapeutic outcomes require proper drug selection and effective drug delivery. 
Many effective drug delivery methods have been reviewed and discussed above; one of 
these being transdermal drug delivery. Transdermal drug delivery is an alternative choice 
for therapeutic agents, not only for systemic drug delivery, with avoidance of hepatic 
first-pass metabolism and increase of patient’s comfort compared with the oral and 
parental route, respectively, but particularly for targeted local drug delivery to the skin, 
and sometimes it is the only route that can be given, as described before in the previous 
section (page 48).  
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The human skin is a readily accessible surface for drug delivery. However, to consider 
the cutaneous route viable, sufficient amounts are required in local tissue. In the last 60 
years or so, many terms have been used to describe transdermal drug (substance) 
delivery, e.g. penetration of a substance from the outside of the skin through the skin and 
into the systemic circulation, or the passage of a substance from the entire surface of the 
skin through its complex layers into the blood circulation. Rothman described this as 
percutaneous absorption as mentioned by Cleary (Cleary et al., 1984). Some describe it 
as the administration of therapeutic agents through intact skin in sufficient quantities for 
systemic or local effects. Others have used different terms such as sorption, persorption, 
permeation, and penetration (Cleary et al., 1984). All of these relate to the passively 
driven force of transfer; some terms such as sorption, have other conflicting senses. Thus 
the best definition of transdermal drug delivery can be described as: the absorption 
through the skin that involves passive diffusion through the outer and middle structure of 
the skin until the systemic circulation is attained (Schuplein and Blank, 1971, Cleary et 
al., 1984) or local effects are produced, and the likelihood of unwanted side effects or 
toxic effects may occur. 
Transdermal drugs are available today as topically applied creams, ointment, patches, and 
gel. Many studies, including those on transdermal drug delivery have been required to 
verify what causes the skin to have these barrier properties which prevent substance 
permeation. In 1924, Rein claimed a negative charge existed; impermeable to anions and 
that electrostatically traps cations, it was a barrier layer in the dermis, assuming 
transepidermal absorption through the cell (Katz and Poulsen, 1971). In 1953 Blank 
(Blank, 1953) adapted this by eliminating the stratum corneum layers from the surface of 
the skin, and found that water was lost rapidly from the skin, and considerably more after 
elimination of the stratum corneum. In 1965–1971 Scheuplein and colleagues (Schuplein, 
1965, Scheuplein, 1967, Schuplein and Blank, 1971) demonstrated that transdermal 
permeation was limited by the stratum corneum via a passive process. 
Michaels and colleagues determined that the diffusion coefficient of ideal drugs in the 
stratum corneum, resulted in significant permeability of some drugs (Michaels et al., 
1975). This demonstration assisted in the development of active transdermal patches in 
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the 1970s. The initial first patch was approved by the FDA in 1979. It delivered 
scopolamine over three days to treat motion sickness (Shaw and Chandrasekaran, 1978). 
The next patch was then approved containing nitroglycerin for cardiovascular disease 
(Dasta and Geraets, 1982), followed by other patches containing clonidine for 
hypertension, estradiol as hormone replacement therapy, and nicotine used as a method to 
quit smoking. 
Drug delivery through the skin offers advantages over other pathways including: 
avoiding the hepatic first pass effect, avoiding the physiological environment and 
chemical or metabolic degradation in GIT such as changing pH, luminal micro flora, etc. 
It has an advantage that the treatment can be interrupted or eliminated when necessary 
(Godwin and Michniak, 1999). Improved patient compliance is especially notable for 
patches that require only once weekly application e.g. once a week transdermal estradiol 
of adhesive patch appears to be an acceptable means of hormone replacement therapy 
compared with the twice a week patch (Harrison et al., 1997). 
The continuous permeation of drug through the skin allows for more steady blood 
concentrations. Although IV infusion at constant rate achieves this objective, it is more 
invasive than transdermal drug delivery. In addition, the slow rise in plasma 
concentration for transdermal drug delivery can reduce the risk of side effects.  
Generally drug absorption into the skin occurs by passive diffusion, and because of the 
barriers imposed by the skin, this process occurs very slowly. The rate of drug transport 
across the stratum corneum follows Fick`s law of diffusion (Michaels et al., 1975, Barry 
and Williams, 1995), which depends on the aqueous solubility, oil/water partition 
coefficient, concentration in the formulation vehicle, molecular size and shape, the 
surface area of the skin to be exposed, thickness of the stratum corneum, etc. Since, the 
stratum corneum is thickest in the palm of the hand and soles of the feet, but thinnest in 
the lips, armpits, genital, and scalp regions of the body, choosing the site of application is 
very important for this type of drug delivery.  
Furthermore a drug may need assistance to enhance its penetration through the skin. 
These methods can be categorized as physical and chemical methods of enhancement. 
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Physical methods including: iontophoresis which applies a small amount of electric 
current to drive polar and neutral molecules through the skin (Banga et al., 1999, Denet et 
al., 2003). In contrast, electroporation applies a high voltage for a very short time which 
enhances the permeability of the skin (Banga et al., 1999, Denet et al., 2003). 
Phonophoresis or sonophoresis is the use of ultrasound within the therapeutic range of 
0.5–5 MHz to enhance the delivery of topically applied drugs (James et al., 1993). 
Chemical methods include the use of chemical penetration enhancers and development of 
prodrugs with proper physicochemical properties appropriate for transdermal delivery. 
See section 1.5 (page 57) for more details. 
1.3  Skin metabolism 
Skin metabolism is a protective function in the epidermis and dermis, making the second 
penetration barrier to drug permeation through the skin possible. The biochemical barrier 
makes drug delivery through the skin more difficult in addition to the first barrier “the 
epidermis” or mainly “the stratum corneum”. The metabolism of skin has been well 
documented with many different organs in the body, which have the capability to 
metabolize certain drugs/substances. Among these organs, the liver can still be 
considered the most important organ for metabolism of drugs/substances in the body 
(Pannatier et al., 1978, Tauber and Rost, 1987). The levels of some enzyme activities in 
the skin are relatively low when compared with the liver (Pannatier et al., 1978, Noonan 
and Wester, 1985, Noonan and Wester, 1989, Sartorelli et al., 2000). However skin 
metabolism is important, due to its large surface area which is approximately 1.8–2 m², 
and the constancy to environmental facts. This is especially true for the epidermis, which 
constitutes part of the major interface between the body and the environment. Thus, the 
role of the skin cannot be overlooked. In addition, studying the metabolism in the skin is 
imperative, and useful information can be obtained which can improve knowledge 
regarding health hazards. A study by Yourick (Yourick and Bronaugh, 2000), in 
predicting the extent of 2-nitro-p-phenylenediamine (2NPPD) and/or 2NPPD metabolite, 
may be used for future safety assessment purposes in systemic absorption relative to a 
dermal exposure. 
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The enzymatic activity of human skin is mostly estimated, and by assuming that these 
enzymes are constrained in the epidermal layer, the real activities range from 80 to 240% 
of those in the liver (Noonan and Wester, 1989), and sometimes exceed that of the 
corresponding hepatic enzyme (Martin et al., 1987). Thus the enzymatic activity taking 
place in the multiple layers of the skin imposes a great influence on the efficacy and 
safety of transdermal drug delivery (Noonan and Wester, 1985, Bando et al., 1997, 
Sartorelli et al., 2000). The effectiveness of skin metabolism is typically in the prevention 
of systemic toxicity of transdermal delivery drugs, such as the metabolism of benzoyl 
peroxide, which yields a benzoic acid metabolite in the skin (Nacht et al., 1981, Sartorelli 
et al., 2000). In contrast the process is also helpful and useful in the case of prodrugs, 
which are designed for the purpose of enhancing percutaneous penetration.  
Skin metabolism can be affected by a number of factors, including, physicochemical 
properties, the amount of drug applied, the concentration of drug, the area applied, the 
duration of time to be applied, and the level of metabolizing enzymes which is affected 
by age, sex, race, skin condition, enzyme inducers and inhibitors, and duration of the 
applied drug to the enzymes. In addition, there is a predictable difference in simultaneous 
skin transport and metabolism between species, especially in esterase activity (Tauber 
and Rost, 1987, Steinstrasser and Merkle, 1995, Rittirod et al., 1999). 
Skin metabolism has at least two broad enzymatic categories/reactions; phase I 
(oxidation, reduction, and hydrolysis), and phase II (conjugation) biotransformation 
reactions (Pannatier et al., 1978, Martin et al., 1987, Tauber and Rost, 1987, Boehnleine 
et al., 1994, Sartorelli et al., 2000).  
The  metabolism enzymes available in the skin are similar to the most important 
metabolism enzymes in the liver (Sartorelli et al., 2000), and other organs (Pannatier et 
al., 1978). Phase I enzymes like alcohol and aldehyde dehydrogenase can be found in the 
human skin. These enzymes are involved in the metabolism of a variety of endogenous 
and exogenous alcohol and aldehyde substances in the body to prevent systemic toxicity, 
cytotoxicity, mutagenicity and carcinogenicity (Cheung et al., 1999). Table 1.1 shows the 
most important metabolizing pathways. In phase I oxidation/reduction/hydrolysis of the 
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substance is mediated by cytochrome P450 isoenzymes to be finally conjugated in phase 
II. Phase II generally converts lipophilic drugs to hydrophilic derivatives, to be easily 
excreted from the body. However, such metabolism results in the detoxification of 
compounds. Thus, if the chemical had not been detoxified, and was highly reactive, it 
might accumulate inside the skin layers which could result in binding to nuclei/protein in 
cells, which could cause morphological changes in the gene, resulting in genetic cancer, 
or dermatitis. Hence, the balance between the two pathways (phase I and phase II) of skin 
metabolism has been mediated to avoid any toxicity (Smith et al., 2003). 
Table 1.1 Some cutaneous xenobiotic metabolising pathways (Sartorelli et al., 2000). 
Phase I Phase II 
Oxidation 
Hydroxylation 
Deamination 
Dealkylation 
Epoxidation 
Aldehyde oxidation 
Alcohol oxidation 
Reduction 
Azo reduction 
Nitroxide reduction 
Quinone reduction 
Hydrolysis 
Carboxylester hydrolysis 
Sulfate ester hydrolysis 
Phosphate ester hydrolysis 
Peptide hydrolysis 
Epoxide hydrolation 
Glucuronidation 
Sulfation 
Glutathione conjugation 
Acetylation 
Amino acid conjugation 
Methylation 
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Finally, skin metabolism is hard to determine in vivo as the analyzed sample may contain 
other metabolites not related to skin metabolism. Thus, the bioavailability of a 
metabolized drug by the skin can be practically estimated (Nakashima et al., 1987), and 
the appropriate method to analyze endogenous and exogenous samples in the 
extracellular space of skin tissues is by using microdialysis (MD). 
1.4 Pathways of transport 
As discussed before, the skin has multiple barriers which prevent the easy permeation of 
drugs. However the topical drug product (emulsion, gel, liquid formulation, etc) applied 
on the skin and released from the formulation, is thought to permeate through the skin 
tissue by a passive diffusion process through viable epidermis. The process usually is 
thought to obey Fick's laws of diffusion, and the drug is delivered then to the site of its 
action, or reaches the systematic circulation. For example drugs/substances with a low 
molecular weight (<500 g/mol) and with a log P of > 1 are very likely to be able to 
penetrate the lipid in the stratum corneum effectively (Smith et al., 2003). Nevertheless, 
to complete this process, there are three possible pathways of transport across the skin 
which have been recognized by Schuplein (Schuplein, 1965) Figure 1.3 and Figure 1.4. 
1. Transcellular permeation, through the cells. 
2. Intercellular permeation, between the cells. 
3. Transappendageal permeation, via the hair follicles, sebaceous and sweat glands. 
From the three main pathways by which drugs can cross the skin and reach the systemic 
circulation, the first two pathways require further diffusion (passive diffusion) through 
the rest of the epidermis and dermis (Figure 1.4). The first pathway, “transcellular 
permeation” was initially considered to be the most likely, since most of the volume is 
comprized of cells, in vivo experiments have indicated that solutes which are more lipid 
soluble and do not alter the epidermis follow intracellular permeation (Albery and 
Hadgraft, 1979) and that the intercellular route may provide the major pathway for 
transdermally delivered drugs. Transcellular permeation is a direct route by which the 
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drugs cross the skin by directly passing through both the phospholipid membranes and 
the cytoplasm of the dead keratinocytes that constitute the stratum corneum (Figure 1.4). 
Although this is the path of shortest distance, the drugs encounter significant resistance to 
permeation. This is because the drugs must cross the lipophilic membrane (stratum 
corneum) of each cell, then the hydrophilic cellular contents (viable epidermis) 
containing keratin, and then the hydrous layer (dermis) one more time (McCarley and 
Bunge, 2001), which makes multiple transfers between these cells and the intercellular 
domains the only way. Thus more hydrophilic drugs are unable to permeate through the 
stratum corneum, and more lipophilic drugs tend to be retained in the stratum corneum 
(Naik et al., 2000). Due to the hydrophilic properties of the dermis few drugs have the 
properties to cross via this pathway. 
The second pathway is more common; in this pathway the drugs cross the skin by passing 
through the small spaces between the cells of the skin, making the route more 
complicated (Figure 1.3). Although the thickness of the stratum corneum is only about 
20–40 µm, the actual diffusional path of most molecules crossing the skin is in the order 
of 300–500 µm (Hadgraft, 2001). 
The third pathway allows diffusion leakage into the epidermis and direct permeation into 
the dermis. The appendages may be important at short diffusion times and for polar 
molecules, but are usually considered to be of minor importance because the appendages 
occupy only a very small proportion of the total skin surface, approximately 0.1% 
(Schuplein, 1967).  
For drugs penetrating directly across the intact stratum corneum, the mechanism of drug 
entry may be transcellular and/or intercellular and/or transappendage. The mechanism of 
drug entry is affected by many factors, including the duration of time the drug is applied, 
physiochemical properties of the drug (such as pKa, protein binding, size of the 
molecule, stability, solubility, partition coefficient), physiological factors (such as 
integrity and thickness of stratum corneum, amount of sweat glands and follicles, skin 
humidity, metabolism), and chemical factors (such as vehicle effects, enhancer, content). 
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In addition, penetration can be improved by developing/amending methods, techniques, 
and/or systems used to enhance, increase, facilitate, the absorption process of the drug in 
the viable epidermis. These methods are discussed in detail in section 1.5 (page 57). A 
good example is the use of penetration enhancers such as water, alcohol, etc. 
 
 
 
 
 
Figure 1.3 Cross section of the human skin showing the three main pathways of drug 
transport through the skin (modified from Barts medical image library at 
Queen Mary). 
Transappendageal 
permeation, via 
sebaceous gland 
Passive diffusion, 
via epidermis 
Transappendageal 
permeation, via 
the hair follicle 
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Figure 1.4 Enlargement of the human epidermis showing the “passive diffusion via 
epidermis” of the transcellular and intercellular routes through the skin 
layers (modified from Barts medical image library at Queen Mary). 
1.5 The physiology and properties of the barrier of the stratum 
corneum 
The primary physiological barrier to drug absorption across the skin is the stratum 
corneum (SC) (Marzulli, 1962, Katz and Poulsen, 1971, Michaels et al., 1975, Barry, 
1983a, Kligman, 1983, Noonan and Wester, 1985, Noonan and Wester, 1989), the 20–40 
µm thick matrix, forming the outer layer of skin. It consists of dehydrated keratinocytes, 
anucleate cells, which are separated from the dermis by a thin underlying membrane, and 
is frequently studied by the researcher as a separate membrane. The stratum corneum 
prevents any harmful material from entering from the outside to inside which may cause 
inflammation. Thus in inflammatory skin diseases the stratum corneum is affected, which 
may allow harmful material to enter, causing unwanted effects. Removing the stratum 
corneum, either by removing the stratum corneum using tape stripping, or extracting the 
lipids from the horny layer, will result in a stratum corneum similar to that seen in 
inflammatory skin diseases. Morgan and colleagues demonstrated that removing the 
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stratum corneum by tape stripping enhanced penciclovir and acyclovir absorption by 
1300 and 440 fold respectively. The results of this study confirmed that the stratum 
corneum is the main barrier in the absorption for hydrophilic drugs (Morgan et al., 2003). 
Another study using the same method of tape stripping showed that the absorption of 
EMLA (Eutectic Mixture of Local Anaesthetics containing 2.5% each of 
lidocaine/prilocaine) cream was accelerated by removal of the stratum corneum, and the 
pain assessment for 15 minutes was less in a patient whose stratum corneum had been 
removed compared with patient whose stratum corneum was intact (Singer et al., 1998). 
Any substance that penetrates the stratum corneum is subjected to metabolism in the 
viable epidermis which is the major site of metabolism in the skin (Noonan and Wester, 
1985, Noonan and Wester, 1989). Therefore the ideal drug needs to penetrate the stratum 
corneum to be absorbed quickly, in sufficient quantity, and thus be available to exert its 
local or systemic effect. 
Many researchers have currently developed systems and methods, and the future research 
studies may promise to enhance the absorption through the stratum corneum. This 
includes the drug/vehicle interaction (e.g. eutectic system in EMLA cream, metabolism 
of prodrugs), vesicles and particles (e.g. as liposomes and analogues), stratum corneum 
modification (e.g. chemical enhancers, hydration), stratum corneum bypass (e.g. laser 
ablation, micro-needles, follicular delivery), and electrically assisted methods 
(ultrasound, iontophoresis, etc) (Barry, 2001). The modification of the stratum corneum 
by using penetration enhancers (or accelerants) is more popular and widely used in 
transdermal drug delivery of topical steroids (Barry, 1983b). The penetration enhancers 
are substances used to temporarily diminish the stratum corneum, such as water, 
hydrocarbons, fatty acids, esters and alcohols, azone and its derivatives, sulphoxides and 
analogues, pyrrolidones, surfactants (anionic, cationic and nonionic), amides,  epidermal 
enzymes, and lipid synthesis inhibitors (Barry, 2001). Penetration enhancers are 
substances that enhance the penetration of transdermal drugs, and are defined as 
penetration enhancers, absorption promoters, or accelerants. Barry and Williams (Barry, 
1983b, Barry and Williams, 1995) described the attributes of the ideal penetration 
enhancer as the following; 
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1. Pharmacologically non effective, with no action at receptor sites, and/or anywhere 
in the body. 
 
2. Nontoxic, not irritating, and not allergenic, in acute or chronic cases. 
 
3. Onset of action should be rapid, and duration of activity should be predictable and 
suitable for the drug used. 
 
4. Stratum corneum should immediately and fully recover to its normal barrier 
property after removal of the enhancer. 
 
5. The barrier function of the skin should be reduced in one direction only. 
Endogenous materials should not be lost to the environment by diffusion out of 
the skin. 
 
6. The enhancer should be chemically and physically compatible with all drugs and 
adjutants to be formulated in topical preparations and devices. 
 
7. Spread well on the skin, with a suitable skin “feel”. 
 
8. Easy to be formulated into transdermal preparations, transdermal procedure, and 
skin patches. 
 
9. Tasteless, odourless, colourless, and non expensive. 
 
10. Should be an excellent solvent for the drug. 
 
In addition to the attributes of the ideal penetration enhancer described by Barry and 
Williams, Kang et. al. said that there should be; 
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11. There is no interaction between skin and enhancer, unless the stratum corneum 
barrier properties are retained. Chemical enhancers selectively interact with the 
lipid components of stratum corneum (Kang et al., 2006). 
Penetration enhancers may act by one or more of three main mechanisms (Barry and 
Williams, 1995): 
 Disruption of the highly ordered lipid structure of the stratum corneum, 
 Interaction with intracellular protein, and 
 Improved partitioning of a drug, co-enhancer or solvent into the stratum 
corneum. 
1.6  Other topical delivery 
As discussed before, the stratum corneum (SC) is the major barrier preventing 
drugs/substances from penetrating through the skin. However other topical drug delivery 
can be used avoiding the main barrier (stratum corneum) in the skin, through the mucosal 
membrane. Where there is no SC available to prevent the absorption of topically applied 
drugs, which enables the drug to avoid the barrier and penetrate easily through the skin to 
reach the systemic circulation, or exert its effect locally. This includes, the mouth 
(sublingual or buccal), respiratory tract (nasal mucosa, hypopharynx, lungs), and vagina. 
In comparison, the respiratory tract provides a large area of absorption, the nasal region is 
rich with blood vessels, and the lungs contain bronchi which divide into bronchioles and 
then into alveoli surrounded by blood vessels. An example of drugs taken by this route, 
via inhalation, is salbutamol for the treatment of asthma, or through the nasal mucosa 
such as nasal sprays, nasal drops, etc. Such a type of delivery is limited for multi-usage as 
it may lead to disruption of nasal blood vessels and bleeding may occur. The mouth is 
rich with blood vessels, so drugs delivered into mouth via sublingual or buccal mucosa 
will have a fast absorption rate e.g. isosorbide dinitrate is absorbed quickly, which is 
important in a case of acute myocardial infarction (MI), where a fast onset of action is 
required. However sometimes this is not useful such as in acute seizure where the oral 
route is dangerous, and hazardous. Furthermore, females can suffer from infection and 
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other conditions in the genital organs, and a vaginal topical route can be used to treat the 
affected area. However this route is limited to certain diseases. 
1.7 TDS® delivery system 
One of the main projects in this thesis, is to study the TDS® drug delivery system 
(Transdermal Technologies Inc., Florida, USA), which is a unique liquid formulation 
applied locally via a metered pump dispenser, not requiring a patch or other appliance for 
precise delivery of the drug dose systemically and locally without causing any damage to 
the skin. The novel proprietary transdermal technology has been developed for use in 
pharmaceutical, cosmetic and over the counter (OTC) products. The TDS® consists of 
nutritional and/or nontoxic substances. The system is a stable solution principally 
containing water, ethanol, and propylene glycol, in addition to cationic surfactants 
(quaternary ammonium compounds) and non-ionic surfactants (long chain fatty acids). 
The solution is formulated to be a spray and the volatile compound can be evaporated 
quickly, leaving the drug in a concentrated solution over the skin, and resulting in a rapid 
absorption into the stratum corneum. Due to the reversible alteration in the fluid of the 
lipid tissue in the stratum corneum, the drug is then released from the stratum corneum 
over time. TDS® formulations have been developed for transdermal administration, 
combining a rapid onset of action with a convenient and patient friendly method of 
administration, and containing substance to preserve the health of skin integrity.  
The TDS® systems have been evaluated by the Institute for In Vitro Sciences in 
Gaithersburg, Maryland USA for primary skin irritation, sensitivity, and toxicity. All 
materials are tested within non-irritating limits. Unless the outer layer (stratum corneum) 
of the skin is disrupted or removed by any kind of physical or chemical action, drug 
molecules can be delivered by the TDS® system reliably through the skin. It is capable of 
delivers drugs with a molecular weight less than 500 daltons, such as lipophobic, non-
polar molecules, and in doses adequate to achieve therapeutic concentrations. 
Furthermore, the technology is used and available on the market and it is established in 
OTC medication such as the self administered analgesic, Penetran Plus®. Also the TDS® 
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system has been studied for two popular drugs, lidocaine and testosterone. The TDS® 
lidocaine (Tucker et al., 2006) and TDS® testosterone (Chik et al., 2006) have been tested 
in 100 and 12 subjects, respectively, without any side effect/events observed during and 
after the study finished, resulting in a positive result of the two treatments. 
1.8 Pharmacokinetic studies 
The word pharmacokinetic (PK) appears to have been first utilized in 1953 by Friedrich 
Hartmut Dost (Dost, 1953). Pharmacokinetics (in Greek: "pharmacon" meaning drug, and 
"kinetikos" meaning putting in motion) is a branch of pharmacology devoted to 
measuring the outcome of the substances that are administered to a living organism. 
Pharmacokinetics is defined as the movement of drug into, through, and out of the body 
as the metabolite/unchanged substance, expressed as the time course of its absorption, 
distribution, metabolism and excretion (ADME). 
Absorption is the entry of a substance into the body; resulting in its bioavailability in the 
blood stream. Blood then passes and disperses or disseminates the substance throughout 
the fluids and tissues of the body into the cells. However the drug may transform into its 
metabolite before it reaches the receptor site, the phenomenon called metabolism or 
biotransformation. The drug then can be eliminated from the body by a process known as 
excretion. However in rare cases, some drugs irreversibly accumulate or stay longer than 
usual in the body tissue. The measurement of drug concentration using pharmacokinetics 
as a mathematical pattern has been expanded to include statistical data analysis. This can 
define and answer most difficult questions which may arise from analyzed data.  
Pharmacokinetics is often studied in conjunction with pharmacodynamics, to achieve its 
useful potential. While pharmacokinetics explains what the body does to the drug, it also 
determines the onset of action or lag time, duration of action, and efficiency of a drug’s 
effect. Pharmacodynamics describes what a drug does to the body, drug-receptor 
interaction, which involves receptor binding, post-receptor effects, and chemical 
interactions. The concentration of drug in plasma is often assumed to behave linearly or 
at least log linearly with drug effects. This means there is enough drug concentration at 
Introduction 
Page 63 of 334 
 
the specific receptor target to provide a therapeutic response. However, the absence of 
equilibrium between plasma and receptor, the presence of metabolites, drug interaction 
and drug tolerance may be complicated when choosing an appropriate dosage regimen. 
The pharmacokinetics of a drug depend on patient related factors as well as on the drug's 
chemical properties. Some patient related factors (e.g., age, gender, genetic) can be used 
to predict the pharmacologic response of populations. For example, the half life of some 
drugs, especially those that require both metabolism and excretion, may be longer in the 
elderly. Other factors are related to individual physiology, such as the effects of some 
individual factors (e.g., disease status, dehydration, obesity), that can be reasonably 
predicted, but other factors are idiosyncratic and thus have unpredictable effects. Because 
of individual differences, drug administration must be based on each patient's needs 
traditionally, by empirically adjusting dosage until the therapeutic objective is met. This 
approach is frequently inadequate because it can delay optimal response or result in 
adverse effects. Knowledge of pharmacokinetic principles helps prescribers adjust dosage 
more accurately and rapidly. 
1.9 Clinical trials 
A clinical trial (also called clinical research or clinical study) is a research study in 
human volunteers (healthy or patients, dependent upon the study purpose) to answer 
specific questions. 
Clinical trials are conducted in phases (phase I, phase II, phase III, and phase IV–post 
marketing), each phase having a different purpose and questions to help the researchers 
get the answers and information they need. In phase I trials, researchers test an 
investigational drug or formulation in a small number of subjects, usually healthy 
subjects in the first instance, where it is possible to identify side effects, efficacy, 
pharmacological activity, and determine the safe dosage range. Most clinical trials in 
phase I include both pharmacokinetics and pharmacodynamics. The study data and 
information obtained with successful drug or dosage form from phase I can be interpreted 
and used to design phase II trials. 
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In phase II trials, the investigational drug is given to a large number of patients. The 
objective of phase II is to examine the efficacy and evaluate further the safety of the 
investigational drug in patients. The drug is given initially in a low dose and is gradually 
increased to monitor the tolerability, safety, and identify the suitable dose, dosage form, 
and the side effects of the treatment. All the study data and information obtained from 
phase I and phase II, with a potentially successful drug with a sufficient measure of 
effectiveness and acceptable side effects can be interpreted and used to design phase III 
studies. 
In phase III trials, the investigational drug is given to a larger number of patients, usually 
hundreds to thousands, to confirm its effectiveness, monitor side effects, compare it to 
commonly used treatments, and collect information that will allow the investigational 
drug to be used safely. Phase IV trials are usually achieved after the drug has been 
marketed. Post marketing studies define further information and any unanswered 
questions from phase III, including the different effects due to drug benefits, risks, use, 
and include factors such as gender, ethnicity, etc. 
1.9.1 Good clinical practice (GCP) 
Good clinical practice is a global ethical and methodological quality standard for 
designing, conducting, performing, monitoring, auditing, recording, analyzing and 
reporting of clinical trials, and to confirm that the study information and reported results 
are convincing, accurate, and precise. Also reliability and privacy of the study subjects 
are protected [EMEA, ICH GCP 1.24] (EMEA, 2002). 
The EU Clinical Trials Directive (2001/20/EC) appeared in law on the 1st of May 2004 
and has been incorporated into UK law by the medicines for human use (Clinical Trials) 
regulations 2004. The medicines for human use (Clinical Trials) Amendment regulations 
2006 were placed before parliament on 20 July 2006 and became law on 29 August 2006 
for clinical trials. The amendment regulations implement the EU Directive (2005/28/EC) 
on good clinical practice and also include further requirements relating to agreements for 
expenses/fees; informing the licensing authority of serious breaches of GCP and/or the 
protocol; and the expansion of the breach notices (warning notices) organisation. 
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Together the medicines for human use (Clinical Trials) regulations 2004 and the 
medicines for human use (Clinical Trials) amendment regulations 2006 and clinical trials 
regulations were complied with throughout this project. 
1.9.2 Good laboratory practice (GLP) 
Good laboratory practice (GLP) is a dedicated standard laboratory framework by which 
the studies are designed, conducted, monitored, recorded, documented, and archived 
(MHRA, 2007). The study is designed to be able to report data to avoid any risk, hazard, 
and harmful material to individuals, users, or effect the environment. Thus GLP is 
applicable to chemical industries, pharmaceuticals, agrochemicals, cosmetics, vitamins 
and supplements, and food additives. The safety assessment is obtained before a study is 
conducted to ensure the study is regulated and compliance is verified. 
1.9.3 Good manufacturing practice (GMP) 
Good manufacturing practice (GMP) is a standard of quality assurance exercise, 
conducted and employed to certify that the developed chemical products are consistently 
formed and qualified for their proposed use, which is required by the 
regulatory/authorities (MHRA, 2008). 
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1.10 Objectives of the project 
The purpose of this project was to study the pharmacokinetics of transdermal drug 
delivery in healthy humans. The studies were performed to 1) study transdermal drug 
delivery of diazepam, currently available in different routes of delivery, 2) develop and 
validate methods to analyze tetracaine in skin samples, and 3) assess appropriate methods 
to measure the transdermal delivery of drug. 
The aim of this work was to: 
1. Conduct and investigate pharmacokinetic studies in healthy human volunteers for 
the development and assistance of drug delivery through the skin. The TDS® 
diazepam is a liquid combined formulation using a pump dispenser to deliver 
diazepam through the skin into the systemic circulation. The pharmacokinetics 
and skin metabolism of diazepam obtained from this study will be investigated for 
further development of the TDS® system and diazepam skin delivery. 
2. Develop, optimize, and validate bioanalytical methods for analysis of drugs in 
biological matrixes such as plasma, dialysate from microdialysis, and skin tape 
samples. Investigate the quantitative performance of developed CE and HPLC, to 
analyzed tetracaine in skin using tape samples obtained from healthy volunteers 
given tetracaine as a part of pharmacokinetic drug studies, in order to find a rapid, 
simple, inexpensive method to use to measure transdermal drugs. 
3. Investigate the correlation of methods used to measure the pharmacokinetic 
profile of topically applied or transdermal drugs between skin stripping, 
microdialysis, and conventional systemic measurement in blood. The results 
obtained from this study may find a use in determine pharmacokinetic, 
toxicokinetic, forensic measurements of topically applied drugs. 
 
Study comparison of rectal and dermal diazepam 
 
Page 67 of 334 
Chapter 2 Study comparison of rectal and dermal 
diazepam 
2.1 Introduction 
Benzodiazepines exert their effects by interacting with the endogenous γ-aminobutyric 
acid (GABA) molecule, at a specific subunit on the GABAA receptors, in the brain. 
GABAA is an inhibitory receptor site, which when activated, causes an inhibition of 
neurotransmission. Positive allosteric binding modulates the activity of GABAA 
receptors, resulting in hyperpolarisation of post synaptic membranes, due to the presence 
of the negative chloride ion. Mild inhibition of neuronal activity exerts an anxiolytic 
effect in patients, while moderate to high inhibition induces sedation and sleep, and may 
cause death. The anticonvulsant effect of diazepam and other benzodiazepines may be 
due to the binding affinity to sodium (Na) channels rather than benzodiazepine receptors. 
This is seen in the slow recovery of Na channels from inactivation.  
The most widely used drugs for treatment in acute seizures are benzodiazepines, such as 
diazepam, clonazepam, with no benzodiazepine having been confirmed to be better than 
another (Treiman, 1989, Rey et al., 1999). Although, diazepam is superior in the 
management of status epilepticus, lorazepam is preferable for the initial management of 
status epilepticus (Treiman, 1989).  
The physicochemical properties of benzodiazepines such as lipid solubility, and protein 
binding, facilitate their penetration through the blood brain barrier (BBB) and 
cerebrospinal fluid, which results in rapid onset of action. The penetration mainly occurs 
by passive diffusion (Pardridge, 1995), according to Fick’s law. The lipid characteristic 
of diazepam enhances its solubility to penetrate the BBB and to target GABA receptors, 
and together with its metabolites exert its pharmacological action.  
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2.1.1 Diazepam 
 
N
N
O
Cl
CH3
    
N
NH
O
Cl  
 
                Diazepam 
 
       Desmethyldiazepam  
Figure 2.1 Chemical structures of diazepam and desmethyldiazepam. 
Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one) is a 
psychotropic drug which is a benzodiazepine derivative, from the class of 1, 4-
benzodiazepines (Figure 2.1). Diazepam can be used as a sedative and hypnotic in the 
management of short term insomnia, a muscle relaxant and anticonvulsant in the 
management and control of muscle spasm and alcohol withdrawal syndrome, an 
anxiolytic, to suppress tension and agitation, and it also has amnesic properties. It has a 
long duration of action. Its actions are mediated by enhancement of GABA activity. 
Diazepam binds to specific receptors in the central nervous system (CNS) and particular 
peripheral organs. The benzodiazepine receptors in the CNS have a close functional 
connection with the receptors of the GABA-ergic transmitter system. After binding to the 
benzodiazepine receptor, diazepam enhances the inhibitory effect of GABA-ergic 
transmission. 
Diazepam may be administered orally, intravenously (IV), intramuscularly (IM), or 
rectally. Oral diazepam has a rapid absorption and fast onset of action, especially in the 
fasting state, which confers a rapid and nearly complete absorption (Ochs et al., 1982). 
Oral dose of diazepam results in a plasma concentration in the range of 20 to 1010 µg/L, 
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and the metabolite desmethyldiazepam in the range of 60 to 1770 µg/L (Rutherford et al., 
1978, Greenblatt et al., 1981), with peak plasma levels achieved between 30 to 120 
minutes. In fact, the oral route is the most frequent for therapeutic use, accidental 
poisonings and abuse. It is inappropriate to administer diazepam orally during seizures. 
While the IM route may currently be the only practical approach, it has no apparent 
pharmacokinetic advantage over the oral route. Serum plasma concentrations of 
diazepam in 6 healthy subjects after administration of diazepam 20 mg IV, IM, and orally 
were 1600, 290, 490 µg/L respectively, tmax values were 15, 60, 30 minutes respectively 
(Martindale, 1982b). The time for diazepam to exert a pharmacological response is 15 
minutes to 1 hour for IV and IM routes of administration (Martindale, 1982b). In patients 
with active seizures, the IV route may be used for cessation of seizures because it has a 
rapid onset of action; yet this method is by no means without risk, hence facilities for 
protecting the airway and reversing respiratory depression with mechanical ventilation 
should be at hand. Venous thrombophlebitis can be reduced by using an emulsion 
(Diazemuls®), but at the expense of a lower plasma concentration than for IV (Valium®) 
(Fee et al., 1984). This could not be confirmed by Naylor and Burlingham (Naylor and 
Burlingham, 1985). Similarly, the rectal route can be used to treat acute repetitive 
seizures. It can be administered relatively easily and safely by non-medical personnel; 
however, suppositories generally have less predictable bioavailability as a result of slow 
and erratic absorption. Administration of rectal solutions and gels have their own 
problems which include leakage of the active ingredient through the cracks as recently 
found in the tips of the 10 and 20 mg Diastat® AcuDial® gel prefilled syringes, the 
consequence of which was an FDA alert. Leakage of gel/solution may result in reduced 
delivery of active diazepam, and thus less than that required for effective treatment of 
acute repetitive seizures, ultimately increasing the incidence of more serious problems, 
including status epilepticus.  
Thus, looking for an alternative route, such as transdermal delivery, is desired. 
Transdermal delivery has the advantage of maintaining a constant blood level of drug, 
that might be equivalent to the intravenous infusion route (Schwarz et al., 1995). Several 
studies have been conducted to enhance diazepam penetration through the skin. The 
potential of transdermal diazepam has been previously studied in vitro. Although, 
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diazepam penetrated human and hairless mouse skin, in twin chamber diffusion cells 
(Table 2.1), it was not effective in penetrating human skin in the Franz cell technique 
which was similar to the topical administration to human skin (Koch et al., 1987). 
Nevertheless, the stratum corneum is a remarkably efficient barrier. Thus attempts to use 
chemical enhancers or physical methods might be effective to assist delivery of diazepam 
through the skin into the systemic circulation. By using submicron emulsions in vivo, the 
transdermal delivery of diazepam was effective and equivalent to the level of parenteral 
delivery (Schwarz et al., 1995). 
Table 2.1 Diffusion rate, permeability coefficient, and diffusion coefficients for 
human skin with twin-chambered diffusion cells (Koch et al., 1987). 
Tissue I.D 
NO. 
Flux 
(µg/cm2/h) 
Permeability 
Coefficient (10-2 cm/h) 
Lag Time  
(hours) 
Diffusion Coefficient 
(10-6 cm2/h) 
1-Trial 1 0.29 1.2 0.64 0.76 
Trial 2 0.30 1.0 0.24 2.01 
Trial 3 0.24 0.8 0.19 3.31 
2-Trial 1 0.28 0.9 0.13 1.73 
3-Trial 1 0.42 1.4 0.43 1.12 
Trial 2 0.38 1.2 0.35 1.37 
Twin chambered (TC) cells have a 0.79-cm2 surface area for diffusion. 
The lipophilic properties of diazepam allow the molecules to penetrate both the BBB and 
the placenta, resulting in wide distribution throughout the body after administration. 
Furthermore, diazepam is highly protein bound to human plasma albumin (about 98.5%) 
and desmethyldiazepam also appears to bind the same protein (Divoll and Greenblatt, 
1981). This is explains the accumulation of diazepam in the adipose tissue and muscle 
after diazepam absorption and distribution, because it is able to build up in the body 
tissues, particularly in the fat tissue. Thus the concentrations of diazepam may exceed the 
normal therapeutic level. 
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Diazepam is metabolized in the liver via cytochrome P450 enzyme, resulting in at least 
three pharmacologically active metabolites, with half life ranging between 1–5 days. The 
most important pharmacologically active metabolite of diazepam is desmethyldiazepam, 
also known as nordiazepam (7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-
one) (Figure 2.1). Other active metabolites include temazepam and oxazepam 
(Martindale, 1996c). These metabolites are conjugated with glucuronide, and are excreted 
primarily in the urine and in the breast milk. Because of these active metabolites, the 
serum/plasma values of diazepam alone are not useful in predicting the effects of the 
drug. 
In this study a novel transdermal drug delivery system was developed (TDS®, 
Transdermal Technologies Inc, Florida, USA) to deliver diazepam through intact human 
skin. The Transdermal Drug Delivery System is a liquid formulation that can be 
combined with a drug entity to form a novel and more convenient pharmaceutical dosage 
form (spray form), to enhance drug delivery through the skin. This dosage form would 
provide a fast, simple, easy, and effective method, without leaving any residue. Early 
studies have shown that the TDS® is capable of transporting drug molecules across 
human skin (Hadley et al., 1998). Recent studies of the TDS® for lidocaine and 
testosterone administration have reported no side effects, and resulted in a) acceptable 
anaesthesia 5 minutes post application of TDS® lidocaine (Tucker et al., 2006), and b) 
TDS® testosterone was bioequivalent to AndroGel® (Chik et al., 2006). 
2.2 Study aims 
This study had two main objectives. The primary objective was to determine the 
pharmacokinetic profile of a topically applied formulation of diazepam (TDS® diazepam) 
administered by pump dispenser spray to healthy adult subjects, in comparison with 
rectal diazepam. 
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2.3 Materials and methods 
2.3.1 Study approval 
The study was approved by St Thomas Hospital Research Ethics Committee; EudraCT 
Number: 2006-002609-29. This committee is recognized by United Kingdom of Ethics 
Committee Authority under the medicine for human use (Clinical Trial Regulation) 2004, 
and is authorized to carry out the ethical review for clinical trials of investigations of 
medical products. 
2.3.2 Good clinical practice  
This study was conducted in accordance with all stipulations of the protocol and the 
Medicines for Human Use (Clinical Trials Regulations) 2004; The European Clinical 
Trials Directive (EC2001/20) transposed into UK law, and in accordance with the 
Declaration of Helsinki. 
2.3.3 Subjects 
This study involved 12 (3 male and 9 female) Caucasian healthy volunteers aged 18 to 50 
years for a period of 49 days.  
2.4 Assay procedures 
2.4.1 Drug assays 
After obtaining approval for the study from the Ethics Committee, the two dosage forms 
of diazepam were taken to the Analytical Unit of the Department of Cardiac and Vascular 
Sciences, St George’s, University of London, to test the stability of the diazepam 
(Diastat®), and the quality control of the new dosage form TDS® diazepam, which was 
carried out as agreed with Analytical Services International Ltd. 
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2.4.1.1 Chemicals and reagents 
The reference product was rectal diazepam Diastat®, AcuDial™, diazepam rectal gel 
(http://www.diastat.com/) and the TDS® was prepared by Transdermal Technologies Inc., 
Florida, USA. Diazepam was added to TDS® to give TDS® diazepam (five depressions of 
the pump spray contained 10 mg diazepam; batch number CT2007007) which was 
prepared and supplied by the Barts Pharmacy Production Department in The Royal 
London Hospital. 
The Agilent 1100 series HPLC was from Agilent Technologies UK Ltd., West Lothian, 
UK. The Supelcosil LC-18-DB, 5µm, 15cm column was obtained from Sigma Aldrich, 
Poole, Dorset, England. All HPLC grade solvents were obtained from Rathburn 
Chemicals Limited, Walkerburn, Scotland. All AnalaR grade reagents were obtained 
from Merck (BDH) Limited, Poole, Dorset, England. De-ionized water was obtained 
from the St George’s – University of London de-ionized water supply, operating a system 
installed by ELGA Limited, High Wycombe, England. The polypropylene storage and 
dilution tubes were obtained from Sarstedt Ltd, Beaumont Leys, Leicester, England. 
2.4.1.2 Stability of diazepam in Diastat® and TDS® diazepam formulations 
at various temperatures 
In this study, an HPLC/UV assay was performed to measure the stability of diazepam 
solutions at various temperatures. Two solutions were supplied, both containing 
diazepam at 10 mg/mL. In addition, four rectal preparations (Diastat®), and one TDS® 
diazepam were analyzed for diazepam. To prevent evaporation changes affecting the 
measurements, the diazepam solutions provided were aliquoted into sealed tubes. These 
tubes were then stored at approximately 4ºC, 20ºC and 35ºC. The concentration of these 
aliquots from each temperature was measured over a period of 33 days, with nine 
separate measurements made. On each occasion the concentration of the diazepam in the 
aliquots stored at 4ºC, 20ºC and 35ºC was measured by HPLC/UV using calibration 
standards prepared from a stock stored at –20ºC. 
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The reagents and consumables were acetonitrile for HPLC, phosphoric acid AnalaR, de-
ionized water (ELGA), prazepam, and diazepam. 
2.4.1.2.1 Internal standard  
Prazepam was used as internal standard, and prepared by adding 0.5mL of prazepam 
(10mg/mL in acetonitrile) in 50mL acetonitrile, and completed to 100mL with de-ionised 
water. 
2.4.1.2.2 Diazepam rectal preparation storage 
The Diastat® samples were stored at approximately 4°C prior to analysis. 
2.4.1.2.3 Diazepam solution storage (Diastat®) 
All solutions were stored at approximately 4°C prior to analysis. The samples were 
allowed to reach room temperature (nominally 20°C) and then aliquoted and stored at 
approximately 4ºC, 20ºC and 35ºC. 
Over a period of 33 days one aliquot from each solution at each temperature was assayed 
by HPLC/UV. 
2.4.1.2.4 Sample preparation (Diastat®) 
All dispensers were adjusted to deliver a 10 mg dose, one 10 mg dose from each 
dispenser was dispensed into a 100 mL volumetric flask, and the flasks were made up to 
100 mL with 50% acetonitrile in de-ionized water and placed in an ultrasonic bath for 15 
minutes. Then 10 mL of each solution was diluted to 20 mL with 50% acetonitrile, then 
500 µL of each solution was mixed with 500 µL 50% acetonitrile in de-ionized water 
containing prazepam as an internal standard (25µg/mL). The tubes were capped and 
mixed by inversion. 
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2.4.1.2.5 Calibrator preparation (Diastat®) 
500 µL of each calibration solution was mixed with 500 µL 50% acetonitrile in de-
ionized water containing prazepam as an internal standard. The tubes were capped and 
mixed by inversion. An aliquot from each tube was transferred into labelled auto sampler 
tubes. 10 µL of each aliquot was injected onto the HPLC/UV. 
2.4.1.2.6 Sample preparation (diazepam solution) 
One aliquot from each solution at each temperature was allowed to reach room 
temperature. 50 µL of each solution was pipetted into a labelled polypropylene tube. 
10mL of sample diluent (50% acetonitrile in de-ionized water) was added (1:201 
dilution). 500 µL of each solution was mixed with 500 µL 50% acetonitrile in de-ionized 
water containing prazepam as an internal standard. The tubes were capped and mixed by 
inversion. An aliquot from each tube was transferred into labelled auto sampler tubes. 
10µL of each aliquot was injected onto the HPLC/UV. 
2.4.1.2.7 Calibrator preparation (diazepam solution) 
500 µL of each calibration solution was mixed with 500 µL 50% acetonitrile in de-
ionized water containing prazepam as an internal standard. The tubes were capped and 
mixed by inversion. An aliquot from each tube was transferred into labelled auto sampler 
tubes. 10 µL of each aliquot was injected onto the HPLC/UV. 
2.4.1.2.8 Diazepam solution storage (TDS® diazepam) 
The solution was stored at approximately 4°C prior to analysis. The sample was allowed 
to reach room temperature (nominally 20°C) before analysis by HPLC/UV. 
2.4.1.2.9 Sample preparation (TDS® diazepam solution) 
The solution was allowed to reach room temperature. Four separate 50 μL aliquots of the 
solution (10 mg/mL) were pipetted into four labelled polypropylene tubes. 10 mL of 
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sample diluent (50% acetonitrile in de-ionized water) was added (1:201 dilution) to each 
tube. 500 μL of each solution was mixed with 500 μL 50% acetonitrile in de-ionized 
water containing prazepam as an internal standard. The tubes were capped and mixed by 
inversion. An aliquot from each tube was transferred into labelled auto sampler tubes. 10 
μL of each aliquot was injected onto the HPLC/UV. 
2.4.1.2.10 Calibrator preparation (diazepam solution) 
500 μL of each calibration solution was mixed with 500 μL 50% acetonitrile in de-
ionized water containing prazepam as an internal standard. The tubes were capped and 
mixed by inversion. An aliquot from each tube was transferred into labelled auto sampler 
tubes. 10 μL of each aliquot was injected onto the HPLC/UV. 
2.4.1.3 Calibration samples 
A stock solution containing diazepam was prepared by pipetting 1 mL of diazepam 
solution (10mg/mL) into a 10 mL volumetric flask and making up to the mark with 50% 
acetonitrile in de-ionized water to produce a sub-stock. 
5 mL of the stock solution was pipetted into a 50 mL volumetric flask and made up to the 
mark with 50% acetonitrile in de-ionized water to produce a sub-stock (cal1). Then 
working calibration solutions were prepared by diluting the sub stock (cal 1) with 50% 
acetonitile in de-ionized water as tabulated in Table 2.2.  
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Table 2.2 Calibration solutions preparation from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/mL) 
Volume of 
sub stock (mL)
7  10 0.00 0.00  
6 10 10.0 1.00  
5 10 20.0 2.00  
4 10 40.0 4.00  
3 10 60.0 6.00  
2 10 80.0 8.00  
      Cal 1 = Sub stock  100.0  
The calibration solutions were stored at approximately 4ºC. 
2.4.1.4 Instrumentation 
Solvent delivery was achieved using an Agilent series 1100 pump set at 1.0 mL/minute. 
Sample injection was performed by using an Agilent series 1100 auto injector. 
Chromatography was on a Supelcosil LC-18-DB, 5 µm, 15 cm x 4.6 mm column 
maintained at 50ºC with an Agilent series 1100 column oven. Detection was by an 
Agilent series 1100 UV detector set at 245 nm. 
A Windows XP computer running AZUR version 4.6 was used to record the output from 
the detector and perform integration of peak areas. The AZUR software was supplied by 
Jasco, England. 
2.5 Overall study design 
This was a randomized, single-dose, two-period, cross-over phase I (pharmacokinetic) 
study. Subjects were randomized in a 1:1 ratio to receive either a 10 mg dose of 
transdermal diazepam followed by a 10 mg dose of rectal diazepam, or vice-versa. The 
study consisted of two administration days (separated by 14 days) with a further safety 
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visit seven days after the second administration. This safety visit was done by telephone. 
Subjects went in the study for a maximum of 49 days, including screening. 
2.6 Screening 
Subjects attended the study site for screening, within 28 days of the first treatment day. They 
had had the nature of the study, the procedures and the risks fully explained, and were given 
time to consider, and the opportunity to ask any questions they had. Before any screening 
procedures occurred they signed an Informed Consent Form. At this time, a 20 mL blood 
sample was taken for routine biochemical and haematological screening, and a urine 
specimen was obtained for pregnancy testing, urinalysis and drug screening (SureStep™, 
Inverness Medical International, Cranfield, England). Only people who met the inclusion 
and exclusion criteria were allowed to participate, referred to Appendix 5.  
2.7 Admission and procedure 
On each of the two treatment days, subjects were admitted to the Study Centre, in The 
Clinical Microvascular Unit, St Bartholomew’s Hospital at about 07:30 (AM) in the 
morning. After confirming the suitability of the subject, blood pressure, radial pulse, 
respiratory rate, and body temperature were measured after subjects had rested for 10 
minutes. Then, a 20 G cannula was placed in a large antecubital vein for blood collection for 
each treatment day. A 20 mL blood sample was taken for routine biochemical and 
haematological screening. In the study plan subjects were randomized in a 1:1 manner 
(Table 2.3) to receive either a 10 mg dose of transdermal diazepam followed by a 10 mg 
dose of rectal diazepam, or vice-versa (separated by 14 days). However due to the time 
taken in the preparation of TDS® diazepam, the subjects could not be given the 
formulations in random order. Therefore, the subjects were divided into two groups, the 
first Saturday from the first week for group A to receive rectal diazepam, and the second 
Saturday from the second week for group B to receive rectal diazepam. Serial 5 mL blood 
samples were collected at 0, 15 min, 30 min, 45 min, 1, 1½, 2, 2½, 3, 4, 5, 6, 8, 10 and 12 
hour time points, after topical application of TDS® diazepam or rectal administration of 
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diazepam. The first 1–2 mL of each subsequent collection was discarded as this represented 
residual blood and saline from within the cannula. Following each blood collection the 
cannula was flushed with 7 mL sterile saline to preserve patency. 
After collection the sample was transferred to K3EDTA containing tubes, mixed then 
centrifuged at 3000 g for 10 minutes. The plasma was transferred to labelled tubes (cryo-
vials) and stored at 4º C. At the end of the study day the plasma samples were transported 
and stored at –20º C until the whole study finished. After that, all samples were analyzed. 
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Table 2.3 Randomization (R), single dose treatment, two-period, cross over with 14 
days washout period. 
 
The TDS® diazepam dose was sprayed topically to the upper chest and gently rubbed into 
the skin. Hypoallergenic surgical gloves were worn (prior to the administered dose) to 
prevent self dosing. Rectal diazepam was administered according to routine clinical practice 
following how to administer and dispose of Diastat®, AcuDial™ (http://www.diastat.com/). 
A digital photograph was taken of the application site prior to administration and after 30 
minutes (for TDS® diazepam dosing), and at the final visit. 
Providing subjects were considered fit for discharge from the study centre, they were 
allowed to depart after the final blood sample for pharmacokinetic testing had been taken 
(after 12 hours). 
Subjects No (R000) 
Treatment Washout period 
Day 
Treatment 
Day 1 Day 2 
R001 
R002 
R003 
R004 
R005 
R006 
R007 
R008 
R009 
R010 
R011 
R012 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
14 days 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
TDS® DZ10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ 10 mg 
RDZ: Rectal diazepam, TDS®DZ: Transdermal drug delivery system-diazepam 
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Upon return to the Study Centre at pre-defined times, 5 mL of blood was collected at the 
24, 32, 48 and 72 hours time points; vital signs were also recorded at these time-points. 
At the final visit, 25 mL blood was collected from which 20 mL of blood was taken for 
routine biochemical and haematological screening. 
2.8 Study restriction 
2.8.1 Concomitant therapy 
The subjects were not allowed to use any medications (prescribed or over-the-counter 
including herbal remedies, but excluding oral contraceptives) judged to be clinically 
relevant by the principal investigator during the 14 days preceding the study, and during 
the course of the study (until the final visit). 
Any concomitant medication and significant non drug therapies were recorded in the 
CRF. 
2.9 Treatments 
The investigational medicinal product in this phase I study was TDS® diazepam (10 mg 
diazepam per application, requiring five sprays from a metered-dose pump dispenser). 
The reference product was rectal diazepam (one DiaStat® AcuDial™ containing 10 mg 
diazepam). Study medication was supplied by the Barts Pharmacy Production 
Department in packages containing sufficient rectal diazepam and diazepam for 
transdermal use for the entire study.  
The topical (transdermal) application was applied to the upper chest by rubbing the skin; 
DiaStat® diazepam was administered rectally with a check for leakage 5 minutes after 
dosing. 
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2.10 Safety and tolerability 
Adverse events were recorded throughout the study, at all visits and during any telephone 
calls. The skin at the application site was assessed at each clinic visit by the investigator. 
Any dermal irritation was scored according to the OECD Guideline for Testing of 
Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion (Table 
2.4 and Table 2.5) (OECD/OCDE, 1992). Details on medical history and concomitant 
illnesses were recorded on the day of screening by conducting a medical interview of the 
subject or subject’s relative (s) and/or review of the subject’s medical records. Any 
changes observed or reported during the study were recorded. A brief physical 
examination was performed at screening and at the final visit. Vital signs were recorded 
at every visit, both pre and post-administration at defined time-points. Clinical laboratory 
tests were performed at screening, and on the day of each diazepam administration. 
Clinical and digital photographic assessment of the TDS® diazepam skin application site 
occurred before and after dosing and at follow up when the subject returned to the study 
centre for the final visit. The photograph did not identify the subjects visually. Clinic 
assessments of vital signs and physical examinations were done. 
Drug accountability records for treatment compliance were checked by the monitor 
during site visits and at the completion of the trial. 
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Table 2.4 Erythema and eschar formation, the OECD guideline for testing of 
chemicals. 
Erythema and eschar formation Score 
No erythema 0 
Very slight erythema (barely perceptible) 1 
Well-defined erythema 2 
Moderate to severe erythema 3 
Severe erythema (beet redness) to eschar formation preventing grading of 
erythema 
4 
 
Table 2.5 Oedema formation, the OECD guideline for testing of chemicals. 
Oedema Formation Score
No oedema 0 
Very slight oedema (barely perceptible) 1 
Slight oedema (edges of area well-defined by definite raising) 2 
Moderate oedema (raised approximately 1 mm) 3 
Severe oedema (raised more than 1 mm, extending beyond 
area of exposure) 
4 
2.11 Plasma analysis 
A high performance liquid chromatographic assay, with mass spectrometric detection, 
(HPLC/MS) for the measurement of diazepam and metabolites (desmethyldiazepam, 
temazepam, oxazepam) in human plasma samples from healthy volunteers given 
diazepam as part of a clinical study (pharmacokinetic study) was used. The assays were 
performed at the Analytical Unit, St George's, University of London, using a liquid/liquid 
extraction method. 
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2.11.1 Instrumentation  
Solvent delivery was achieved using a Perkin Elmer series 200 pump set at 1mL/minute. 
Sample injection was performed by using a Perkin Elmer series 200 auto injector. 
Chromatography was on a Supelcosil LC-18-DB, 5µm, 15cm, 4.6 mm column (serial 
number 62200-04) maintained at 50ºC with a Perkin Elmer series 200 column oven. 
Detection was by Applied Biosystems SCIEX API2000 Mass spectrometer. The mobile 
phase consisted of formic acid 1mL/L (85%), and methanol 75%, isocratic. 
A Windows NT computer running Analyst software (current version) was used to control 
the HPLC/MS, record the output from the detector, perform integration of peak areas and 
calculate the diazepam and metabolites concentrations. The Analyst software was 
supplied by Applied Biosystems, England. 
MS Settings: A SCIEX API4000 triple quadrupole mass spectrometer equipped with a 
heated nebulizer interface was used to introduce the sample into the mass spectrometer. 
Nitrogen was used as the collision gas. The NM20ZA high purity nitrogen and air 
generators were supplied by Peak Scientific Instruments. 
2.11.2 Good laboratory practice 
This study was conducted in accordance with United Kingdom Statutory Instrument 1999 
No 3106 as amended by SI 2004 No. 994, The Good Laboratory Practice (Codified 
Amendments Etc) Regulations, The Good Laboratory Practice Regulations, Department 
of Health, London, and the OECD Principles on Good Laboratory Practice (revised 1997, 
Issued Jan 1998) ENV/MC/CHEM (98) 17. The final report fully and accurately reflects 
the raw data generated during the conduct of the study. 
The study was carried out as agreed with Analytical Services International Ltd. and 
documented in the Analytical Unit Study Plan number. 
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2.11.3 Chemicals and reagents 
The SCIEX API2000 equipment was obtained from Applied Biosystems, England. The 
high purity air and nitrogen generators were obtained from Peak Scientific Instruments 
Ltd., Renfrew, Scotland. All AnalaR grade reagents and Hipersolv solvents were 
obtained from Merck (BDH) Limited, Poole, Dorset, England. The Supelcosil LC-18-
DB, 5µm, 15cm, 4.6 mm column (serial number 62200-04) was obtained from Merck 
(BDH) Limited, Poole, Dorset, England. De-ionized water was obtained from St 
George’s, University of London, de-ionized water supply, operating a system installed by 
ELGA Limited, High Wycombe, England. Drug-free human plasma was obtained from 
Biological Specialty Corporation, USA. The polypropylene dilution tubes were obtained 
from Sarstedt Ltd, Beaumont Leys, Leicester, England. The auto-sampler tubes were 
obtained from NLG Analytical, Adelphi Mill, Bollington, Cheshire, England. 
Diazepam, desmethyldiazepam, temazepam and oxazepam, for calibrator and control 
sample preparation, were obtained as 1mg/mL calibrated solutions in methanol supplied 
by Cerilliant and purchased from LGC Promochem, UK. Diazepam-d5, 
desmethyldiazepam-d5, temazepam-d5 and oxazepam-d5, for use as internal standards, 
were obtained as 0.1mg/mL calibrated solutions in methanol supplied by Cerilliant 
(certifications referred in Appendix 7 ) and purchased from LGC Promochem, UK.  
2.11.4 Quality assurance statement 
The study described in this report has been subject to Quality Assurance evaluation by 
the Analytical Unit’s independent Quality Assurance Officer. The study was inspected 
for the items, and at the intervals, specified below. The findings of each inspection were 
reported to the study director and analytical unit management. 
The study report inspection was designed to confirm that, as far as can be reasonably 
established, the methods described and the results incorporated in this study are a true 
and accurate reflection of the raw data. 
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2.11.5 Calibration curve criteria 
The calibration curves contained seven, non-zero, calibrators, containing diazepam, 
desmethyldiazepam, temazepam and oxazepam, assayed in duplicate. Nominal values for 
all analytes were 5, 10, 25, 100, 250, 500 and 1000 µg/L Two analyte-free samples were 
analyzed, one with internal standard and one without internal standard; neither were 
included when fitting the calibration line. 
For the calibration curve to be acceptable, the correlation coefficient (r) between 
concentration and peak area ratio, with respect to the internal standard, must be 
equivalent to, or better than, 0.98. 
The following conditions were also met in developing a calibration curve: 
 no more than 20% deviation of the LLOQ from nominal concentration 
 no more than 15% deviation of standards, other than LLOQ, from nominal 
concentration 
At least 66% of the non-zero standards must meet the above criteria, including the LLOQ 
and the calibration standard at the highest concentration. 
Using these criteria, all calibration curves were well within the ranges allowed. 
2.11.6 Accuracy 
For run acceptance there should be no more than 15% deviation of the controls from their 
nominal concentrations. At least 66% of the controls must meet the above criteria. Using 
these criteria, accuracy for the above quality control samples were well within the ranges 
allowed, as shown under accuracy. 
2.11.7 Calibration 
A combined stock solution containing diazepam, desmethyldiazepam, temazepam and 
oxazepam was prepared by pipetting 1 mL of each stock solution into a 10 mL 
volumetric flask and making up to the mark with 25% methanol in de-ionized water to 
produce a sub-stock. 
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1 mL of the combined stock solution was pipetted into a 100 mL volumetric flask and 
made up to the mark with 25% methanol in de-ionized water to produce a sub-stock 
(cal1). Then working calibration solutions were prepared by diluting the sub stock (cal 1) 
with 25% methanol in de-ionized water  
Table 2.6 Calibration solution preparation from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/L) 
Volume of 
sub stock (mL)
8  10 0.00 0.00  
7 10 5.0 0.05  
6 10 10.0 0.10  
5 10 25.0 0.25  
4 10 100.0 1.00  
3 10 250.0 2.50  
2 10 500.0 5.00  
      Cal 1 = Sub stock  1000.0  
The calibration solutions were stored at approximately 4ºC. 
2.11.8 Quality control samples 
A combined stock solution containing diazepam, desmethyldiazepam, temazepam and 
oxazepam was prepared by pipetting 1 mL of each stock solution into a 10 mL 
volumetric flask and making up to the mark with 25% methanol in de-ionized water to 
produce a sub-stock. 
0.25 mL of the stock solution was pipetted into a 10 mL volumetric flask and made up to 
the mark with analyte free human plasma to produce a sub-stock (QC 4). Then working 
controls were prepared by diluting the sub stock (QC 4) with human plasma as in Table 
2.7. 
Study comparison of rectal and dermal diazepam 
 
Page 88 of 334 
Table 2.7 Quality control preparation from sub-stock (QC4). 
QC 
No. 
Total 
Volume (mL) 
Assay 
conc (µg/L) 
Volume of 
sub stock (mL)
1 25 20.0 0.20 
2 25 200.0 2.00 
3 10 750.0 3.00 
      QC 4 = Sub stock 2500.0  
 
The control solutions were stored frozen at approximately –20ºC. 
2.11.9 Internal standard solution 
A combined stock solution containing diazepam-d5, desmethyldiazepam-d5, temazepam-
d5 and oxazepam-d5 was prepared by pipetting 1 mL of each stock solution into a 200 
mL volumetric flask and making up to the mark with de-ionized water. 
2.11.10 Extraction buffer 
Phosphate buffer (0.5 M, pH 7) containing approx. 5 mg/100 mL Orange G was prepared 
by dissolving 26g of di-sodium hydrogen phosphate, and 14g potassium dihydrogen 
phosphate in 500mL volumetric flask containing de-ionised water, and Orange G approx 
5mg/100mL. The Orange G was used to make the interface between the aqueous layer 
and the solvent layer easier to visualize. 
2.11.11 Extraction calibrators 
0.1 mL of calibration solution, 0.1 mL blank plasma, 0.05 mL internal standard, 0.25 mL 
extraction buffer and 2 mL ethylacetate were pipetted into a 4.5 mL polypropylene tube. 
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2.11.12 Control samples 
0.1 mL of control sample, 0.1 mL 25% methanol in de-ionized water, 0.05 mL internal 
standard, 0.25 mL extraction buffer and 2 mL ethylacetate were pipetted into a 4.5 mL 
polypropylene tube (Flow Chart 2.1). 
The tubes were capped, mixed (30 minutes, minimum) and then centrifuged (1509–2054 
g Relative Centrifugal Force (RCF), for 5 minutes, minimum). The organic phase (upper 
layer) from each tube was transferred to a 4.5 mL polypropylene tube and evaporated to 
dryness in the SpeedVac. The dried extracts were reconstituted in 250 µL 25% methanol, 
mixed for 1 minute and transferred to auto sampler vials. 50–100 µL of each extract was 
injected onto the analytical column. 
2.11.13 Test substances 
Diazepam, desmethyldiazepam, temazepam and oxazepam, for calibrator and control 
sample preparation, were obtained as 1 mg/mL calibrated solutions in methanol supplied 
by Cerilliant and purchased from LGC Promochem, UK. 
Diazepam-d5, desmethyldiazepam-d5, temazepam-d5 and oxazepam-d5, for use as 
internal standards, were obtained as 0.1 mg/mL calibrated solutions in methanol supplied 
by Cerilliant and purchased from LGC Promochem, UK. 
2.11.14 Calibrator and control matrices 
Calibrators were prepared in 25% methanol and spiked into plasma prior to extraction. 
Controls were prepared in diazepam, desmethyldiazepam, temazepam and oxazepam-free 
plasma. 
2.11.15 Quality control 
The three quality control samples were dispersed throughout the analytical run, with one 
quality control sample run in duplicate after every 8–15 study samples (e.g. calibration 
curve, the low quality control samples, 8–15 study samples, the medium quality control, 
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8–15 study samples, the high quality control sample, 8–15 study samples, the low quality 
control sample etc.). The nominal values for low, medium and high control samples were 
20, 200 and 750 µg/L, respectively. A minimum of two sets of quality control samples at 
each level were included in each full analytical run. Appropriate controls were included 
in shorter runs. 
The concentration of both the control samples and the patient samples were calculated by 
using the peak areas of each analyte with respect to the peak of the appropriate internal 
standard. The following conditions were met for run acceptance: 
 No more than 15% deviation of controls from their nominal concentration 
At least 66% of the controls must meet the above criteria. 
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Flow Chart 2.1 Schematic diagram of diazepam extraction procedures. 
 
Method details 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calibrators 
To a 4.5 mL propylene tube add 
100 µL calibrator 
100 µL blank plasma 
50 µL internal standard 
250 µL extraction buffer 
2 mL ethylacetate 
Samples and Quality Controls 
To a 4.5 mL propylene tube add 
100 µL sample/control 
100 µL 25 % methanol 
50 µL internal standard 
250 µL extraction buffer 
2 mL ethylacetate 
Mix for 30 minutes (minimum, IKA-Vibrax-VXR 
mixer) centrifuge for at least 5 minutes (3000-3500 g) 
Transfer solvent layer to 4.5 mL conical propylene 
tube and evaporate to dryness in SpeedVac 
Reconstitute in 250 µL 25 % methanol 
Vortex mix for 1 minute 
(Minimum, IKA-Vibrax-VXR mixer) 
Centrifuge for 2 minutes (1509 – 2054 g -optional) 
Transfer all the extract to labelled autosampler tubes 
Inject 50-100 µL of each extract onto the analytical 
column 
Internal standard: 
0.5 µg/mL diazepam-d5 
0.5 µg/mL desmethyldiazepam-d5 
0.5 µg/mL temazepam-d5 
0.5 µg/mL oxazepam-d5 
Extraction buffer: 
Phosphate buffer (0.5 M, pH 7) containing approx. 5 mg/100 mL 
Orange G to make the interface between the aqueous layer and 
the solvent layer easier to visualise 
HPLC conditions: 
Column: Any suitable 15 cm x 4.6 mm C 18 column 
Mobile phase: 
Methanol 75 % (acceptable range: 65 %-85 %) 
De –ionised water to 100 % 
Formic acid (1mL/L) 
 
Flow rate: 1.0 mL/minute (acceptable range: 0.8 – 1.2 
mL/minute) 
MS/MS setting: A SCIEX triple quadrupole mass spectrometer equipped with a turbo-ion spray (heated electro-spray, ESI) source 
was used to introduce the sample into the mass spectrometer. Nitrogen was used as the collision gas. The mode of operation was 
multiple reaction mode (MRM) 
 
Sample ID   Initial ion (m/z)  Product ion (m/z)  Ionisation mode 
Diazepam    285±0.5   193±0.5   positive 
Desmethyldiazepam   271±0.5   140±0.5   positive 
Temazepam   301±0.5   255±0.5   positive 
Oxazepam    287±0.5   241±0.5   positive 
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2.11.16 Validation of an HPLC/MS assay to measure diazepam and 
metabolites in human plasma 
2.11.16.1 Calculation of results 
Unless stated otherwise, all the results shown were calculated using a 1/x2 weighted 
regression. The peak area ratio, regression coefficient and the slope of the calibration line 
etc. were calculated from the peak area data by the Analyst program. 
2.11.16.2 Precision 
Precision was assessed using three quality control samples with nominal diazepam and 
metabolite values of 20, 200 and 750 µg/L. 
2.11.16.3 Within-assay reproducibility 
The three quality control samples were, initially, each extracted six times in one batch. 
Subsequently, the three quality control samples were each extracted six times in two 
additional batches. On each occasion a separate calibration curve was extracted.  
The lower limit of accurate quantification was set at the value of the lowest calibrator and 
the upper limit of accurate quantification was set at the value of the highest calibrator. 
The repeatability at these levels was investigated by extracting the lowest and highest 
calibrator six times in three separate assays. 
Table 2.8, Table 2.9, Table 2.10, and Table 2.11 shows the within assay reproducibility 
of diazepam, desmethyldiazepam, temazepam, and oxzepam, respectively. 
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Table 2.8 The within assay reproducibility of three batches of diazepam. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Batch 1, mean (n=6) 5.18 20.12 198.67 787.01 1036.21 
Standard Dev. 0.25 1.99 9.67 54.44 40.43 
%CV 4.91 9.93 4.87 6.92 3.90 
Accuracy 103.54 100.60 99.33 104.94 103.62 
Batch 2, mean (n=6) 5.07 19.97 197.48 759.57 979.42 
Standard Dev. 0.53 1.99 7.28 29.47 43.15 
%CV 10.37 9.95 3.69 3.88 4.41 
Accuracy 101.40 99.85 98.74 101.28 97.94 
Batch 3, mean (n=6) 5.25 19.31 202.53 797.33 976.78 
Standard Dev. 0.41 0.60 4.64 29.37 53.31 
%CV 7.89 3.13 2.297 3.687 5.46 
Accuracy 105.07 96.55 101.26 106.31 97.68 
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Table 2.9 The within assay reproducibility of three batches of desmethyldiazepam. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Batch 1, mean (n=6) 5.27 20.46 194.87 734.88 993.18 
Standard Dev. 0.24 1.68 10.65 41.29 45.98 
%CV 4.60 8.21 5.46 5.62 4.63 
Accuracy 105.46 102.30 97.43 97.98 99.32 
Batch 2, mean (n=6) 4.67 19.63 203.97 757.28 973.20 
Standard Dev. 0.24 1.42 7.08 14.19 29.29 
%CV 5.04 7.23 3.47 1.87 3.01 
Accuracy 93.39 98.17 101.99 100.97 97.32 
Batch 3, mean (n=6) 4.99 19.99 203.03 788.50 1000.65 
Standard Dev. 0.31 0.76 5.30 19.14 25.943 
%CV 6.19 3.83 2.61 2.43 2.59 
Accuracy 99.80 99.95 101.51 105.13 100.06 
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Table  2.10 The within assay reproducibility of three batches of temazepam. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Batch 1, mean (n=6) 5.22 20.00 192.97 732.99 982.56 
Standard Dev. 0.37 2.23 7.83 52.99 48.54 
%CV 7.17 11.15 4.06 7.23 4.94 
Accuracy 104.37 100.00 96.48 97.73 98.26 
Batch 2, mean (n=6) 5.27 18.62 195.93 736.16 947.58 
Standard Dev. 0.46 1.06 8.03 24.36 34.24 
%CV 8.67 5.71 4.09 3.31 3.61 
Accuracy 105.41 93.12 97.96 98.15 94.76 
Batch 3, mean (n=6) 4.54 18.99 203.26 769.91 977.60 
Standard Dev. 0.13 0.47 3.80 12.95 35.87 
%CV 2.92 2.45 1.87 1.68 3.67 
Accuracy 90.88 94.94 101.63 102.65 97.76 
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Table 2.11 The within assay reproducibility of three batches of Oxazepam. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Batch 1, mean (n=6) 5.10 19.72 194.91 731.49 991.56 
Standard Dev. 0.42 1.54 12.26 47.82 59.55 
%CV 8.16 7.83 6.29 6.54 6.01 
Accuracy 102.07 98.62 97.45 97.53 99.16 
Batch 2, mean (n=6) 4.77 19.99 201.73 738.89 973.84 
Standard Dev. 0.20 1.29 5.72 14.45 31.68 
%CV 4.22 6.44 2.83 1.96 3.25 
Accuracy 95.37 99.95 100.86 98.52 97.38 
Batch 3, mean (n=6) 4.73 20.03 196.26 741.45 959.86 
Standard Dev. 0.55 0.81 3.23 13.76 29.92 
%CV 11.53 4.03 1.65 1.86 3.12 
Accuracy 94.58 100.17 98.13 98.86 95.99 
2.11.16.4 Between-assay repeatability 
For each of the three assays mentioned above the mean concentration from each assay 
was used to calculate the between assay reproducibility. Table 2.12, Table 2.13, Table 
2.14, and Table 2.15 shows the between assay repeatability of diazepam, 
desmethyldiazepam, temazepam, and oxzepam, respectivel 
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Table 2.12 The between assay reproducibility of three batches of diazepam. 
 LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Mean (n=3) 5.17 19.80 199.56 781.30 997.47 
Standard Dev. 0.09 0.43 2.64 19.52 33.58 
%CV 1.78 2.18 1.32 2.50 3.37 
Accuracy 103.34 99.00 99.78 104.17 99.75 
Table 2.13 The between assay reproducibility of three batches of desmethyldiazepam. 
 LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Mean (n=3) 4.98 20.03 200.62 760.22 989.01 
Standard Dev. 0.30 0.41 5.01 26.93 14.19 
%CV 6.06 2.07 2.49 3.54 1.43 
Accuracy 99.55 100.14 100.31 101.36 98.90 
Table 2.14 The between assay reproducibility of three batches of temazepam. 
 LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Mean (n=3) 5.01 19.20 197.39 746.35 969.24 
Standard Dev. 0.41 0.71 5.30 20.46 18.93 
%CV 8.09 3.71 2.68 2.74 1.95 
Accuracy 100.22 96.02 98.69 99.51 96.92 
Table 2.15 The between assay reproducibility of three batches of oxazepam. 
 
LLOQ QC1 QC2 QC3 ULOQ 
Expected Conc. (µg/L) 5.00 20.00 200.00 750.00 1000.00 
Mean (n=3) 4.87 19.92 197.63 737.28 975.09 
Standard Dev. 0.21 0.17 3.61 5.17 15.89 
%CV 4.23 0.84 1.83 0.70 1.63 
Accuracy 97.34 99.58 98.82 98.30 97.51 
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2.11.16.5 Accuracy 
The criteria for the acceptance of the quality control samples were that the mean 
measured values should be within ±15% of the expected value. Using these criteria, 
accuracy for the above quality control samples were well within the ranges allowed, as 
shown under accuracy, above. 
2.11.16.6 Recovery 
Absolute recovery of diazepam and metabolites was tested at the same nominal 
concentrations as the quality control samples. Absolute recovery of the internal standards 
was tested at a nominal concentration of 250µg/L. 
2.11.16.6.1 Extracted control sample 
100µL of each aqueous control sample, 100µL blank human plasma and 50µL internal 
standard solution was processed as per the method. 
2.11.16.6.2 Non-extracted control sample 
100µL of each aqueous control sample was mixed with 50µL internal standard solution 
and 100µL 25% methanol. 
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Table 2.16 Diazepam, and metabolites recovery after extraction (Ext) compared to non 
extracted samples. 
Diazepam 
 100% 
QC1 
Ext  
QC1 
100% 
QC2 
Ext  
QC2 
100% 
QC3 
Ext  
QC3 
Mean (n=4) 20.01 7.56 198.91 68.76 753.78 234.56 
Recovery  37.8%  34.4%  31.3% 
Desmethyldiazepam 
 100% 
QC1 
Ext  
QC1 
100% 
QC2 
Ext  
QC2 
100% 
QC3 
Ext  
QC3 
Mean (n=4) 20.01 17.92 198.82 171.32 754.09 650.02 
Recovery  89.6%  85.7%  86.7% 
Temazepam 
 100% 
QC1 
Ext  
QC1 
100% 
QC2 
Ext  
QC2 
100% 
QC3 
Ext  
QC3 
Mean (n=4) 19.97 14.06 203.50 138.34 737.86 514.55 
Recovery  70.3%  69.2%  68.6% 
Oxazepam 
 100% 
QC1 
Ext  
QC1 
100% 
QC2 
Ext  
QC2 
100% 
QC3 
Ext  
QC3 
Mean (n=4) 19.99 16.82 201.79 183.07 743.80 711.39 
Recovery  84.1%  91.5%  94.9% 
 
2.11.16.7 Auto sampler stability 
In order to assess the stability of the sample extracts a single aliquot of each of the three 
quality control samples were extracted. This extract was then injected seven times over a 
Study comparison of rectal and dermal diazepam 
 
Page 100 of 334 
period of approximately 29 hours. The auto sampler was operated at ambient 
temperature, approximately 20.6ºC (maximum temperature 21.5ºC, minimum 
temperature 19.0ºC), Table 2.17, Table 2.18, Table 2.19, and Table 2.20 shows the 
stability of diazepam, desmethyldiazepam, temazepam, and oxazepam, respectively. 
Table 2.17 The auto sampler stability of diazepam after extraction, over a period of 
approximately 29 hours. 
 QC1 QC2 QC3 Elapsed time  
Data (µg/L) (µg/L) (µg/L) (Hrs) 
1 19.10 195.63 746.70 0 
2 18.43 196.20 741.79 3 
3 21.75 202.07 754.19 6 
4 18.01 188.91 752.14 12 
5 19.01 199.88 725.06 21 
6 19.50 197.66 729.16 26 
7 19.28 194.10 718.04 29 
Table 2.18 The auto sampler stability of desmethyldiazepam after extraction, over a 
period of approximately 29 hours 
 QC1 QC2 QC3 Elapsed time 
Data (µg/L) (µg/L) (µg/L) (Hrs) 
1 20.13 188.46 715.13 0 
2 19.30 183.82 696.02 3 
3 19.63 184.38 713.90 6 
4 19.37 183.94 720.901 12 
5 19.92 185.32 705.65 21 
6 21.02 186.96 704.42 26 
7 18.72 183.56 715.98 29 
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Table 2.19 The auto sampler stability of temazepam after extraction, over a period of 
approximately 29 hours 
 
 QC1 QC2 QC3 Elapsed time 
Data (µg/L) (µg/L) (µg/L) (Hrs) 
1 18.11 206.69 741.99 0 
2 21.40 205.11 785.17 3 
3 22.41 211.38 740.88 6 
4 21.18 200.59 772.09 12 
5 22.04 200.88 726.37 21 
6 22.38 203.29 807.22 26 
7 17.96 187.37 718.19 29 
 
Table 2.20 The auto sampler stability of oxazepam after extraction, over a period of 
approximately 29 hours 
 QC1 QC2 QC3 Elapsed time  
Data (µg/L) (µg/L) (µg/L) (Hrs) 
1 21.90 196.95 674.17 0 
2 17.34 196.98 744.13 3 
3 19.29 184.62 680.75 6 
4 17.29 186.54 688.28 12 
5 14.36 184.02 750.37 21 
6 21.17 199.49 752.25 26 
7 21.36 197.46 763.35 29 
2.11.16.8 Dilution accuracy 
Assay linearity, with a view to dilution of samples producing results above the ULOQ, 
was assessed by the preparation of an out of range control sample. Diazepam and 
metabolites were added to human plasma to produce a sample with a nominal 
concentration of 2500µg/L (QC4). This sample was diluted 1 in 10 and 1 in 25 using 
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human plasma. Each dilution was assayed in quadruplicate as shown in Table 2.21, Table 
2.22, Table 2.23, and Table 2.24. 
Table 2.21 The dilution accuracy of diazepam concentration samples. 
Data QC4 Diluted 1:10 QC4 Diluted 1:25 
Expected Conc. 2500.00 2500.00 
Mean (n=4) 2489.61 2617.26 
Standard Dev. 75.98 43.25 
%CV 3.05 1.65 
Accuracy 99.58 104.69 
 
Table 2.22 The dilution accuracy of desmethyldiazepam concentration samples. 
Data QC4 Diluted 
1:10 
QC4 Diluted 
1:25 
Expected Conc. 2500.00 2500.00 
Mean (n=4) 2492.99 2467.73 
Standard Dev. 36.47 44.65 
%CV 1.46 1.81 
Accuracy 99.72 98.71 
 
Table 2.23 The dilution accuracy of temazepam concentration samples. 
Data QC4 Diluted 1:10 QC4 Diluted 1:25 
Expected Conc. 2500.00 2500.00 
Mean (n=4) 2549.79 2485.79 
Standard Dev. 50.91 46.95 
%CV 1.99 1.89 
Accuracy 101.99 99.43 
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Table 2.24 The dilution accuracy of oxazepam concentration samples. 
Data QC4 Diluted 1:10 QC4 Diluted 1:25 
Expected Conc. 2500.00 2500.00 
Mean (n=4) 2495.72 2532.12 
Standard Dev. 20.64 13.36 
%CV 0.83 0.53 
Accuracy 99.83 101.28 
2.11.16.9 Stability 
In order to assess the stability of the analytes in human plasma the three quality control 
samples were stored either at room temperature (temperature range 19.5ºC to 22.5ºC) for 
approximately 24 hours or at approximately 4ºC (temperature range 4.0ºC to 6.6ºC) for 
approximately 24 hours. These samples were then extracted as per the method on page 88 
, and Flow Chart 2.1. 
Table 2.25 Stability of diazepam in human plasma at room and 4 ºC temperature over 24 
hours. 
Stability data Data QC1 QC2 QC3 
Expected Conc. (µg/L)  20.00 200.00 750.00 
Time 0  Mean (n=6) 20.12 198.67 787.01 
Room temperature Mean (n=4) 18.42 203.98 759.06 
4°C  Mean (n=4) 17.85 198.59 761.48 
 
Table 2.26 Stability of desmethyldiazepam in human plasma at room and 4 ºC 
temperature over 24 hours. 
Stability data Data QC1 QC2 QC3 
Expected Conc. (µg/L)  20.00 200.00 750.00 
Time 0  Mean (n=6) 20.46 194.87 734.88 
Room temperature  Mean (n=4) 19.83 206.76 741.16 
4°C  Mean (n=4) 20.98 205.69 760.79 
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Table 2.27 Stability of temazepam in human plasma at room and 4 ºC temperature over 
24 hours. 
Stability data Data QC1 QC2 QC3 
Expected Conc. (µg/L)  20.00 200.00 750.00 
Time 0  Mean (n=6) 20.00 192.97 732.99 
Room temperature  Mean (n=4) 18.51 198.66 702.68 
4°C  Mean (n=4) 19.07 201.17 748.32 
Table 2.28 Stability of oxazepam in human plasma at room and 4 ºC temperature over 
24 hours. 
Stability data Data QC1 QC2 QC3 
Expected Conc. (µg/L)  20.00 200.00 750.00 
Time 0  Mean (n=6) 19.72 194.91 731.49 
Room temperature Mean (n=4) 19.92 203.76 726.61 
4°C  Mean (n=4) 20.29 198.38 750.40 
2.11.16.10 Freeze / thaw stability 
In order to assess the stability of the analytes in human plasma samples during three 
freeze/ thaw cycles aliquots of each of the three quality control samples were stored 
frozen. These samples were then removed from the freezer, allowed to defrost and then 
extracted as per the method on page 88, and Flow Chart 2.1. The control samples were 
then re-frozen. A total of three freeze / thaw cycles were performed. The maximum and 
minimum temperatures recorded were -14.3ºC and -26.5ºC respectively. 
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Table 2.29 Stability of diazepam in human plasma during three freeze/ thaw cycles. 
 
Data QC1 QC2 QC3 
 Expected Conc. 20.00 200.00 750.00 
Time 0 stability data Mean (n=6) 20.12 198.67 787.01 
Freeze / thaw stability - Cycle 1 Mean (n=4) 18.98 201.37 774.95 
Freeze / thaw stability - Cycle 2 Mean (n=4) 17.91 191.75 730.93 
Freeze / thaw stability - Cycle 3 Mean (n=4) 18.29 195.131 759.25 
Table 2.30 Stability of desmethyldiazepam in human plasma during three freeze/ thaw 
cycles. 
 
Data QC1 QC2 QC3 
 Expected Conc. 20.00 200.00 750.00 
Time 0 stability data Mean (n=6) 20.46 194.87 734.88 
Freeze / thaw stability - Cycle 1 Mean (n=4) 20.69 210.70 762.91 
Freeze / thaw stability - Cycle 2 Mean (n=4) 19.28 191.21 729.68 
Freeze / thaw stability - Cycle 3 Mean (n=4) 18.76 193.99 740.42 
Table 2.31 Stability of temazepam in human plasma during three freeze/ thaw cycles. 
 
Data QC1 QC2 QC3 
 Expected Conc. 20.00 200.00 750.00 
Time 0 stability data Mean (n=6) 20.00 192.97 732.99 
Freeze / thaw stability - Cycle 1 Mean (n=4) 18.28 200.36 749.54 
Freeze / thaw stability - Cycle 2 Mean (n=4) 19.61 194.03 744.87 
Freeze / thaw stability - Cycle 3 Mean (n=4) 18.307 192.06 726.35 
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Table 2.32 Stability of oxazepam in human plasma during three freeze/ thaw cycles. 
 
Data QC1 QC2 QC3 
 Expected Conc. 20.00 200.00 750.00 
Time 0 stability data Mean (n=6) 19.72 194.91 731.49 
Freeze / thaw stability - Cycle 1 Mean (n=4) 19.19 198.88 742.32 
Freeze / thaw stability - Cycle 2 Mean (n=4) 19.51 188.26 741.91 
Freeze / thaw stability - Cycle 3 Mean (n=4) 17.84 188.41 722.29 
2.11.16.11 Matrix effects 
Matrix effects on the measurement of diazepam and metabolites were tested at the same 
nominal concentration as the middle quality control sample (QC2). A matrix effect on the 
measurement of the internal standards was tested at a nominal concentration of 250µg/L. 
A spiking solution containing diazepam, desmethyldiazepam, temazepam, oxazepam and 
the internal standards were prepared by mixing 1mL of the aqueous QC2 (recovery QC2), 
0.5mL of the internal standard solution and 1mL of 25% methanol. 
2.11.16.11.1 Extracted control sample 
In order to assess the possibility of matrix effects (ion suppression) six different plasma 
samples were extracted without internal standard, as per the method. To each of the dried 
extract from the six samples 250µL of the spiking solution was added. 
2.11.16.11.2 Non-extracted reference sample: 
The reference solution was injected without further processing. 
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Table 2.33 Matrix effects on the measurement of diazepam and metabolites. 
 Diazepam Desmethyldiazepam Temazepam Oxazepam 
Data 
100% 
QC2 
Ext. 
QC2 
100% 
QC2 
Ext  
QC2 
100% 
QC2 
Ext  
QC2 
100% 
QC2 
Ext 
QC2 
µg/L 
 
200.0 
(n=4) 
200.0 
(n=6) 
200.0 
(n=4) 
200.0 
(n=6) 
200.0 
(n=4) 
200.0 
(n=6) 
200.0 
(n=4) 
200.0 
(n=6)
Mean  200.0 205.7 200.0 197.5 200.0 196.1 200.0 191.9
SDev. 1.50 3.69 3.97 3.94 2.35 5.21 2.03 4.87 
%CV 0.75 1.80 1.98 1.99 1.177 2.66 1.02 2.53 
Accuracy 100.0 102.9 100.0 98.8 100.0 98.1 100.00 95.9 
 
2.11.16.12 Validation result 
The results from this validation study demonstrate the ability of this method to perform 
the assay for diazepam and metabolites reproducibly and accurately, and to establish 
suitable internal quality control systems for the assay. The assay was designed to provide 
the best sensitivity for the metabolites as these are expected to be present at lower 
concentration than the primary analyte (diazepam). The LLOQ for diazepam and the 
metabolites was 5µg/L with signal to ratio above 10. The separations were 2.66, 2.81, 
3.17, and 3.38 minutes for oxazepam, temazepam, desmethyldiazepam, and diazepam, 
respectively. Under these conditions, the recovery of all three metabolites was greater 
than 70%, but the recovery for diazepam was only approximately 35%. This assay was 
still found to possess both the sensitivity and specificity necessary to measure the analyte 
in human plasma samples at the concentrations attained during clinical therapeutic use of 
the drug. 
2.11.17 Data analysis 
Pharmacokinetic parameters and the statistical analysis were performed using Microsoft 
Excel 2007. Cmax, tmax, tlag were determined directly from the individual plasma 
concentration time points. The AUC was calculated using the linear trapezoidal method. 
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The difference between treatments for AUC0-72h and Cmax were analyzed after logarithmic 
transformation using analysis of variance (ANOVA) for cross over studies. Additionally 
to 90% confidence intervals (CI), the data were summarized by medians, maximum, and 
minimum values. 
The secondary pharmacokinetic variables included: an estimation of t1/2 was made; 
bioavailability of TDS® diazepam relative to rectal diazepam (A:B) was calculated (90% 
CI for the ratio of population Least Squares geometric means [TDS/rectal] for key 
pharmacokinetic variables), also for B:A. The elimination half-life of diazepam from the 
transdermal and rectal routes was compared using non transformed data and parametric 
techniques. 
Bioequivalence testing was based upon the 90% CI for the ratio of population mean 
between two treatments. This is equivalent to the corresponding two one-sided test 
procedures, with the null hypothesis of bioequivalence at the 5% significance level 
(Schuirmann, 1987). Formulations were considered bioequivalence if the 90% CI of the 
ratio, test to reference (A:B), was contained within 80 to 125% (Nation and Sansom, 
1994, FDA, 2001b, EMEA, 2001).  
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2.12 Results 
2.12.1  Analytical result 
The results from this study demonstrate the ability of the HPLC-UV method to separate 
diazepam and the internal standard prazepam reproducibly and accurately at retention 
time of 5.01, and 8.60 minutes, respectively. The LLOQ was set at 10 µg/mL as the lower 
calibration criteria. Figure 2.2 illustrate chromatogram obtained from extracted rectal gel 
containing 10mg/mL diazepam per 2 g gel.  
 
Figure 2.2 Chromatograph obtained from extracted rectal gel (diazepam 50 μg/mL) 
spiked with IS of 25 μg/mL prazepam, displayed at 245 nm. 
2.12.2 Stability test of rectal diazepam (Diastat®) 
The HPLC results from this study demonstrated that the diazepam in the solutions 
supplied was stable at temperatures up to 35ºC for at least 33 days (Figure 2.3, Figure 
2.4), Table 2.34 show the temperature stability test data. 
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Figure  2.3 Stability test for diazepam solution (1) at temperatures of 4, 20, and 35 ºC 
over a period of 33 days. 
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Figure  2.4 Stability test for diazepam solution (2) at temperatures of 4, 20, and 35 ºC 
over a period of 33 days. 
Table  2.34 The temperature stability test data for diazepam. 
Temperature  Mean Temp Minimum Temp Maximum Temp 
4ºC 3.5ºC 2.0ºC 9.5ºC 
20ºC 19.5ºC 18.0ºC 22.0ºC 
35ºC 34.5ºC 29.5ºC 36.0ºC 
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The results from this study also demonstrated the ability of the Analytical Unit to 
perform the assay for diazepam reproducibly and accurately, and to establish suitable 
internal quality control systems for the assay. 
2.12.3 Quality control of TDS® diazepam 
The HPLC results from this study demonstrated that the diazepam in the solutions 
supplied is within the acceptable range (90–110%) and had passed QC. 
2.12.4 Dose calculation  
2.12.4.1 Rectal diazepam 
Statistical analysis and calculation of the mean, standard deviation (SD), coefficient of 
variation percentage (CV%), and standard normal distribution (SND, or z) of the data 
were analyzed (Table 2.35 and Table 2.36), and showed that:  
The minimum and maximum doses of diazepam were 9.48 and 10.04 mg, respectively, 
with an average dose of 9.84 mg, after an application of rectal gel of diazepam to the 
healthy volunteer, the CV% was 2%. The doses came from a minimum and maximum of 
1.97 and 2.17 g of gel, respectively, with an average of 2.13 g gel, CV% was 3%. 
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Table 2.35 Ten samples showing gel weight containing 10 mg diazepam (see Table 
2.36 for the average concentration). 
No of Sample Flask (g) Flask+ Gel (g) Gel (g) z a (SND) 
B01 63.32 65.46 2.15 0.28 
B02 49.05 51.21 2.17 0.60 
B03 61.21 63.31 2.09 -0.61 
B04 64.10 66.26 2.16 0.43 
B05 63.83 65.98 2.15 0.42 
B06 56.14 58.29 2.15 0.32 
B07 62.61 64.76 2.15 0.33 
B08 61.52 63.48 1.97 -2.68 
B09 54.64 56.79 2.15 0.38 
B10 55.06 57.22 2.16 0.53 
Mean   2.13  
SD b   0.061  
CV% c   3%  
Median   2.15  
Q1 d   2.15  
Q3 e   2.16  
z a Standard Normal Distribution (SND), SD b: Standard Deviation, CV% c: Coefficient of 
Variation Percentage, Q1 d: First Quartile, Q3 e: Third Quartile  
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Table 2.36 Ten samples showing the average concentration (mg/L) of diazepam in 
about 2 g gel. 
NO 
Sample 
Conca 
(mg/L) (1) 
Conca 
(mg/L) (2)
Time 
(minutes)
AvergConcb
(mg/L) 
zc 
(SND) 
Dose 
(mg) 
1 98.0 96.8 10 97.4 -0.65 9.74 
2 98.1 98.9 20 98.5 0.041 9.85 
3 98.0 91.6 30 94.8 -2.30 9.48 
4 99.5 97.7 40 98.6 0.104 9.86 
5 98.5 102.0 50 100.25 1.147 10.03 
6 98.2 98.4 60 98.3 -0.085 9.83 
7 101.1 99.6 70 100.35 1.21 10.04 
8 98.0 98.1 80 98.05 -0.24 9.81 
9 100.3 98.6 90 99.45 0.64 9.95 
10 98.1 99.2 100 98.65 0.14 9.87 
Mean    98.44   
SDd    1.58   
CV%e    2%   
Median    98.55   
Q1f    98.11   
Q3g    99.25   
Conca: Concentration, AvergConcb: Average Concentration, zc: Standard Normal Distribution 
(SND), SD d: Standard Deviation, CV% e: Coefficient of Variation Percentage, Q1 f: First Quartile, 
Q3 g: Third Quartile. 
2.12.4.2 TDS® diazepam 
Summary of analysis data of the mean, standard deviation (SD), and coefficient of 
variation percentage (CV%) are shown in Table 2.38: 
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The result shows that minimum and maximum doses of diazepam were 10.12 and 10.22 
mg/mL, respectively, with an average dose of 10.17 mg/mL, after an application of 
diazepam (TDS®) drug, by applying 5 sprays to the skin. 
Table 2.37 Working calibration concentration of diazepam. 
No.# Sample 
Peak area  
diazepam 
Peak area 
ratio 
Results (μg/mL) 
1 100μg/mL Calibrator 2202.13 0.62 101.11 
2 80μg/mL Calibrator 1955.81 0.49 80.34 
3 60μg/mL Calibrator 1441.37 0.36 59.81 
4 40μg/mL Calibrator 978.17 0.24 39.31 
5 20μg/mL Calibrator 509.91 0.12 20.08 
6 10μg/mL Calibrator 247.59 0.06 10.01 
Table 2.38 Diazepam concentration in sample solution. 
No.# Sample 
Peak area 
diazepam 
Peak area 
ratio 
Results (μg/mL) 
1 Dilution 1 1185.99 0.310 10224.05 
2 Dilution 2 1189.83 0.310 10219.28 
3 Dilution 3 1177.97 0.307 10121.83 
4 Dilution 4 1241.13 0.307 10125.87 
   Mean 10172.76 
   SD 56.53 
   CV% 1% 
   Median 10172.58 
   Maximum 10224.05 
   Minimum 10121.83 
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2.13 Plasma assay 
2.13.1 Analyte mass transitions 
Table 2.39 show diazepam, metabolites, and internal standard mass transitions. 
Table 2.39 Analyte mass transitions, showing Q1 Mass and Q3 Mass. 
Analyte name 
Initial ion (m/z),
Q1 Mass (amu) 
Product ion (m/z)
Q3 Mass (amu) 
Ionisation mode
(TIC) 
Diazepam 285.1 193.3 Positive 
Desmethyldiazepam 271.1 140.2 Positive 
Temazepam 301.1 255.3 Positive 
Oxazepam 287.1 241.2 Positive 
Diazepam-d5 290.2 198.2 Positive 
Desmethyldiazepam-d5 276.1 140.1 Positive 
Temazepam-d5 306.2 260.3 Positive 
Oxazepam-d5 292.1 246.3 Positive 
2.13.2 Quality control data results 
Table 2.40, Table 2.41, Table 2.42, and Table 2.43 show a summary of statistical analysis 
of the mean, standard deviation, and coefficient of variation percentage, from the QC 
results obtained during the study of diazepam, desmethyldiazepam, temazepam, and 
oxazepam. 
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Table 2.40 Three quality control (QC) measurements of diazepam. 
Data QC 1 QC 2 QC 3 
Expected Conc (µg/L). 20.00  200.00 750.00 
N  32 of 32 32 of 32 32 of 32 
Mean (µg/L) 20.51 205.52 753.01 
Low (µg/L) 18.46 182.04 688.79 
High (µg/L) 22.80 227.18 818.83 
SD 1.27 8.83 26.98 
CV% 6.21 4.29 3.58 
Accuracy 102.53 102.76 100.40 
 
Table 2.41 Three quality control (QC) measurements of desmethyldiazepam. 
Data QC 1 QC 2 QC 3 
Expected Conc (µg/L). 20.00 200.00 750.00 
N 32 of 32 32 of 32 32 of 32 
Mean (µg/L) 20.78 203.69 742.40 
Low (µg/L) 17.71 189.66 704.72 
High (µg/L) 22.62 225.72 832.38 
SD 1.21 8.82 26.94 
CV% 5.82 4.33 3.63 
Accuracy 103.91 101.84 98.99 
 
Table 2.42 Three quality control (QC) measurements of temazepam. 
Data QC 1 QC 2 QC 3 
Expected Conc (µg/L). 20.00 200.00 750.00 
N 31 of 32 32 of 32 32 of 32 
Mean (µg/L) 21.17 212.89 765.23 
Low (µg/L) 18.72 194.90 700.88 
High (µg/L) 22.81 227.82 840.33 
SD 1.24 9.23 31.53 
CV% 5.85 4.34 4.12 
Accuracy 105.84 106.44 102.03 
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Table 2.43 Three quality control (QC) measurements of oxazepam. 
Data QC 1 QC 2 QC 3 
Expected Conc (µg/L). 20.00 200.00 750.00 
N  32 of 32 32 of 32 32 of 32 
Mean (µg/L) 20.69 205.48 753.62 
Low (µg/L) 18.29 185.29 685.36 
High (µg/L) 22.82 224.47 809.22 
SD 1.22 9.35 29.84 
CV% 5.90 4.55 3.96 
Accuracy 103.43 102.74 100.48 
2.14 Overall study results 
Twelve healthy males and females (Table 2.44) out of thirteen recruited subjects 
completed the protocol in this study. Subject number S01 who did not meet the inclusion 
and exclusion criteria was not included. No side effects/events were observed in any 
subjects in this study. Skin digital photographs of subjects have been taken, prior to, 30 
minutes after, and one week after the diazepam dose. In Figure 2.5 (A: pre- dose, B: 30 
minutes post-dose, and C: one week post-dose) the images show that there was no sign of 
irritation, itching, inflammation, swelling, or other dermatological problems. The 
diagnoses were assessed by a physician for all subjects. All of the plasma samples were 
analyzed for diazepam and its metabolites (desmethyldiazepam, temazepam, and 
oxazepam) by high performance liquid chromatography assay, with mass spectrometric 
detection, (HPLC/MS). The assay was capable of detecting diazepam and 
desmethyldiazepam at concentrations above 5 µg/L, but not for temazepam and 
oxazepam. 
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Table 2.44 Demographic data for 12 subjects in the rectal and TDS® diazepam study. 
 
Subject Age 
(years) 
Sex Height 
(m) 
Weight 
(kg) 
Body Mass 
Index (kg/m2)
S02 41 M 1.81 85 26 
S03 25 M 1.81 114 35 
S04 25 F 1.77 67 21 
S05 19 F 1.68 58 21 
S06 22 F 1.76 62 20 
S07 24 F 1.58 50 20 
S08 33 F 1.70 67 23 
S09 22 F 1.63 55 21 
S10 32 F 1.55 58 24 
S11 25 F 1.74 78 26 
S12 25 F 1.66 78 28 
S13 47 M 1.69 68 24 
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Figure  2.5 Application of TDS® diazepam on the chest shows no marks in A (pre-
dose), B (30 minutes post-dose), and C (one week post-dose) at the site area. 
Figure  2.6 and Figure  2.7 show the plot of the mean plasma concentration in 12 subjects, 
linear and logarithmic axis respectively, for diazepam after both treatments. Figure  2.8, 
Figure  2.9, Figure  2.10, Figure  2.11 show the plot of 12 subjects with the mean line for 
rectal and TDS® diazepam, respectively. In Figure  2.11, diazepam was detected after 24 
hours; this may be due to diazepam metabolism. The comparison of plasma concentration 
of diazepam (µg/L) versus time (h), shows that diazepam concentration in plasma was 
higher after rectal diazepam (Diastat®) compared to TDS® diazepam.  
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In addition, Figure 2.12 and Figure 2.13 show the plots of the mean plasma concentration 
in 12 subjects, linear and logarithmic axis respectively, for desmethyldiazepam, after both 
treatments. Figure 2.14 and Figure 2.15, show the plots of desmethyldiazepam linear and 
logarithmic axis, respectively, from 12 subjects, with the mean value, following rectal 10 
mg doses of diazepam. Figure 2.16 and Figure 2.17 show the plots of desmethyldiazepam 
linear and logarithmic axis, respectively, in 12 subjects, with the mean value, following 
TDS® 10 mg doses of diazepam. Figure 2.18 and Figure 2.19 show the DotPlots of the 
plasma Cmax concentration for diazepam and desmethyldiazepam, respectively. 
Furthermore, the pharmacokinetic parameters of diazepam and desmethyldiazepam, 
AUC, Cmax, and tmax are summarized in Table 2.47 and Table 2.48. The AUC, Cmax, and 
tmax values were calculated for 0–72 hours. The geometric mean, mean, the 25th quartile, 
median, 75th quartile of the AUC0-72h, and Cmax were higher following application of 
rectal diazepam (Diastat®). The tlag was 0.25 h for rectal diazepam, and less than 0.75 h in 
the TDS® 10 mg dose of diazepam.  
From these results, the 90% CI on the relative difference of diazepam ratio (Table 2.45) 
for the AUC0-72h (up to 43.30%) and the Cmax (0–72h) (up to 22.40%) between TDS® 
diazepam (A) and rectal diazepam (Diastat®) (B) were not contained within the 
bioequivalence limit (80–125%), Cmax (0–72h): 7.3–10.1–14% and AUC0-72h: 19.7–27.2–
37.6% (Figure 2.20). 
In addition the CI values obtained for the desmethyldiazeapam ratio are summarized in 
Figure 2.21 show that the AUC0-72h (up to 81.10%) and the Cmax(0–72h) (up to 79.9%) 
between TDS® diazepam (A) and rectal diazepam (Diastat®) (B) were not contained 
within the bioequivalence limit (80–125%), Cmax (0–72h): 37.6%–45%–53.8% and 
AUC0-72h: 33.4%–44.0%–57.8% (Figure 2.21). In subject number nine (S09), Cmax and 
AUC ratio were 79.9% and 79.2%, respectively, and in subject number four (S04) Cmax 
and AUC ratio were 65.9% and 81.1%, respectively. 
Table 2.40 summarized the QC sample result obtained during the analysis of diazepam by 
HPLC/MS. From the concentration obtained, mean, low, high standard deviation, 
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coefficients of variation (CV%), and accuracy, the CV for imprecision and inaccuracy 
were all below 15%. 
Table 2.45 Bioequivalence parameters for TDS® diazepam (test formulation, A) versus 
rectal diazepam (reference formulation, B). 
 
-90% CI Point 
Estimate % 
+90% CI 
tmax 1.63 2.13 6.75 
Cmax (A:B) 
Cmax (B:A) 
7.3 
715.8 
10.1 
990.1 
14.0 
1367.7 
AUC0-72h (A:B) 
AUC0-72h (B:A) 
19.7 
266.1 
27.2 
367.6 
37.6 
507.8 
 
Table 2.46 Bioequivalence parameters for desmethtyldiazepam, TDS® diazepam (test 
formulation, A) versus rectal diazepam (reference formulation, B). 
 -90% CI 
Point 
Estimate % +90% CI 
tmax -20 -4 12 
Cmax (A:B) 
Cmax (B:A) 
37.6 
186.0 
45.0 
222.4 
53.8 
266.0 
AUC0-72h (A:B) 
AUC0-72h (B:A) 
33.4 
172.9 
44.0 
227.5 
57.8 
299.4 
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Table 2.47 Derived diazepam pharmacokinetic parameters for rectal and TDS® diazepam (10mg). 
 Rectal Rectal TDS TDS - Rectal Rectal TDS TDS/Rectal Rectal TDS TDS/Rectal 
 t½ tmax tmax Difference Cmax Cmax Ratio AUC0-72h AUC0-72h Ratio 
Subject (h) (h) (h) (h) (µg/L) (µg/L)  (µg/L.h) (µg/L.h)  
S02 73.2 0.50 3.00 2.50 308.7 37.0 12.0% 4401.5 1218.6 27.7% 
S03 53.3 1.00 4.00 3.00 375.4 21.0 5.6% 4318.8 1103.0 25.5% 
S04 57.4 0.75 2.00 1.25 286.8 33.8 11.8% 5321.4 1695.1 31.9% 
S05 147.0 0.50   309.7   2737.2   
S06 53.6 0.50 12.00 11.50 198.7 27.6 13.9% 4403.5 1608.8 36.5% 
S07 32.4 0.50 1.50 1.00 349.2 26.5 7.6% 5503.8 495.5 9.0% 
S08 63.3 0.50 24.00 23.50 254.3 7.3 2.9% 4500.3 380.0 8.4% 
S09 50.5 1.00 3.00 2.00 343.3 63.4 18.5% 4253.8 1842.0 43.3% 
S10 396.0 0.50 2.50 2.00 359.2 23.6 6.6% 4083.8 1238.1 30.3% 
S11 22.3 0.75 2.00 1.25 138.3 17.0 12.3% 1518.9 651.1 42.9% 
S12 39.4 0.75 2.50 1.75 297.8 66.8 22.4% 3900.1 1584.4 40.6% 
S13 28.9 1.00 3.00 2.00 378.7 53.1 14.0% 4358.8 1837.9 42.2% 
           
Geomean 59.2    289.7 29.1 10.1% 3929.3 1104.5 27.2% 
Mean 84.8    300.0 34.3 11.6% 4108.5 1241.3 30.8% 
SD 103.2    72.9 19.2 5.7% 1066.1 533.1 12.5% 
CV 121.7%    24.3% 56.0% 49.6% 25.9% 42.9% 40.8% 
          
Minimum 22.3 0.50 1.50 1.00 138.3 7.3 2.9% 1518.9 380.0 8.4% 
25th 37.7 0.50 2.25 1.50 278.7 22.3 7.1% 4037.9 877.1 26.6% 
Median 53.4 0.63 3.00 2.00 309.2 27.6 12.0% 4338.8 1238.1 31.9% 
75th 65.8 0.81 3.50 2.75 351.7 45.1 14.0% 4427.7 1652.0 41.4% 
Maximum 396.0 1.00 24.00 23.50 378.7 66.8 22.4% 5503.8 1842.0 43.3% 
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Table 2.48 Derived desmethyldiazepam pharmacokinetic parameters for rectal and TDS® diazepam (10mg). 
 Rectal TDS TDS - Rectal Rectal TDS TDS/Rectal Rectal TDS TDS/Rectal 
 tmax tmax Difference Cmax Cmax Ratio AUC0-72 AUC0-72 Ratio 
Subject (h) (h) (h) (µg/L) (µg/L)  (µg/L.h) (µg/L.h)  
S02 72 72 0.00 27.6 15.0 54.3% 1440.6 899.3 62.4% 
S03 72 72 0.00 22.9 13.5 59.0% 1302.6 806.9 61.9% 
S04 72 72 0.00 38.7 25.5 65.9% 1932.4 1567.0 81.1% 
S05 24 32 8.00 23.7 6.8 28.7% 754.8 132.6 17.6% 
S06 72 72 0.00 41.1 19.7 47.9% 1848.6 1031.3 55.8% 
S07 48 24 -24.00 57.6 15.2 26.4% 3537.8 578.7 16.4% 
S08 72 1.5 -70.50 41.0 11.6 28.3% 2194.8 726.8 33.1% 
S09 72 32 -40.00 31.8 25.4 79.9% 1875.2 1485.9 79.2% 
S10 72 32 -40.00 37.6 15.6 41.5% 1686.5 1002.2 59.4% 
S11 24 48 24.00 20.7 8.7 42.0% 1275.8 429.8 33.7% 
S12 48 72 24.00 36.4 17.7 48.6% 2103.5 992.6 47.2% 
S13 24 48 24.00 32.5 15.1 46.5% 1939.7 810.5 41.8% 
          
Geomean    33.0 14.8 45.0% 1714.9 753.8 44% 
Mean    34.3 15.8 47.4% 1824.4 872.0 49% 
SD    10.2 5.7 16.0% 678.4 401.7 21% 
CV    29.8% 36.2% 33.7% 37.2% 46.1% 43.6% 
         
Minimum 24.00 1.50 -70.50 20.7 6.8 26.4% 754.8 132.6 16.8% 
25th 42.00 32.00 -28.00 26.6 13.0 38.3% 1406.1 689.7 33.5% 
Median 72.00 48.00 0.00 34.5 15.2 47.2% 1861.9 854.9 51.5% 
75th 72.00 72.00 12.00 39.3 18.2 55.5% 1980.7 1009.5 62.1% 
Maximum 72.00 72.00 24.00 57.6 25.5 79.9% 3537.8 1567.0 81.1% 
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Figure 2.6 Mean plasma diazepam concentration versus time in 12 subjects following 
a 10 mg dose rectally (filled red circles) and dermally by TDS® diazepam 
(filled blue squares), linear concentration axis. 
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Figure 2.7 Mean plasma diazepam concentration versus time in 12 subjects following 
a 10 mg dose rectally (filled red circles) and dermally by TDS® diazepam 
(filled blue squares), logarithmic concentration axis. 
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Figure 2.8 Plasma diazepam concentration versus time in 12 subjects following a 10 
mg dose rectally. Mean values are represented by a heavy line with filled 
circles, linear concentration axis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Plasma diazepam concentration versus time in 12 subjects following a 10 
mg dose rectally. Mean values are represented by a heavy line with filled 
circles, logarithmic concentration axis. 
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Figure 2.10 Plasma diazepam concentration versus time in 12 subjects following a 10 
mg dose of TDS® diazepam. Mean values are represented by a heavy line 
with filled squares, linear concentration axis. 
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Figure 2.11 Plasma diazepam concentration versus time in 12 subjects following a 10 
mg dose of TDS® diazepam. Mean values are represented by a heavy line 
with filled squares, logarithmic concentration axis. 
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Figure 2.12 Mean plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose rectally (filled red circles) and dermally by TDS® 
diazepam (filled blue squares), linear concentration axis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Mean plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose rectally (filled red circles) and dermally by TDS® 
diazepam (filled blue squares), logarithmic concentration axis. 
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Figure 2.14 Plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose rectally. Mean values are represented by a heavy 
line with filled circles, linear concentration axis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose rectally. Mean values are represented by a heavy 
line with filled circles, logarithmic concentration axis. 
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Figure 2.16 Plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose of TDS® diazepam. Mean values are represented 
by a heavy line with filled circles, linear concentration axis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Plasma desmethyldiazepam concentration versus time in 12 subjects 
following a 10 mg dose of TDS® diazepam. Mean values are represented 
by a heavy line with filled circles, logarithmic concentration axis. 
0
5
10
15
20
25
30
0 12 24 36 48 60 72
Hours post-dose
P
la
sm
a 
de
sm
et
hy
l-d
ia
ze
pa
m
,  
µg
/L
1
10
100
0 12 24 36 48 60 72
Hours post-dose
P
la
sm
a 
de
sm
et
hy
l-d
ia
ze
pa
m
,  
µg
/L
Study comparison of rectal and dermal diazepam 
 
Page 130 of 334 
360300240180120600
Cmax  TDS
Cmax rectal
Diazepam ng/mL
Dotplot of Cmax  TDS, Cmax rectal
 
 
Figure 2.18 Plasma diazepam Cmax concentrations following rectal dose and TDS® dose 
in 12 subjects, Dotplot. 
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Figure 2.19 Plasma desmethyldiazepam Cmax concentrations following rectal dose and 
TDS® dose in 12 subjects, Dotplot. 
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Figure 2.20 Pharmacokinetic parameters of diazepam AUC0-72h, Cmax, ratio percentage 
TDS/Rectal in 12 subjects, Dotplot. 
 
 
 
Figure 2.21 Pharmacokinetic parameters of desmethyldiazepam AUC0-72h, Cmax, ratio 
percentage TDS/Rectal in 12 subjects, Dotplot. 
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2.15 Discussion 
No serious or unexpected adverse events were reported or observed during the study. 
The drug formulations and protocol requirements were well tolerated by all subjects. 
The TDS® diazepam preparation was shown to be able to deliver diazepam systemically 
in human subjects. However, the maximum concentrations of diazepam and 
desmethyldiazepam following TDS® diazepam administration were found to be lower 
than those found for rectal diazepam (Diastat), the mean ratio was 11.6 and 47.4%, 
respectively. In this study, the results of the AUC and Cmax between the two treatments 
show that TDS® diazepam (A) and rectal diazepam (Diastat®) (B) were not contained 
within the bioequivalence limit (80–125%), Cmax (0–72h): 7.3 to 14% and AUC0-72h: 
19.7 to 37.6%. The plasma concentrations of all subjects administered TDS® diazepam 
were all below the anticonvulsant plasma concentrations of 150–350 µg/L. 
The plasma concentration of diazepam needed to stop convulsions is not well 
established, although a range of 150–350 µg/L has been suggested (Agurell et al., 1975), 
which was supported by Knudsen with a range from 200–300 µg/L (Knudsen, 1977). 
Additionally, the recurrence of seizures in two children was observed in Agurell et al’s 
study, even though the anticonvulsion plasma level was of the order of 150 to 200 µg/L 
(Agurell et al., 1975). A study by Ogutu et al (Ogutu et al., 2002) following rectal 
administration of diazepam not only failed to terminate all of the convulsions but also 
reported variable plasma drug concentrations over time ( 112–1953 µg/L, 0.17–36h) 
compared with the IV group (402–1507 µg/L, 0.42–3.13 h). The pharmacokinetic 
characteristics have also been studied for oral diazepam, which were highly variable 
even in a relatively homogeneous population (Greenblatt et al., 1989 ). 
Similarly, in this study, Diastat® only achieved the suggested effective plasma 
concentration (138.3–378.7 µg/L) in the range 150–350 µg/L in 11 of 12 subjects; 
probably due to variability in diazepam metabolism between individuals, which could 
explain the results of the Ogutu et al. study. Desmethyldiazepam was not quantified in 
all children who received diazepam IV but it was measured in three children who 
received rectal diazepam. The pharmacokinetics of a particular dose of diazepam seem 
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to vary widely between subjects, an observation noted by Ogutu et al. (Ogutu et al., 
2002); “One child had a plasma diazepam concentration below 200 µg/L 5 min 
following IV administration. Even after a repeat dose of diazepam 30 min later, plasma 
diazepam concentrations in this child declined rapidly from 414 µg/L at 5 minutes after 
the repeat dose to less than 200 µg/L within 20 min. Two children who received 
diazepam p.r. also failed to achieve a plasma concentration of 200 µg/L. Despite not 
achieving this target, all three children stopped convulsing, although convulsions 
recurred within 30 min in each child.” 
Due to the presence of active metabolites, the serum/plasma concentration of diazepam 
alone is not useful in predicting the effects of the drug. Diazepam and its metabolites 
were analyzed, and only diazepam and desmethyldiazepam were assayed in all subjects 
for both treatments, (i.e. diazepam was metabolized in both dosage forms). 
Desmethyldiazepam is an active sedative, which is excreted by the kidneys. In fact a 
study by Nicholson and co-workers has reported that desmethyldiazepam (10 mg) can 
improve sleep compared to clorazepate (15 mg) (Nicholson et al., 1976). Furthermore, in 
one subject in the TDS® treatment group, no diazepam was observed; however 
desmethyldiazepam was present. This may be due to the rapid skin metabolism of 
diazepam, or accumulation of diazepam in subdermal adipose tissue. 
Future development of this novel system will focus on staged adjustments to the TDS® 
formulation, dose and/or concentration of the TDS® diazepam system, in order to attain 
the therapeutic concentration range with the aim of developing a more convenient 
alternative to rectal or intravenous diazepam treatments. Additionally, we may need to 
consider further the influence of metabolism in the skin of diazepam. There are 
numerous enzymes beneath the stratum corneum viable skin (Noonan and Wester, 
1985). The entire skin-to-liver metabolism ratio has been suggested to be 0.8–2.4 for 
different enzyme systems (Noonan and Wester, 1989) for slowly penetrating 
compounds. Such compounds possessing lipophilic characteristics like diazepam might 
be expected to be metabolized more completely. The presence of desmethyldiazepam 
concentrations in the first time point after the administration of the TDS® system in five 
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subjects suggested that desmethyldiazepam had a half life of more than 14 days in this 
study. 
2.16 Conclusions 
The TDS® diazepam preparation was shown to deliver diazepam systemically in human 
subjects. The concentrations of diazepam and desmethyldiazepam following TDS® 
diazepam administration were found to be lower and not bioequivalent to the rectal 
diazepam (Diastat®). Poor absorption and accumulation of diazepam in the skin might 
be the main reason for its low bioavailability in the circulation. Additionally, the 
presence of various metabolic enzymes in the skin may cause a decline of diazepam 
concentration.  
This suggests that in future studies concerned with the bioequivalence, absorption, and 
bioavailability of topically applied drugs, skin metabolism of the drug needs to be 
considered. 
 
Comparison of CE/HPLC methods 
 
Page 135 of 334 
Chapter 3 CE and HPLC method development for the 
analysis of tetracaine tape stripping 
samples 
3.1 Introduction 
Analysis of biological matrices such as blood, plasma, serum, and urine, to quantify and 
determine drugs and their metabolites in vivo is used to evaluate and interpret 
bioequivalence, pharmacokinetic (PK), toxicokinetic, and forensic studies. Sensitivity 
and selectivity are necessary for accurate, precise, reproducible and stable methods in 
preclinical and clinical pharmacology. Typically rapid and simple methods are required 
in clinical PK studies because of high numbers of samples to assay and low cost benefit. 
The development of analytical methods using the guidance and principles of validation 
approved by the FDA is directly related to the quality and the performance of these 
studies. FDA guidance and principle (FDA, 2001a) information generally applies to 
bioanalytical procedures such as gas chromatography (GC), high performance liquid 
chromatography (HPLC) or liquid chromatography (LC), and combined GC and HPLC 
with mass spectrometry (MS) procedures such as LC-MS, LC-MS-MS, GC-MS, and GC-
MS-MS performed for the quantitative determination of drugs and their metabolites in 
biological matrices such as blood, plasma, serum, or urine. Also it can be applied to other 
bioanalytical methods such as capillary electrophoresis (CE), as well as other biological 
matrices such as skin samples. 
The guidance and principles of the validation process of analytical methods needs to be 
explored before addressing the methods themselves; for example instruments and any 
software being used must be qualified or validated according to standard operating 
procedures. Then the methods which apply to sample preparation, method development, 
validation and application can be addressed. 
Analytical methods are employed to separate a mixture of unknown compounds into 
individual compounds that can be identified and determined, together with the purity or 
concentration of compounds. In clinical practice precise values typically are expected. 
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However the sensitivity and selectivity of analytical methods usually depends on the 
analyzed compound/sample quantity. Thus selecting the appropriate analytical method is 
important, so that a rapid and simple method is developed. 
In this study HPLC and CE with ultraviolet (UV) absorbance detection have been 
selected for comparison, in the separation and quantitation of tetracaine and procaine, 
after application of tetracaine gel locally. Tetracaine was obtained by a tape sampling 
technique. HPLC with UV detection has been used for determination and quantification 
of tetracaine in plasma samples (Menon and Norris, 1981, Mazumdar et al., 1991, Rauf et 
al., 2002), and UV absorbance was capable of detecting tetracaine and its metabolite. 
Also HPLC has been compared with CE, in different fluids such as the determination of 
cetirizine dihydrochloride in human plasma (Kowalski and Plenis, 2007), the 
determination of mycophenolic acid in human plasma (Carlucci et al., 2007), the 
determination of carvedilol in serum (Clohs and McErlane, 2003), the determination of 
diazepam in pharmaceutical tablets (Aurora Prado et al., 2005), the measurement of 
histamine in seafood (Muscarella et al., 2005), the determination of flavonoids in 
Achillea mellefolium (Kocevar et al., 2008), and the determination of xyloglucan 
structures in blackcurrants (Hilz et al., 2006). All of them concluded that CE was 
preferable to HPLC. 
3.1.1 Beyond cocaine  
The synthetic local anaesthetics are structurally related to cocaine. Cocaine was the first 
alkaloid extracted from the coca plant leaves (Erythroxylum coca) (Jesus and Angel, 
2003). The leaves were used as a stimulant and adopted many years ago as part of 
traditional native South American and Indian cultures. 
In 1860, a collection of coca leaves was sent to the chemist Albert Niemann, in his 
German laboratory, to extract and isolate the active compound, which was named 
cocaine. In 1865 Lossen determined the correct molecular formula C17H21NO4. In 1898, 
the structure of cocaine was drawn by the chemist Richard Willstatter (Jesus and Angel, 
2003). This was of significant importance to researchers and chemists, so that they could 
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modify the structure of cocaine and synthesise other similar compounds with local 
anaesthetic properties. 
In 1884, Koller and Brettauer revealed that the hydrochloride salt form of cocaine had 
beneficial anaesthetic and mydriatic effects when a topical solution was applied to the 
eye. This result encouraged a common intention to use the drug as a local anaesthetic. 
However its unwanted side effects including high toxicity and dependence forced the 
chemist to look for alternative anaesthetic drugs. 
Since 1884, chemists have attempted to discover and develop a novel local anaesthetic 
with reduced side effects. It was not until 1904 that the German chemist, Alfred Einhorn 
developed 4-aminobenzoic derivatives. His first active drug from cocaine was 
synthesized in 1905, and named novocaine, which is now known as procaine (Jesus and 
Angel, 2003). Procaine was found to be more safe, but less effective, and produced some 
allergic reactions. This led to the discovery of other anaesthetic drugs such as tetracaine 
in 1930 (Biscoping and Bachmann-Mennenga, 2000), and lidocaine in1943 (Jesus and 
Angel, 2003). 
Local anaesthetics are drugs used clinically to reversibly block the conduction of 
impulses in the nerve ends, leading to loss of sensation (numbness) in the applied area, 
such as local anaesthetics on the skin. Local anaesthetics can be classified by their 
chemical structure into either an amide group such as lidocaine, mepicaine, prilocaine, 
ropivacaine, or an ester group such as cocaine, procaine, and tetracaine. 
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3.1.2 Tetracaine  
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Figure 3.1 Chemical structures of tetracaine, 4-hydroxybenzoic acid and 4-
aminobenzoic acid. 
Tetracaine is a white odourless, hygroscopic, crystalline powder, with slightly bitter 
numbing taste. Soluble 1:7.5 in water, 1:40 alcohol, 1:30 chloroform, and insoluble in 
ether, or acetone (Martindale, 1982a). The dissociation constant (pKa) is 8.39, and the 
partition coefficient Log P (octanol/water) is 3.5.  
Tetracaine, also known as amethocaine C15H24N2O2.HCl (2-dimethylaminoethyl 4-
butylaminobenzoate), is a potent local anaesthetic of the amino ester group, and is used 
for topical anaesthesia in ophthalmology, spinal anaesthesia and nerve block. It is also the 
first alternative anaesthetic for nasal septoplasty since cocaine (Drivas et al., 2007). 
Tetracaine has been incorporated into a mucosa adhesive polymer film to reduce the pain 
of oral wounds as a consequence of radiation and antineoplastic drugs.  
Tetracaine can be found as the hydrochloride in solutions, creams, gels, and as the base in 
ointments. The topical formulation of tetracaine gel as a local anaesthetic was developed 
in the early 1990s, enabling a more rapid and long duration of action than the mixture of 
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lidocaine and prilocaine known as EMLA cream (McCafferty et al., 1989, Woolfson et 
al., 1990 , Martindale, 1996b, Bishai et al., 1999, Boyd and Jacobs, 2001). The onset of 
action is 30 to 45 minutes, while EMLA cream is about 1 hour, without any risk of 
methemoglobinaemia. Nichani et al. (Nichani et al., 2008) mentioned that Ametop and 
EMLA were equally effective when applied for the same time, and used as local 
anaesthetics during grommet insertion. Although, the ear has a thin layer, this needs to be 
studied further because Ametop gel may require less time than EMLA to exert its effect 
during grommet insertion, which reflects the fact that Ametop has a more rapid onset of 
action than EMLA in skin, and Ametop is superior to EMLA cream (Browne et al., 1999, 
Choy et al., 1999, Arrowsmith and Campbell, 2000).  
Additionally, in vivo, Ametop has a local vasodilatation effect, which results in an 
increase in blood flow by decreasing the microvessel tone and activity close to the local 
tissue of the skin (Wiles et al., 2008). This may be an advantage when it is used prior to 
central venous catheter placement, or when a difficulty occurs whilst attempting to obtain 
IV access or blood, especially in newborns.  
The pharmacokinetics of tetracaine can be illustrated by the administration of tetracaine 
into humans via any available route, such as the application of Ametop gel into the skin. 
However, the bioavailability of tetracaine or its metabolite in plasma from the application 
of Ametop gel is dependent on the absorption of tetracaine from the skin, which is mainly 
related to the duration and the area of application. However this may differ from subject 
to subject, is also affected by the area where it is applied, and the thickness of the dermis. 
Thus tetracaine may continuously be released from storage sites in the skin  (Mazumdar 
et al., 1991). 
The pharmacodynamics and toxicity of tetracaine are related to the concentration of the 
drug in plasma. In addition, the CNS toxicity of local anaesthetics proportionally depends 
on the speed of absorption, and individual variability (Scott, 1986). When tetracaine is 
applied locally to healthy subjects, a plasma concentration of up to 200 µg/L produces no 
signs or symptoms of toxicity because of the slow release of the drug from the dermis 
(Mazumdar et al., 1991). Additional side effects of local tetracaine gel may include 
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transient erythema, itching and swelling of the epidermis at the local site, and rarely 
blistering. 
The determination of tetracaine in biological samples has been performed mainly in 
plasma. Several methods are available such as HPLC (Menon and Norris, 1981, 
Mazumdar et al., 1991), HPLC with multiwavelength detector (Rauf et al., 2002). 
Nevertheless human plasma contains proteins and endogenous compounds that may 
interfere with the chromatographic system, causing an increase in the pressure due to 
blockage of the column. There are several reported ways to extract tetracaine from 
plasma e.g. organic extraction or solid phase extraction, but these are time consuming. 
Thus the use of coupled columns (RAM-columns) as alternative methods, or micellar 
liquid chromatography (MLC) have been proposed (Escuder et al., 2001). In addition 
GC-MS (Kudo et al., 2001, Hino et al., 2002), direct ultraviolet spectrophotometry and 
colorimetry (Robert and Albert, 2006), liquid-liquid-liquid microextraction (LLLME) 
coupled with HPLC (Zhaohui et al., 2006), and raman spectroscopy (Dennis et al., 2004) 
can also be used.  
However tetracaine is unstable in plasma, and can rapidly hydrolyze to 4-butyl 
aminobenzoic acid (BABA) (Keiko et al., 2001, Hino et al., 2002), and 
dimethylethanolamine (DMEA) (Rauf et al., 2002). Therefore to determine tetracaine 
alone is not enough, and BABA must also be determined. BABA is stable for several 
months in blood when stored at –20 C° (Keiko et al., 2001). In a study involving ten 
children (aged 1–5 years), tetracaine cream 4% was applied to each hand; only BABA 
and not tetracaine was detected in the serum (van Kan et al., 1997), and also after 
injection for spinal anaesthesia (Kudo et al., 2001). In another study involving ten 
subjects, tetracaine was detected in plasma in only three, when 2g of tetracaine cream 5% 
had been applied to the dorsum of the hand (Mazumdar et al., 1991). However the 
degradation of tetracaine by human plasma can be inhibited by the addition of a 
cholinesterase inhibitor such as physostigmine (Rauf et al., 2002). 
The proposed study will use samples from tape stripping of the skin in healthy 
volunteers. The amount of the drugs in tape samples is greater than the amount in plasma 
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samples of topically applied drugs (Bareggi et al., 1998). Thus using simple and rapid 
techniques such as CE is possible. CE is a simple and fast technique to determine 
tetracaine in skin using tape stripping samples, since high sensitive techniques such as 
LC-MS are not required to detect such concentrations of drugs and UV absorption is 
sufficient to detect such concentrations, and has a low cost compared with MS detection. 
In addition using HPLC techniques is possible and can be compared with CE to find out 
more appropriate and reliable methods. 
3.2 Capillary electrophoresis (CE) 
Capillary electrophoresis, also known as capillary zone electrophoresis (CZE) is an 
alternative to the chromatographic techniques for drug analysis. It was developed in the 
1980s and expanded in the 1990s. It uses narrow-bore (20–200 µm internal diameter) 
capillaries, and it has become a complementary separation technique which can separate 
a variety of compounds using an electric field, with most CE being carried out in as 
aqueous medium. The separation is based on the differences in electrophoretic mobility 
of buffer analytes. Weak acids/bases, analyte charge is dependent on pH and pKa, but 
strongly charged solutes like strong acids and bases are preferred. For fully dissociated 
ions, the ionic volume can be changed by the choice of buffer counter-ion or ion pairs. 
The separation resembles a cross between traditional polyacrylamide gel electrophoresis 
(PAGE) and modern HPLC. In addition CE can be interfaced with a UV detector 
(CE/UV) and mass spectrometer (CE/MS). 
The basic component of CE is relatively simple (Figure 3.2). All that is required is a 
fused-silica capillary with an optical viewing window, high voltage, controllable 
temperature, two electrodes, an aqueous buffer and a detector such as UV. 
The fused silica capillary in CE is made of a polyimide coated tube. The polyimide is 
removed to open a window to allow UV spectrophotometric detection through the 
capillary and measurement of the light absorption of compound (s). The new capillary 
must be flushed before it can be used to ensure a fully and uniform charge is on its 
surface. This is done by flushing the capillary for 20 min at a temperature of 40 ºC with 1 
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molar (M) sodium hydroxide, then returning the temperature to 25 ºC and flushing it 
again with 0.1 M sodium hydroxide for 10 minutes, 5 minutes with water, and 10 minutes 
with buffer. Sometimes it needs to be flushed as described between method runs if there 
is a change in migration time, resolution, or a noisy baseline. The fused silica capillary 
forms a hydrodynamic connection between the sample and the buffer solution by placing 
the capillary ends in the buffer solution to fill the capillary with buffer solution. Then the 
sample is introduced by dipping the end of the capillary in the sample solution. A small 
amount of the solution is taken for analysis so that a symmetric shape peak can be read 
by the detector. 
Most CE is carried out in an aqueous medium, thus the compound should be soluble in 
water, and dissociate to suitable ions. 
A wide range of different background electrolytes (BGE) can be employed in CE. The 
BGE salt is most effective within one or two pH units of its pKa, for example, phosphate 
is used around pH 2.5 and pH 7, borate around pH 9. The typical buffer concentration is 
50–100 mM. In addition various BGE additives can be used to change the selectivity of 
the separation. 
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Figure 3.2 Basic components of a capillary electropherograph system. 
The mechanism of separation of compounds by CE is charged species travel at different 
velocities (ѵ) (Equation 3.1) depending upon their mobility (µa), which is determined by 
dividing the velocity by the electric field. This is dependent on the buffer composition, 
pH, and temperature: 
 
ѵ ൌ Iefftm ൌ
Ieff Ltot
tm ݒ ൌ μa ൈ E   
Equation 3.1 Ion velocity formula in capillary electrophoresis 
 
Where: 
ѵ                = Ion velocity (cm/s) 
µa              = Apparent electrophoretic mobility (cm2/vs) 
E               = Electrical field strength (v/cm) 
tm             = Migration time (s) 
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v              = Applied voltage (v) 
I eff/ Ltot    = Effective/total capillary length (cm) 
Electro-osmotic-flow 
One of the most important phenomenons in CE is the electro-osmotic-flow (EOF). EOF 
is a result of the surface charge on the capillary wall. The silanol groups in the fused 
silica are ionized when in contact with the buffer, and this ionisation is controlled by the 
pH of the buffer. 
The EOF is defined by the formula in Equation 3.2: 
ѵ݁݋ ൌ א ζ4ߨߟ ൈ E
 
Equation 3.2 The formula for electro-osmotic-flow on the capillary wall. 
Where א is the dielectric constant, η is the viscosity of the buffer (cp), and ζ is the zeta 
potential (mv).  
3.2.1 Use of short effective length capillaries in CE 
Effective length (ltot) of the capillary can be measured as the distance from the injection 
end to the detector, ranging from 40 to 75 cm. However, an effective length of 8.5 cm can 
be employed for short-end injection techniques. This is has advantage of reducing 
analysis time including the migration time, as well as improving peak efficiency and 
sensitivity. The minimum capillary length from the inlet to the detector should be 25 cm, 
and the minimum total length 33.5 cm. For reversed mode the shortest effective length 
should be 8.5 cm from the outlet end of the capillary to the detector. This is can be 
applied by changing method parameter only such as changing the positive voltage to 
negative, applying a vacuum instead of pressure. Figure 3.2 shows the basic components 
of CE and the application of reversed mode from the outlet to the detector. 
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3.3 High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) is the most widely used analytical 
technique for the separation of mixed components, qualitative/quantitative analysis, or 
preparation of components of interest. HPLC is applied in the analytical separation of 
drugs in preclinical, clinical pharmacology, and others e.g. therapeutic drug monitoring, 
to help the drug development process. HPLC is used to separate a mixture of substances 
by pumping liquid (mobile phase) together with the analyte which is introduced in small 
volume at high pressure through the column (stationary phase). In the column the analyte 
(s) is/are resolved into their components as they are retarded by physical interaction 
between the substance being analyzed (analyte) and the stationary phase. The nature of 
the substance or the analyte, the column, temperature of the column, and the mobile 
phase reveal the amount of retardation, and the time at which the analyte elutes from the 
column after the component in the analyte interacts with the stationary phase in the 
column and a delay in elution occurs. Reducing the retention time speeds up the method, 
which may help in the high demand on an analytical laboratory.  
A typical HPLC instrument includes a high pressure pump, injector, column, detector, 
and data recorder or system. Different types of high pressure pump, injector, column, 
detector, and data recorder or system depend on the analyte and application. The high 
pressure pump is needed to force the analyte together with the mobile phase through the 
stationary phase, and for large particles less pressure is required to maintain flow rate 
stability. The flow rate can range from 0.01 to 10 mL/min with maximum pressure up to 
5000 psi (345 bar, 340 atm). Many methods have been attempted to overcome the 
pressure limitation of HPLC, via increasing the temperature (Lestremau et al., 2006), 
using a monolithic column (Ishizuka et al., 2002). A pressure drop over the column of 
only about 400 bar can be achieved with conventional methods in HPLC (Lestremau et 
al., 2006). The alternative method is the introduction of ultra performance liquid 
chromatography (UPLC), which capable of providing liquid flow at pressure up to 
15,000 psi (about 1000 bar) (Plumb et al., 2004). Additionally, a degassing system can be 
considered e.g. helium purging, vacuum degassing. 
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The column is stainless steel, 5–25 cm long, 2–5 mm internal diameter, 1–5 µm particle 
size, and 50,000–90,000 plates/m. It is usually packed with silica particles, although there 
are different packing materials or phases, for different separation modes in HPLC. The 
types of HPLC modes available include partition, adsorption (liquid-solid), ion exchange, 
size exclusion or gel. Partition chromatography is used mainly for polar or non polar 
analytes, with low molecular weight (MW < 3000), using bonded stationary phases. 
In the normal mode, the stationary phase is silica or chemically modified silica by polar 
groups such as cyano (most polar), diol, and amino (least polar), and the solvent is of low 
polarity e.g. hexane, methylene chloride or a mixture of these. Therefore least polar 
compounds are eluted first, and polar compounds will be retained by the polar stationary 
phase.  
Reversed phase chromatography is the most commonly used mode of separation in 
HPLC. A polar solvent e.g. water, methanol, or a mixture of both, is used to elute analyte 
from silica gel modified by bonding non-polar groups such as long hydrocarbon chains. 
Therefore polar compounds are not retained and non-polar compounds will be retained 
on the hydrocarbon chain because of Van der Waal’s forces. A high polarity mobile 
phase will elute polar analytes faster, but with less resolution.  
Recently, hydrophilic interaction liquid chromatography (HILIC), also called aqueous 
normal phase, has been introduced. Compounds not well retained in reversed phase 
because of their high polarity, such as amino acids, may separate on a HILIC phase. 
HILIC chromatography phases are classified for neutral polar or ionic surface into 
unbonded silica silanol, amino bonded, amide bonded, and zwitterion bonded. 
Other separation modes include size exclusion chromatography, also called gel 
permeation chromatography, which is used for proteins and polymers, and the separation 
depends on the size of the molecules. Large molecules excluded from pores and not 
retained elute first. Ion exchange chromatography, the retention is based on the attraction 
between the analyte ions and the charged bond in the stationary phase, e.g. aminoacids 
can be separated on a cation exchange column.  
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Once the compounds are separated, they are carried out by the mobile phase to a detector. 
Different kinds of detectors, including ultra violet (UV), fluorometric (fluorescence), 
electrochemical (ECD), mass spectrometry (MS), can be attached to HPLC depending on 
the structure and properties of the analyzed analyte or compound. 
The most commonly used detector in HPLC is the UV/Visible detector. The UV/Visible 
detector has a wavelength range from 190-600 nm, and is selective and highly sensitive at 
the maximum absorption wavelength of the molecule. UV absorbance depends on the UV 
wavelength and the functional group in the chemical structure of the compound analyzed.  
Fluorometric detection is a highly selective and sensitive method, as long as the analyte 
fluoresces. 
Mass spectrometry (MS) is the mass to charge ratio (m/z). There are numerous types of 
ionization techniques, such as electrospray, atmospheric pressure chemical ionization, 
electron impact. MS measures the molecular weight as a mass weight of compound 
which is useful in providing both qualitative and quantitative identification with high 
sensitivity and more selectivity compared to other LC detectors. The MS combines with 
the HPLC to form LC/MS, LC/MS/MS. 
3.3.1 Column performance  
The aim in chromatography techniques is to resolve analyte peaks in a short separation 
time. Thus, understanding the measurement of resolution is imperative. Therefore 
resolution is the separation of two peaks in terms of ratio in the time difference (tr) to the 
sum of peak widths (w) as shown in Equation 3.6, the higher the ratio, the higher the 
resolution (Rs). 
Good column performance is essential for providing a Gaussian symmetrical peak shape 
in chromatography, and requires measurements of the following parameters; column 
efficiency (HETP), column permeability (kv0), retention or capacity factor (k), and 
selectivity (α).  
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HETP is a measure of column efficiency; which is described as the column length over 
the number of theoretical plates. The theoretical plate is a separated layer within the 
column which separate equilibrations of the analyzed between the stationary and mobile 
phase, and reflected by the column permeability. Column permeability or specific 
permeability is defined as the resistance of the column to permit the flow, high flow 
resulting in low pressure, which depends on the packing materials of the column. 
Selectivity is employed for measurement of relative retention of two substances being 
separated;  
ߙ ൌ tr2tr1    
Equation 3.3 Selectivity formula. 
Where tr1 and tr2 are the retention time of peaks 1 and 2, respectively, and k1 and k2 are 
the corresponding capacity factors. 
However for a mixture of substances capacity factors should be applied. The retention 
factor is a useful value for the column performance; Figure 3.3 shows the retention 
parameters. 
݇ ൌ tR െt0t0    
 
Equation 3.4 Capacity factor formula. 
k: capacity factor 
tR: the time between the injection point and the maximum detector response called the 
retention time. 
t0: the time required for an analyte not retained by the stationary phase to pass through the 
column. 
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Figure 3.3 Schematic of a simple chromatogram. 
3.3.2 Data processing in HPLC 
The data processing is qualitative and/or quantitative, or molecular weight distribution. 
After analysis the compound can be identified from its retention time, off line UV 
spectrum, on flow emission spectrum, or multichannel dio-array detection (DAD). The 
amount of compound can be measured from calibration standards. 
3.4  Method development of CE and HPLC 
The analytical method must be adequately accurate, precise, and sensitive to determine 
the actual amount of drug or substance in the body. At least three phases of method 
development in most chromatography techniques must be applied to ensure valid and 
precise methods were applied. These include optimized selectivity for target compounds, 
the selection of the mobile and stationary phase in HPLC or buffer in CE. After 
optimizing selectivity, stability of the selective compound needs to be reproducible for 
either migration time in CE or retention time in HPLC and resolution. The last phase is to 
optimize sensitivity and quantitative reproducibility. 
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The overall concept in chromatographic techniques is to maximize peak resolution in the 
shortest time. Thus understanding and applying method parameters is essential, to 
optimize separation efficiency by measuring the resolution factor (Rs) of the different 
peaks migration or retention time (tm or tr), and the total peak widths (W1+W2). Rs is 
proportional to differences in time and inversely to the widths, with higher Rs value 
resulting in higher resolution, and efficient separation. 
 
Rs for CE: 
Rs ൌ tm2 െtm1W1 ൅W2   
Equation 3.5 Resolution factor in CE. 
 
Rs for HPLC: 
 
Rs ൌ tr2 െtr1W1 ൅W2  
Equation 3.6 Resolution factor in HPLC. 
tr2/m2
tr1/m1
t0 Time
w1 w2
 
Figure 3.4 Chromatography model to determine peak resolution. 
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3.5 Description of the study 
The validation of CE and HPLC assays to determine tetracaine in skin using tape 
stripping samples during clinical use of the drug. 
3.6 Objectives 
The main objective of this study was to develop, optimize, and validate a rapid and 
simple method of analysis, to determine tetracaine in skin using tape samples from 12 
healthy volunteers given tetracaine as a part of a pharmacokinetic drug delivery study. 
The second objective was to investigate the quantitative performance of the developed 
CE and HPLC methods and compare the two results.  
3.7 Materials and methods 
3.7.1 General chemicals 
All chemicals listed below were supplied by Sigma Aldrich Company, Poole, UK;  
1) Tetracaine hydrochloride (HCl) (Lot no 065k1501) (99% purity) for 
calibrator and control sample preparation was obtained as a white powder. 
2) Procaine hydrochloride (HCl) (Lot no 114k0569) (100% purity) for use as 
internal standard, was obtained as a white powder. 
3)  4-Butylaminobenzoic acid (Lot no 02514BJ) (97% purity), was obtained as 
white/yellowish powder. 
4) N, N-Dimethylethanolamine (Lot no 02514BJ) (97% purity) was obtained 
as redistilled, ≥ 99.5%. 
5) Methyl 4-hydroxybenzoate (Lot no 016K00602) (99% purity) was obtained 
as a white powder. 
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6) Propyl 4-hydroxybenzoate (Lot no 016K0699) (100% purity) has been 
obtained as a white powder. 
 
NH2
O
O
N
CH3
CH3
   
NH
O
OH
CH3  
 
Procaine     4-butylaminobenzoic acid 
Figure 3.5 Chemical structures of procaine and 4-butylaminobenzoic acid. 
3.7.2 Adhesive tape 
The adhesive tape used in this study was 19mm width, Tesa 4205 PV5, Beiersdorf, 
Hamburg Germany, supplied by TESA UK. 
3.7.3 Procaine (Internal Standard)  
The stock solution of procaine was prepared by dissolving 356.5mg procaine 
hydrochloride in 1 L de-ionized water. The concentration of the stock solution with 
respect to procaine was (after correcting for the salt and assuming purity of 100%) 
300µg/mL. 
The stock solutions for tetracaine calibration and quality control were stored at 
approximately –20ºC. 
3.7.4 Method I 
To develop, optimize, and validate a CE method to determine tetracaine in skin tape 
samples, obtained from healthy subjects. 
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3.7.4.1 Materials 
The concentrations of tetracaine in skin from tape stripping samples were determined by 
CE. All HPLC grade solvents were obtained from Rathburn Chemicals Limited, 
Walkerburn, Scotland. All AnalaR grade reagents were obtained from Merck (BDH) 
Limited, Poole, UK. 
3.7.4.2 CE instrumentation and capillaries 
The analyses were carried out on an Agilent 3DCE G1600AX capillary electropherograph 
capable of employing up to 30 kV, controlled by a 3D-CE Chemstation 
Rev.B.02.01[244] (Agilent, West Lothian, UK) for acquisition and handling of data. 
Fused silica capillaries, 485mm total length with a window at 85mm from one end ×50 
μm i.d. (Composite Metal Services, Ilkley, UK) were conditioned on first use by flushing 
with 1M NaOH (BDH, Poole, UK) at > 950 mbar, 40 °C for 20 min. Pre-conditioning on 
injection was a 3 min flush with 0.1M NaOH (BDH, Poole, UK), then 3 min flush with 
background electrolyte (BGE). In the final separation a potential of –25kV was 
employed. The capillary was thermostated at 25.0 °C. The injections of the samples into 
the system were carried out hydrodynamically for 10 seconds at –50 mbar. Detection was 
by photodiode-array over 195–360 nm, but 312 nm with bandwidth 10nm was used for 
quantitation since 312 nm is the maximum for tetracaine. The run time was 2 min. Both 
BGE vials were replenished every 12 injections. All samples and standards in the auto-
sampler were kept at ambient temperature. 
3.7.4.3 Background electrolyte (Buffer) 
0.1 M Tris-phosphate at pH 2.5 was used as the aqueous background electrolyte. The 
buffer was prepared by diluting 20 mL phosphoric acid (0.5 M) with 60 mL de-ionized 
water followed by adding 15 mL of 0.5 M Tris to obtain a solution at pH 2.5. This 
solution was made up to 100 mL with de-ionized water. Then the pH was checked and 
adjusted if necessary. 
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3.7.4.4 Method development 
3.7.4.4.1 Overall description of method development 
Flow Chart 3.1 describes method development process for CE. 
3.7.4.4.2 UV absorbance 
The UV detector was set at 312, and 210 nm absorption wavelengths (λmax).  
3.7.4.4.3 Optimization of buffer pH  
The influence of pH of 0.1 M Tris-phosphate BGE was studied over the range 2 to 3.5.  
3.7.4.4.4 Optimization of temperature 
Precise temperature control is important. Thus various temperatures were studied: 15, 20, 
25, 30 °C. 
3.7.4.4.5 Optimization of buffer concentration 
Different buffer concentrations at constant pH in the range of 0.05 to 0.2 M were 
investigated. 
3.7.4.4.6 Optimization of voltage 
The optimum voltage was determined by performing runs at increasing voltage until 
deterioration in resolution was noted.  
3.7.4.4.7 Optimization of injection time 
Injections time were studied starting from 1 to 65 seconds.  
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3.7.4.4.8 Sensitivity 
The lower limit of detection was determined as the concentration of tetracaine that had a 
peak height three times higher than the baseline noise. The lower limit of quantification 
was defined as the lowest calibration concentration of tetracaine. 
 
3.7.4.4.9 Specificity 
Specificity or selectivity is the ability to measure the analyte of interest free of 
interference from other components in the sample, interference from the tape, from the 
buffer, drug excipients, and drug metabolites. 
3.7.4.5 Recovery 
Absolute recovery of tetracaine was determined using tape samples spiked with tetracaine 
at the same nominal concentration as the calibration curve samples using Equation 3.7 
Peak area ratio measurements from extracted samples were compared with the peak areas 
ratio from direct solvent injection of the test compounds. Mean and standard deviations 
were calculated from at least six measurements at each level. Two samples of solution 
and six samples of tapes were loaded with 50, 100, 200, 400, 600, 800, 1000, 1200μg of 
tetracaine, and 1500μg procaine as internal standard. 
 
Recovery ൌ AB ൈ 100  
 
Equation 3.7 Absolute recovery formula. 
Where, A is the peak area ratio of tetracaine in the tape, and B the peak area ratio of 
tetracaine in 50% methanol/water. 
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3.7.4.6 Stability 
The stability of tetracaine was determined using tape samples spiked with tetracaine at 
the same nominal concentration as the quality control samples. The stability of the 
samples was measured before and after extraction. Both samples were kept at ambient 
temperature for 24 hours and then stored at –20 ºC for at least 3 weeks. Samples were 
loaded with 100 (Q1), 250 (Q2), 1000 (Q3), μg of tetracaine, and 1500μg procaine as 
internal standard. 
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CE condition: 
Capillary: 485mm (400mm to window) 
× 50μm internal diameter fused silica 
capillary  
Mobile phase: 50% methanol/de -
ionised water  
Injection rate: –500 mBar.sec. at –
25kV, 25 C° 
Flow Chart 3.1 Method of development of capillary electrophoresis for tetracaine. 
 
Method of development of CE for tetracaine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solubility 
50% methanol/water 
Voltage 
15, 20, 25, 30 
kV
BGE Molarity 
 50, 100, 150, 
200 mM 
Background 
electrolyte pH 
2, 2.5, 3, 3.5 
Temperature 
15,20,25,30 
°C 
Injection time 
range 
(1-65 seconds) 
Charge
CZE vary pH 
100 mM Tris-Phosphate 
Optimization and solution 
Chromophore 
Peak 
Capillary Zone Electrophoresis 
(CZE) 
Internal standard and background 
electrolyte (BGE): 
Procaine (1500 µg) was internal 
standard (I.S.) 
100 mM BGE of phosphoric acid-Tris 
pH 2.5 
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3.7.4.7 Assay procedures for tetracaine in CE 
3.7.4.7.1 Calibrators and quality control samples 
Stock solutions for tetracaine (5mg/mL) were prepared in 50% methanol/water and for 
procaine 300μg/mL in water (Internal Standard (I.S.)). All stock solutions were stored at 
–20ºC. All calibrators and quality control samples were prepared by appropriate dilution 
of the stock.  
3.7.4.7.2 Tetracaine calibrator 
The stock solution of tetracaine was prepared by dissolving 287.29 mg of tetracaine 
hydrochloride in 50mL of 50% v/v aqueous MeOH. The concentration of the stock 
solution with respect to tetracaine was (after correcting for the salt and assuming a purity 
of 100%) 5.0mg/mL. 
3.7.4.7.3 Tetracaine quality control (QC)  
The stock solution of tetracaine was prepared by dissolving 143.65 mg of tetracaine 
hydrochloride in 25mL of 50% v/v aqueous MeOH. The concentration of the stock 
solution with respect to tetracaine was (after correcting for the salt and assuming a purity 
of 100%) 5.0mg/mL. 
3.7.4.7.4 Working standard solutions 
Calibrator 
50 mL of the tetracaine stock standard solution was pipetted into a 100mL volumetric 
flask and made up to the mark with 50% v/v aqueous MeOH to produce a sub-stock (Cal 
10). Working calibration solutions were prepared by diluting the sub stock (Cal 10) with 
50% v/v aqueous MeOH as tabulated in Table 3.1. 
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Table 3.1  Working calibration concentrations with related dilutions in 50% v/v 
aqueous MeOH. 
Cal No. Volume of sub 
stock 
Volume of 50% v/v 
aqueous MeOH 
Total 
volume 
Nominal 
concentration 
 (mL) (mL) (mL) (µg/mL) 
1 0.05 24.95 25.0 5 
2 0.25 24.75 25.0 25 
3 0.50 24.50 25.0 50 
4 2.0 23.0 25.0 200 
5 4.0 21.0 25.0 400 
6 6.0 19.0 25.0 600 
7 8.0 17.0 25.0 800 
8 10.0 15.0 25.0 1000 
9 12.0 13.0 25.0 1200 
10 
(Sub stock) 
50.0 mL stock 
solution 
50.0 100 
 
2500 
Calibrator 1 and calibrator 9 were used as lower limit of quantitation (LLOQ) and upper 
limit of quantitation (ULOQ), respectively. 
Quality control (QC) samples 
12.50 mL of the tetracaine stock solution was pipetted into a 25mL volumetric flask and 
made up to the mark with 50% v/v aqueous MeOH to produce a sub-stock (QC 4, 2.50 
mg/mL). Working controls were prepared by diluting the sub stock with 50% v/v 
aqueous MeOH as tabulated in Table 3.2. 
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Table 3.2 Working quality control concentrations with related dilutions in 50% v/v 
aqueous MeOH. 
Cal No. Volume of sub 
stock 
Volume of 50% v/v 
aqueous MeOH 
Total 
volume 
Nominal 
concentration 
 (mL) (mL) (mL) (µg/mL) 
1 
(Low) 
1.0 24.0 25 100 
2 
(Medium) 
2.5 22.50 25 250 
3 
(High) 
10.0 15.0 25 1000 
4 
(sub stock) 
12.5mL stock 
solution 
12.5 25 2500 
 
3.7.4.8 Calculating Inaccuracy and imprecision 
Inaccuracy was tested by the determination of low, medium and high quality control 
samples, together with the LLOQ and ULOQ samples. Each control sample contained 
tetracaine. The nominal values for the low, medium and high control samples were 100, 
250 and 1000μg respectively. The nominal values for the ULOQ and LLOQ were the 
same nominal concentration as the highest and the lowest calibration standards, 
respectively. 
Assay imprecision was measured both within and between batch by the analysis of three 
control samples, the LLOQ and the ULOQ. Within-batch and between-batch imprecision 
was calculated by the nested analysis of variance (ANOVA) using internationally agreed 
methods (ISO-5725, 1994), calculated and plotted using Excel 2007 and Minitab 15 © 
2006 Minitab Inc. 
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3.7.5 Method II 
To develop, optimize, and validate a HPLC method to determine tetracaine in skin tape 
samples, obtained from healthy subjects. 
3.7.5.1 Overall description of the method 
This study describes a HPLC method for the determination of tetracaine in tape 
samples obtained from tape stripping of human skin using procaine as an internal 
standard. Analytes were separated on a Luna PFP (2), 3µm, 150mm x 4.6 mm column 
at ambient temperature, the mobile phase consisted of 10 mM KH2PO4 at pH 2.5, and 
methanol (35:65, v:v). Tetracaine and the internal standard were monitored by 
ultraviolet absorption at 312 nm. The overall method was validated and used in the 
analysis of tetracaine/procaine ratio in 106 skin tape samples. The tetracaine/procaine 
ratio in these skin tape samples were previously measured by the developed and 
validated CE method, as described and discussed in this chapter. 
3.7.5.2 Materials 
As described previously in method I, section 3.7.4.1, but the system was HPLC. 
3.7.5.2.1 Chromatographic conditions and instrumentation 
1) The experiment was carried out using a Shimadzu LC-6A pump, Gilson 
231 autosampler fitted with a 200 μL injector loop, Gilson diluter 401. 
The system was coupled to a Shimadzu SPD-6A UV/Vis detector. 
2) The separation was carried out using a Luna PFP (2) column, 3µm, 
150mm x 4.60 mm from Phenomenex, Macclesfield, U.K. The analytes 
were eluted using isocratic elution with a flow rate of 1 mL/min with 
KH2PO4 buffer (pH 2.5) and methanol (35:65, v:v), and were monitored 
by ultraviolet absorption at 312 nm. 
Comparison of CE/HPLC methods 
 
Page 162 of 334 
3) The data acquisition system consisted of a data interface (HP 35900 
interface) and HP Chemstation, version A.04.01. The software was 
operated under Windows 95 environment. 
3.7.5.3 Sensitivity 
As described previously in method I, section 3.7.4.4.8. 
3.7.5.4 Specificity 
As described previously in method I, section 3.7.4.4.9. 
3.7.5.5 Recovery 
Recovery of tetracaine was calculated by dividing the peak area ratio of the standard 
samples spiked with tetracaine by the peak area ratio of the same tetracaine concentration 
in 50% MeOH. 
Recovery was calculated using Equation 3.7, where A is: the peak area ratio of the 
tetracaine in tape sample and B is peak area ratio of the same tetracaine concentration in 
50% v/v aqueous MeOH. 
3.7.5.6 Stability 
The stability of tetracaine was determined using tape samples spiked with tetracaine at 
the concentration of 10 µg/mL stock solutions. Aliquots from this solution were injected 
into the HPLC after each freeze / thaw cycle stored at –20 ºC. 
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3.7.5.7 Assay procedures of tetracaine for HPLC 
3.7.5.7.1 Calibrators and quality control samples 
For tetracaine calibration and tetracaine quality control the concentrations of 5.0mg/mL 
and 2.5mg/mL have been used, respectively, and for procaine as internal standard the 
concentration was the same as in method I. (All after correcting for the salt and assuming 
a purity of 100%). 
3.7.5.7.2 Working standard solutions  
Calibrator 
25 mL of the tetracaine stock standard solution was pipetted into a 100mL volumetric 
flask and made up to the mark with 50% v/v aqueous MeOH to produce a stock solution 
(1.25 mg/mL). Working calibration solutions were prepared by diluting the sub stock 
(Cal 9) with 50% v/v standard as tabulated in Table 3.3. 
Table 3.3 Working calibration concentrations with related dilutions in 50% v/v 
aqueous MeOH. 
Cal No. Volume of sub 
stock 
Volume of 50% v/v 
aqueous MeOH 
Total 
volume 
Nominal 
concentration 
 (mL) (mL) (mL) (µg/mL) 
1 0.006 24.994 25.0 0.3 
2 0.02 24.980 25.0 1 
3 0.06 24.940 25.0 3 
4 0.2 24.800 25.0 10 
5 0.6 24.400 25.0 30 
6 2 23.000 25.0 100 
7 6 19.000 25.0 300 
8 20 5.000 25.0 1000 
9 
(Sub stock) 
25.0 mL stock 
solution 
75.0 100 
 
1250 
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Calibrator 1 and calibrator 8 were used as lower limit of quantitation (LLOQ) and upper 
limit of quantitation (ULOQ), respectively. 
Quality control (QC) samples 
12.50 mL of the tetracaine stock solution was pipetted into a 25mL volumetric flask and 
made up to the mark with 50% methanol to produce a sub-stock (QC 4, 1.25 mg/mL). 
Working controls were prepared by diluting the sub stock with standard zero as tabulated 
in Table 3.4. 
Table 3.4 Working quality control concentrations with related dilutions in 50% v/v 
aqueous MeOH. 
Cal No. Volume of sub 
stock 
Volume of 50% v/v 
aqueous MeOH 
Total 
volume 
Nominal 
concentration 
 (mL) (mL) (mL) (µg/mL) 
1 
(Low) 
0.1 24.9 25 5 
2 
(Medium) 
1 24.0 25 50 
3 
(high) 
10.0 15.0 25 500 
4 
(sub stock) 
12.5mL stock 
solution 
12.5 25 1250 
 
3.7.5.8 Calculating inaccuracy and imprecision 
Inaccuracy was tested by the determination of low, medium and high quality control 
samples, together with the LLOQ and ULOQ samples. Each control sample contained 
tetracaine. The nominal values for the low, medium and high control samples were 5, 50 
and 500μg respectively. The nominal values for the ULOQ and LLOQ were the same 
nominal concentration as the highest and the lowest calibration standards, respectively. 
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Assay imprecision was measured both within and between batch by the analysis of three 
control samples, the LLOQ and the ULOQ. Within-batch and between-batch imprecision, 
regression coefficient and the slope of the calibration line were calculated from the peak 
area ratio by excel 2007, using internationally agreed methods (ISO-5725, 1994). 
3.7.6 Method III 
To develop and optimize a CE method to determine BABA in skin tape samples, 
obtained from healthy subjects. 
3.7.6.1 Materials 
As described in the previous method (method I), section 3.7.4.1  
3.7.6.1.1 CE instrumentation and capillaries 
The analyses were carried out to determine BABA in skin tape samples obtained from 
healthy subjects. The method was run in the same system and conditioning applied as 
tetracaine method I, except that fused silica capillaries, 485mm total length with a 
window at 85 mm from one end ×50μm i.d. were used. In the final separation a potential 
of –27kV was employed. The capillary was thermostated at 20.0°C. The injections of the 
samples into the system were carried out hydrodynamically for 7 seconds at –50mbar.  
Detection was by photodiode-array over 195–360nm, but 285 nm with bandwidth 10nm 
was used for quantitation since 285 nm is the maximum for BABA. The run time was 
1.50min. Both BGE vials were replenished every 12 injections. All samples and 
standards in the auto-sampler were kept at ambient temperature. 
3.7.6.2 Background electrolyte (Buffer) 
30 mM disodium tetraborate at pH 8.0 was used as the aqueous background electrolyte. 
The buffer was prepared by dissolving 1.14 g disodium tetraborate in 100mL de-ionized 
water. Then the pH was checked using a pH meter and adjusted, if necessary. 
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3.7.6.3 Method development 
3.7.6.3.1 UV wave length 
The UV detector was set at 285 and 312 nm absorption wave length (λmax) as 285, and 
312 nm were the highly selective wave lengths for BABA, and tetracaine, respectively.  
3.7.6.3.2 Optimization of buffer pH 
The influence of pH of 30 mM disodium tetraborate BGE was studied over the range 7 to 
10.50.  
3.7.6.3.3 Optimization of temperature 
Precise temperature control is important, thus various temperatures were studied from 10, 
15, 20, 25, 30 °C. 
3.7.6.3.4 Optimization of buffer concentration 
Different buffer concentrations at constant pH in the range of 20 to 50 mM were 
investigated.  
3.7.6.3.5 Optimization of voltage 
The optimum voltage was determined by performing runs at increasing voltage until 
deterioration in resolution was noted.  
3.7.6.3.6 Optimization of injection time 
Injections times were studied starting from 1 to 12 seconds.  
3.7.6.4 Sensitivity 
As described previously in method I, section 3.7.4.4.8. 
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3.7.6.5 Specificity 
As described previously in method I, section3.7.4.4.9. 
3.7.6.6 Recovery 
As described in method I , but samples of solution and samples of tape were loaded with 
10, 25, 50, 100, 250, 500, 750, 1000 μg for BABA, and tetracaine, and 1500μg for 
procaine as the internal standard. 
3.7.6.7 Stability of samples 
The stability of BABA was determined using tape samples spiked with BABA at the 
same nominal concentrations as the QC1, QC2, and QC3 samples, as described in 
method I.  
3.7.6.8 Stability of sample injection 
The stability of the injection samples, after adding 30mM disodium tetraborate (BGE) 
was measured every day for at least 10 days for refrigerated samples, and for at least 6 
hours for samples at ambient and 37 ºC temperatures at the nominal concentrations of 
BABA (1000 μg), tetracaine (1000 μg), and  procaine (1500 μg). 
3.7.6.9 Calibrators and quality control samples  
Stock solutions, for 4-butylaminobenzoic acid (BABA) (5mg/mL) were prepared in 50% 
methanol/water and for procaine 300μg/mL in water (Internal Standard (I.S.)). All stock 
solutions were stored at -20ºC. All calibrators and quality control samples were prepared 
by appropriate dilution of the stock.  
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3.7.6.9.1 BABA Calibrator 
The stock solution of BABA was prepared by dissolving 515.4 mg of 4-
butylaminobenzoic acid (BABA) in 50 mL of 99.9% v/v aqueous methanol, and then 
water was added to prepared 50% v/v aqueous MeOH. The concentration of the stock 
solution with respect to BABA was (after assuming a purity of 100%) 5.0 mg/mL. 
3.7.6.9.2 BABA Quality Control (QC)  
The stock solution of BABA was prepared by dissolving 257.7 mg of 4-
butylaminobenzoic acid (BABA) in 25 mL of 99.9% v/v aqueous methanol, and then 
water was added to prepared 50% v/v aqueous MeOH. The concentration of the stock 
solution with respect to BABA was (after assuming a purity of 100%) 5.0 mg/mL. 
Procaine was prepared as mentioned in method I. The stock solutions for tetracaine 
calibrator and quality control were stored at approximately -20ºC. 
3.7.6.9.3 Working standard solutions 
Calibrator 
Working calibration solutions were prepared by diluting the stock solution with 50% v/v 
aqueous MeOH as tabulated in Table 3.5. 
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Table 3.5 Working calibration concentrations with related dilutions in 50% v/v 
aqueous MeOH 
Cal 
No. 
Volume of 
stock solution 
BABA 
Volume of 
stock 
solution TC
Volume of 50% 
v/v aqueous 
MeOH 
Total 
volume 
Nominal 
concentration 
of BABA & TC 
 (mL) (mL) (mL) (mL) (µg/mL) 
1 0.375 0.15 24.475 25.0 75 
2 0.75 0.30 23.95 25.0 150 
3 3.75 1.50 19.75 25.0 750 
4 7.50 3 14.50 25.0 1500 
5 11.25 4.5 9.25 25.0 2250 
6 15.0 6 4.0 25.0 3000 
Stock solutions: BABA 5000 µg/mL and tetracaine (TC)12500 µg/mL 
Calibrator 1 and calibrator 6 were used as upper limit of quantitation (ULOQ) and lower 
limit of quantitation (LLOQ), respectively. 
3.7.6.9.4 Quality Control (QC) samples 
Working controls were prepared by diluting the stock solution with 50% v/v aqueous 
MeOH as tabulated in Table 3.6. 
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Table 3.6 Working quality control concentrations with related dilutions in 50% v/v 
aqueous MeOH 
Cal No. Volume stock 
solution 
BABA 
Volume of 
sub stock TC 
Volume of 50% 
v/v aqueous 
MeOH 
Total 
volume 
Nominal 
concentration 
Of BABA & TC 
 (mL) (mL) (mL) (mL) (µg/mL) 
1 
(Low) 
1.5 0.75 22.75 25 300 
2 
(Medium) 
6.0 3 16 25 1200 
3 
(high) 
12.0 6 7 25 2400 
Stock solutions: BABA 5000 µg/mL and tetracaine (TC)10000 µg/mL 
 
All the samples were placed in tape as described in section3.7.7 (page, 171), and left to 
dry at ambient temperature and transferee to polypropylene tubes, which then extracted 
from the tape as explained later in section 3.7.8 (page, 171), the samples were then drawn 
and placed into 250 auto injector vial, which is diluted before injection in the CE as 1:3 
sample, 1:3 background electrolyte, and 1:3 distilled water.  
The final concentration of calibrations were nominally 25, 50, 250, 500, 750, 1000 μg for 
BABA, and tetracaine. The 25 and 1000μg being the low limit of quantity (LLOQ) and 
the upper limit of quantity (ULOQ) respectively, plus 500 μg I.S. and quality control 
samples were nominally 100, 400, 800μg BABA, and tetracaine plus 500μg I.S. 
3.7.6.10 Calculation of results 
The statistical analysis and graphical presentation was carried out using Excel 2007, 
Window Vista. 
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3.7.7 Preparation of tape samples  
For the purpose of validation and assay calibration, a length of self adhesive tape (Tesa 
4205 PV5) was cut into 10 samples so that each tape was approximately 3 × 2cm. 100µL 
volume of standard or quality control solution were loaded on the adhesive part of each 
tape. The solution was distributed approximately evenly on each tape. The samples were 
left to dry naturally at ambient temperature. This took, approximately 30 minutes. The 
tapes were then transferred into 10mL polypropylene tubes and capped. The tubes were 
stored at –20°C until analysis. The tape samples used in this study were obtained from 
healthy volunteers by applying 3×2 cm tape on their skin gently with the same pressure, 
and then using forceps to strip off, with constant movement. Each volunteer has repeated 
the procedure 10 times to provide 10 samples at each skin site. All samples obtained were 
transferred to 10mL polypropylene tubes, for each site one tube for every volunteer, and 
stored frozen at –20º C until analysis. 
3.7.8  Extraction procedure 
5mL of 100% methanol was dispensed into the tube containing standard/QC tape or 
samples. The contents were mixed for 45 minutes using a shaker. 5mL of internal 
standard solution containing 300μg/mL procaine in water was added to the tube to make 
a 50% v/v aqueous MeOH solution. The contents were mixed again by a shaker for 
another 15 minutes. 200µL of the solution was transferred into a 250µL auto injector vial 
for CE analysis, and same amount for HPLC. In the analysis of BABA, samples were 
diluted before injection as 1:3 sample, 1:3 BGE, 1:3 water. 
3.8 Validation procedures and results 
3.8.1 Results of method I 
3.8.1.1 Method development 
Figure 3.6 and Figure 3.7 show that the UV absorbance of tetracaine was optimum at 312 
nm wave length (λmax). Table 3.7 shows the stable and optimum buffer pH was 2.5, 
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precise and stable temperature was 25 °C, optimum buffer concentration (M) at constant 
pH was 0.1 M Tris-phosphate, and when voltage was changed, the deterioration in 
resolution was noted at –25KV. Additionally Figure 3.8 and Figure 3.9 show the 
response was linear to injection time of 20s, however 10 s was selected.  
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Figure 3.6 UV spectra of tetracaine. 
 
 
Comparison of CE/HPLC methods 
 
Page 173 of 334 
 
Figure  3.7 3-D spectra of procaine (PC) and tetracaine (TC) peaks displayed from a 
capillary electropherograph controlled by 3D-CE Chemstation Rev. B.02.01 
[244]. 
 
PC 
TC 
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Table 3.7 Capillary electrophoresis method development of buffer molarity and pH, 
and instrument temperature and voltage. 
Molarity of buffer 
M 
Mig time 
(min) TC 
Mig time 
(min) PC 
Difference 
time (min) 
PC width 
second 
TC width 
second Rs 
0.05 1.25 1.16 0.10 1.19 1.29 4.59 
0.10 1.40 1.28 0.12 1.18 1.22 5.86 
0.15 1.33 1.23 0.09 1.03 1.00 5.57 
0.20 1.27 1.18 0.09 0.96 0.94 5.48 
pH of buffer 
pH 
Mig time 
(min) TC 
Mig time 
(min) PC 
Difference 
time (min) 
PC width 
second 
TC width 
second Rs 
2 1.07 1.00 0.07 0.92 0.86 4.52 
2.5 1.30 1.19 0.11 1.09 1.15 5.80 
3 1.49 1.33 0.16 1.41 1.42 6.79 
3.5 1.36 1.21 0.15 1.40 1.42 6.17 
Temperature of instrument 
Temp 
°C 
Mig time 
(min) TC 
Mig time 
(min) PC 
Difference 
time (min) 
PC width 
second 
TC width 
second Rs 
20 1.39 1.27 0.12 1.16 1.15 6.08 
25 1.24 1.14 0.10 1.14 1.15 5.41 
30 1.15 1.06 0.09 1.07 1.22 4.66 
Voltage of instrument 
kV 
Mig time 
(min) TC 
Mig time 
(min) PC 
Difference 
time (min) 
PC width 
second 
TC width 
second Rs 
–15 2.37 2.18 0.19 2.34 2.47 4.73 
–20 1.71 1.57 0.14 1.60 1.65 5.18 
–25 1.30 1.19 0.11 1.09 1.15 5.80 
–30 0.99 0.91 0.08 0.80 0.86 6.01 
M: Molarity, Mig: migration, min: minute, TC: tetracaine, PC: procaine, Rs: resolution, 
kV: kilovolt. 
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Figure 3.8 Peak height of tetracaine at two wave lengths, 210 (height 1), 312 (height 2) 
nm, and over injection time in seconds. 
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Figure 3.9 Peak area/time of tetracaine at two wave lengths, 210 (Area 1/time1), 312 
(Area 2/time2) nm, and over injection time in seconds. 
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3.8.1.2 Sensitivity 
The lower limit of detection (LLOD) and the lower limit of quantification (LLOQ) for 
tetracaine were 100 µg/L and 2.5 µg/mL, respectively. 
3.8.1.3 Specificity 
Six samples of blank tape and six samples of tape spiked with tetracaine were prepared 
and carried through the extraction. The concentration of tetracaine used was 2.5 µg/mL 
(LLOQ) and the internal standard was 150 µg/mL. Tetracaine was selective in λmax of 
312 nm (Figure  3.6 and Figure  3.7), and with no significant interfering peaks were found 
at the migration time of tetracaine or procaine. The signal-to-noise ratio at the LLOQ for 
both drugs was greater than 3. Figure  3.10 shows the electropherogram obtained from 
blank tape spiked with IS of 1500 μg procaine, while Figure  3.11, Figure  3.12, Figure 
 3.13, and Figure  3.14 show the electropherograms of tape placed with 50 µg tetracaine, 
Ametop gel 50 µg solution, tetracaine solution, and one of the tape samples from the 
study, respectively, with added IS of 1500 μg procaine. 
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Figure  3.10 Electropherogram obtained from extracted tape sample spiked with IS of 
1500 μg procaine, displayed at 312 nm. 
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Figure  3.11 Electropherogram obtained from extracted tape sample spiked with 50 μg 
tetracaine with added IS of 1500 μg procaine, displayed at 312 nm. 
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Figure  3.12 Electropherogram obtained from Ametop gel solution containing 50 μg 
tetracaine with added IS of 1500 μg procaine, displayed at 312 nm. 
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Figure 3.13 Electropherogram obtained from tetracaine solution containing 50 μg 
tetracaine with added IS of 1500 μg procaine, displayed at 312 nm. 
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Figure 3.14 Electropherogram obtained from tape sample at 4 hours post dose with 
added IS of 1500 μg procaine, displayed at 312 nm. 
Tetracaine 
Tetracaine 
Procaine 
Procaine
minutes
minutes
Comparison of CE/HPLC methods 
 
Page 179 of 334 
3.8.1.4 Calibration curve/linearity 
Figure 3.15 shows a typical calibration line containing seven non-zero calibrators 
assayed. Nominal values were 50, 200, 400, 600, 800, 1000, 1200 μg tetracaine and 1500 
μg procaine. Six batches of calibration curves were plotted using the area ratio of 
tetracaine to IS vs known concentration of tetracaine. All the results were calculated 
using a y =AX + B linear regression (Table 3.8). 
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Figure 3.15 Typical calibration curve and linearity of tetracaine (CE). 
 
Table 3.8 Calibration line parameters for 5 separate runs. 
Batch Slope(A) Intercept(B) r2 
1 0.0194 -0.0192 0.9992 
2 0.0195 0.0099 0.9993 
3 0.0194 0.0155 0.9986 
4 0.0191 0.0070 0.9998 
5 0.0198 0.0041 0.9997 
The regression coefficients for all the calibration curves obtained were greater than 0.99. 
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3.8.1.5 Inaccuracy and imprecision 
The within and between batch, and the total variability obtained from the ANOVA are 
summarized in Table 3.9. The percentage inaccuracy for all the quality control samples 
including LLOQ and ULOQ was below 11%. 
Within assay reproducibility  
For within batch and between batch imprecision the LLOQ and ULOQ and the three 
control samples were each assayed six times in three separate assays. Each assay had an 
individual calibration curve. The coefficient of variation (CV) for imprecision for all the 
quality control samples including LLOQ and ULOQ was below 2.5%. 
Between assay repeatability 
For each of the three assays mentioned above, the mean concentration for each assay was 
used to calculate the between assay reproducibility. The CV for imprecision for all the 
quality control samples including LLOQ and ULOQ was below 12.1%. 
Within and between batch precision was calculated using internationally agreed methods 
(FDA, 2001a). 
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Table 3.9 The within and between batch and the total variability obtained from the 
nested analysis of variance (ANOVA). 
 LLOQ QC1 QC2 QC3 ULOQ 
Nominal conc (μg/mL) 5.00 10.00 25.00 100.00 120.00 
Mean; (μg/mL) n = 18 5.53 10.27 27.35 106.36 121.00 
Inaccuracy (%) 10.58 2.77 9.42 6.36 0.83 
SDw 0.052 0.25 0.31 2.06 1.86 
SDb 0.56 1.24 1.61 8.99 3.27 
SDt 0.56 1.27 1.64 9.23 3.76 
CVw (%) 0.94 2.47 1.13 1.94 1.54 
CVb (%) 10.13 12.06 5.89 8.46 2.70 
CVt (%) 10.18 12.31 6.00 8.68 3.10 
w= within batch; b = between batch; t = total 
3.8.1.6  Recovery 
The absolute recovery of tetracaine from tape samples compared with tetracaine solution 
ranged from 97 to 104%. 
3.8.1.7 Stability 
Stability was assessed both in solution (50% v/v aqueous MeOH) after extraction, and the 
stability of tetracaine before extraction, during three freeze cycles of 10 (Q1), 25 (Q2), 
and 100 μg/mL (Q3) stock solutions. Aliquots from these solutions were injected into the 
CE after each freeze / thaw cycle. Figure 3.16 and Figure 3.17 show that tetracaine 10, 
25, 100 μg/mL were stable in tape prior to and after extraction, respectively. 
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Figure 3.16 Stability measurements of three quality controls, for tetracaine, in tape, 
following three freeze cycles before extraction. 
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Figure 3.17 Stability measurements of three quality controls, for tetracaine, in tape, 
following three freeze cycles, after extraction. 
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3.8.2 Results of method II 
3.8.2.1 Sensitivity 
The lower limit of detection (LLOD) for tetracaine was 3 µg/L. The lower limit of 
quantification (LLOQ) was 30 µg/L. 
3.8.2.2 Specificity 
Figure 3.18 shows a chromatograph of a time zero healthy volunteer sample with no 
significant interfering peaks at the retention time of procaine (150 µg/mL) or tetracaine, 
compared with Figure 3.19, 10μg/mL tetracaine, and Figure 3.21, 1 hour post-treatment 
chromatograph, at λmax of 312 nm.  
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ProcaineµV
Time (Minute)  
Figure 3.18 Chromatogram obtained from extracted tape of time zero healthy volunteer 
sample spiked with IS of 1500 μg procaine, displayed at 312 nm. 
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Time (Minute)  
Figure 3.19 Chromatogram obtained from extracted tape of 10μg tetracaine spiked with 
IS of 1500 μg procaine, displayed at 312 nm. 
µV
Time (minutes)  
Figure 3.20 Chromatogram obtained from blank tape, displayed at 312 nm. 
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Figure 3.21 Chromatogram obtained from extracted tape of 1 hour post-treatment spiked 
with IS of 1500 μg procaine, displayed at 312 nm. 
3.8.2.3 Calibration curve/linearity 
Figure 3.22 shows the calibration line containing the eight non-zero calibrators assayed. 
Nominal values were 0.3, 1, 3, 10, 30, 100, 300, 1000 μg tetracaine and 1500 μg 
procaine. Six batches of calibration curve were plotted using the area ratio of tetracaine to 
IS vs known concentration of tetracaine. All the results were calculated using a 1/x2 
weighted quadratic regression. Linear regression of slope, intercept, r2 are shown in Table 
3.10. 
(minutes)
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Table 3.10 Calibration line parameters for 5 separate runs. 
Batch Slope(A) Intercept(B) r2 
1 0.0240 0.0002 0.9999 
2 0.0239 0.0002 0.9999 
3 0.0244 0.0005 0.9999 
4 0.0240 0.0004 0.9999 
5 0.0242 0.0004 0.9999 
The regression coefficients for all the calibration curves obtained were greater than 0.99.  
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Figure 3.22 Typical calibration curve and linearity of tetracaine (HPLC). 
3.8.2.4 Accuracy and precision 
Accuracy was tested by determination of low, medium and high quality control samples, 
together with the LLOQ and ULOQ samples. Each control sample contained tetracaine. 
The nominal values for the low, medium and high control samples were 5, 50 and 500 μg 
respectively. The nominal values for the ULOQ and LLOQ were the same nominal 
concentration as the highest and the lowest calibration standards, respectively. 
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Assay precision was measured both within and between batch by the analysis of three 
control samples, the LLOQ and the ULOQ. 
3.8.2.4.1 Within assay reproducibility  
For within and between batch precision the LLOQ and ULOQ and the three control 
samples were each assayed six times during one assay. The CV for imprecision and the 
percentage inaccuracy for all the quality control samples including LLOQ and ULOQ 
was below 10 and 5%, respectively. 
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Table 3.11 The within batch imprecision and inaccuracy of three quality controls 
together with LLOQ and ULOQ. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Nominal Conc (μg/mL) 0.03  0.50 5.0 50.0 100.0 
Mean 0.03 0.51 4.86 47.19 95.97 
SD 0.001 0.002 0.019 0.105 2.614 
CV% 4.02 0.41 0.40 0.22 2.73 
Inaccuracy % 3.40 2.65 2.83 5.63 4.25 
3.8.2.4.2 Between assay repeatability 
The mean concentration from each assay was used to calculate the between assay 
reproducibility. The CV for imprecision and percentage inaccuracy for all the quality 
control samples including LLOQ and ULOQ was below 7 and 5%, respectively. 
Table 3.12 The between batch imprecision and inaccuracy of three quality controls 
together with LLOQ and ULOQ. 
Data LLOQ QC1 QC2 QC3 ULOQ 
Nominal Conc (μg/mL) 0.03  0.50 5.0 50.0 100.0 
n = 6 6 6 6 6 
Mean 0.03 0.51 5.03 48.46 92.29 
SD 0.001 0.004 0.083 0.492 0.986 
CV% 3.66 0.85 1.65 1.02 1.07 
Inaccuracy % 4.38 1.61 1.41 3.46 7.71 
Within  and between batch precision was calculated using internationally agreed methods 
(FDA, 2001a). 
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3.8.2.5 Stability 
The CV% of 100 μg/mL tetracaine was less than 2%, when injected into the HPLC after 
each freeze / thaw cycle. 
Table 3.13 Three freeze/ thaw cycles of the 100 µg/mL stock solutions. 
Data Standard 100 µg/mL 
Time 0 100.78 
Freeze / thaw week 1 101.2 
Freeze / thaw week 2 99.79 
Freeze / thaw week 3 103.23 
CV% 1.42 
3.8.2.6 Recovery 
The absolute recovery of tetracaine ranged from 79 to 104%. The result was obtained by 
dividing the peak height for specific tetracaine concentrations in methanol: water, 50:50 
solutions and the peak height of the same concentration in skin tape stripping soaked in 
methanol:water, 50:50 from time zero (sample 0). 
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3.9 Method comparison 
Tape samples obtained from patients’ skin were successfully analyzed by two different 
analytical techniques, short end CE and HPLC. An internal standard was used to 
minimize injection volume variability, and error result from volatile methanol in sample. 
The two methods of measurement were compared to find out if there was any difference 
related to the analysis. The analyzed data were calculated and plotted for both methods, 
Figure 3.23 shows different percentage errors were in a range of ± 20%. and Figure 3.24 
shows Bland–Altman analysis was in a range of ± 1.96 SD from the mean, and Table 
3.14 shows the mean, standard deviation, and standard error of the mean percentage error 
(MPE) and the absolute mean percentage error (AMPE) between the HPLC and the CE 
measurements. 
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Figure 3.23 The percentage difference error between HPLC and CE methods in the 
analysis of tetracaine tape stripping samples (n=102). 
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Figure 3.24 Bland–Altman analysis: correlation of HPLC and CE in the analysis of 
tetracaine tape stripping samples, (SD = ±8.018, Mean = 2.231, n=102). 
 
Table 3.14 The mean percentage error and the absolute mean percentage error between 
the HPLC and the CE measurements. 
Data MPE AMPE 
Mean 2.23 7.86 
SD 8.08 4.63 
n 102 102 
SEM 0.79 0.46 
3.10 Results of method III 
3.10.1 Method development 
Figure 3.25 shows the UV absorbance of BABA was optimum at 285 nm wave length 
(λmax). The optimum buffer pH was 8, precise and stable temperature was 20°C, optimum 
buffer concentration (M) at constant pH was 30 mM disodium tetraborate BGE, and 
when voltage was applied to the instrument, deterioration in resolution was noted at –
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27KV. Additionally the maximum injection time reached was 10s, however 7s was 
selected, which gave a better peak shape and good resolution. 
3.10.2 Sensitivity 
The lower limit of detection (LLOD) for BABA was 1 µg/mL. The lower limit of 
quantification (LLOQ) was 2.5 µg/mL. 
3.10.3 Specificity 
Six samples of blank tape and six samples of tape spiked with BABA were prepared and 
taken through the extraction. The amount of BABA used was 2.5 µg (LLOQ) and the 
internal standard was 1500 µg procaine. BABA was selective at λmax of 285 nm (Figure 
3.25), and no significant interfering peaks were found at the migration time of BABA or 
procaine (Figure 3.26). The signal-to-noise ratio for both drugs was greater than 3. Figure 
3.27 shows the electropherogram obtained from blank tape spiked with 100 μg BABA 
and added IS of 1500 μg procaine, while Figure 3.28 and Figure 3.29 show the 
electropherograms obtained from a patient sample without, and with added 100 μg 
BABA, respectively. 
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Figure 3.25 UV spectra showing that BABA was selective at 285 nm. 
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Figure 3.26 Electropherogram obtained from extracted tape sample spiked with IS of 
1500 μg procaine, displayed at 285 nm. 
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Figure 3.27 Electropherogram obtained from tape sample spiked with 100 μg BABA 
and 100 μg tetracaine with added IS of 1500 μg procaine, displayed at 285 
nm. 
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Figure 3.28 Electropherogram obtained from tape sample 1 hour post dose with added 
IS of 1500 μg procaine, displayed at 285 nm. 
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Figure 3.29 Electropherogram obtained from tape sample 1 hour post dose with added 
100 μg BABA, and IS of 1500 μg procaine, displayed at 285 nm. 
3.10.4 Recovery 
The absolute recovery of BABA spiked in tape compared with BABA solution ranged 
from 89 to 124%.  
3.10.5 Stability of samples 
The CV% of QC1, QC2, and QC3 of BABA were less than 7%, when injected into the 
CE after each freeze / thaw cycle. 
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Table 3.15 Three freeze/ thaw cycles of the QC1, QC2, and QC3 of BABA. 
 
3.10.6 Stability of sample injection 
The stability of injection samples after adding 30mM BGE, was measured for procaine, 
tetracaine, and BABA. BABA was stable during the analysis at ambient and 37 ºC 
temperatures and after at least 10 days refrigeration. Procaine and tetracaine were 
hydrolyzed at ambient and 37 ºC temperatures, and even when the solutions were 
refrigerated. The amount of hydrolysis increased with time and as temperature increased. 
For procaine the hydrolysis was 2.84%, and 11.37%, and for tetracaine the hydrolysis 
was 2.14%, and 5.80%, at ambient and 37 ºC temperatures, respectively. 
 
3.11 Discussion 
The quantitative determination of drugs and their metabolites in biological fluids plays a 
significant role in the evaluation and interpretation of bioequivalence, pharmacokinetic, 
toxicokinetic, and forensic studies. The huge number of samples generated by these 
studies necessitates the development of rapid, simple, and valid, analytical methods. Thus 
the validation of these methods by the latest guidance and principles of validation 
approved by for example, the FDA, is important and critical. 
Data Standard 80 µg/mL Standard 40 µg/mL Standard 10 µg/mL 
Freeze / thaw week 1 81.95 41.21 8.93 
Freeze / thaw week 2 78.30 40.65 9.88 
Freeze / thaw week 3 75.26 43.55 8.83 
Mean 78.51 41.81 9.21 
SD 3.35 1.54 0.58 
CV% 4.26 3.68 6.27 
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In this study CE and HPLC methods were developed, optimized and validated. The first 
technique was a short end injection (reverse) CE method. Applying a short end injection 
with -ve voltage resulted in tetracaine and procaine being fully separated. However, an 
attempt to reduce the migration time even further by reducing the capillary length to 35 
cm from the original 48.5 cm, thereby increasing the potential gradient, resulted in 
tetracaine and procaine not being fully separated and was only about 30 seconds faster. 
The short migration times obtained for procaine (1.25 min) and tetracaine (1.36 min) are 
an advantage of CE compared with the more than 5 min retention time for tetracaine 
using HPLC (Mazumdar et al., 1991), and the HPLC method  developed here on a 
pentafluorophenyl (PFP) column. The new HPLC method resulted in a good separation 
with excellent resolution and minimum tailing. However it is difficult to rationalise the 
precise separation mechanism on a PFP column. PFP is known to exhibit both normal 
and reversed phase characteristics (Marin and Barbas, 2006). The HPLC on a PFP 
column used in this study gave retention times of 2.6 and 3.8 min for procaine and 
tetracaine, respectively. All the validation results met the international requirements as 
outlined by the FDA’s 2001 bioanalytical method validation guidelines (FDA, 2001a).  
CE and HPLC methods with UV detection have been compared for the determination of 
tape samples obtained from healthy volunteers, given tetracaine as part of a 
pharmacokinetic study. UV detection was chosen to be used for its simplicity and low 
cost. Although the HPLC method performed slightly better in terms of sensitivity, both 
methods in this study measured all samples obtained without any problems, including the 
lower concentrations obtained in the tape samples. The data obtained were within ±1.96 
SD, and 17% error of the difference. Nevertheless the purpose of this study was to 
develop a fast and simple analytical method, to determine tetracaine in skin using tape 
samples from 12 healthy volunteers given tetracaine as part of a pharmacokinetic drug 
delivery study. Although the imprecision was higher, the lower operation costs and 
volume of electrolyte used, and faster running time made CE preferable to HPLC for this 
kind of study. This result was confirmed by different authors in a comparison between 
the two methods (Clohs and McErlane, 2003, Aurora Prado et al., 2005, Muscarella et al., 
2005, Kowalski and Plenis, 2007, Carlucci et al., 2007, Kocevar et al., 2008). Sometimes 
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HPLC was not useful (Hilz et al., 2006), due to the physicochemical properties of the 
analyte  resulting in poor resolution and reproducibility (Bexheti et al., 2006). 
In addition BABA has been analyzed by another method using the same samples 
obtained in this study. The CE method was a very short end injection (reversed). 
Applying a short end injection (reversed) by –ve voltage resulted in BABA, tetracaine, 
and procaine being fully separated in very short times 0.85, 0.40 and 0.35 minutes, 
respectively. Applying this method to the samples resulted in negative value for BABA. 
This is suggested that the samples did not contain BABA, but tetracaine and procaine 
were separated. However after adding BGE, tetracaine and procaine were not stable 
resulting in drug hydrolysis, leading to BABA formation from tetracaine, and an 
unknown compound from procaine. Procaine and tetracaine were hydrolyzed at ambient 
and 37 ºC temperature, and even when refrigerated. The hydrolysis increased with time 
and with temperature increase, for procaine the hydrolysis was 2.8%, and 11.4%, and for 
tetracaine the hydrolysis was 2.14%, and 5.80%, at ambient and 37 ºC temperature, 
respectively. The pH was 7.8 close to blood pH. This may promote drug hydrolysis, and 
as suggested by Iglesias-Martinez (Iglesias-Martinez et al., 2006), who found that 
procaine hydrolyzed in alkaline media. Tetracaine belongs to the ester group of 
anaesthetics, metabolized in the plasma by pseudocholinesterase enzyme, resulting in the 
production of BABA. 
3.12 Conclusions 
A simple and rapid short end direction (reversed) CE method using CZE with UV 
detection, and a HPLC method using UV detection to determine tetracaine in skin using 
tape samples have been developed and validated for separation and quantification. Both 
methods have simple tape extraction procedures of tetracaine. The accuracy and 
selectivity of the two methods allowed the measurement of tetracaine in all samples 
obtained from a skin tape stripping study in healthy subjects. The results are shown in 
chapter 4. The separation was fast for both methods, especially for short end direction 
(reversed) CE. Although the imprecision was higher, the lower cost and volume of 
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solvent used and faster running time made CE preferable over HPLC for this kind of 
study. 
In addition BABA was separated by a rapid and simple method. However, no BABA was 
detected (less than 2.5 µg/mL) in TS sample from subjects. 
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Chapter 4 Comparison of tape stripping, 
microdialysis, and systemic measurement 
for pharmacokinetic studies 
4.1 Introduction 
Pharmacokinetics (PK) consists of a drug concentration against time profile. The PK of 
most drugs are characterized by measurement of plasma concentrations instead of local 
tissue concentration. Today many drugs are available to use. They are available in 
different dosage forms, such as oral, intravenous (IV), intramuscular (IM) formulations. 
Once absorbed from the gastrointestinal tract (GIT), an oral drug is available 
systemically, before it can be distributed to the site of action. There are many factors that 
may affect a drug’s therapeutic effect such as drug dosage form, absorption, distribution, 
metabolism, mechanism of action, and elimination. However, systemic measurement of a 
drug is not useful for all drugs. Topical drug products, such as antibacterial, antifungal, 
local anaesthetics, topical corticosteroids, act locally. These pharmaceutical drugs are 
designed to target a specific site in the body, so there is a need to ensure that an adequate 
amount of drug is distributed in the target tissue. When drug is applied to the skin, the 
absorption occurs near the site of action. Although it is not clear if it can reach the tissue 
or other compartments, the concentration of these drugs is mainly localized in the local 
tissue. The plasma concentration of the drug can be measured but this may not reflect the 
actual amount of drug available in the local tissue. Although they may be useful in the 
evaluating the toxicity of the compound (Kudo et al., 2001), plasma measurements may 
be misleading in the design and development of topically applied drugs. Hence, 
conventional drug measurement using systemic blood samples has proved inappropriate 
for this purpose (Benfeldt et al., 2007). When assessing the pharmacokinetics of these 
kinds of drugs appropriate methods must be applied. Thus, in vivo and in vitro 
measurement of a topically applied drug should be obtained by a method that evaluates 
directly local tissue concentration against time, probably in the local interstitial (tissue) 
fluid. 
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The study of drug permeation into the skin is quite simple. Useful information has been 
obtained via in vitro experiments using animal or human skin obtained from a skin bank 
or by donation from patients after surgery. The human or animal skin is usually used as a 
membrane to study the skin as a barrier, and to measure the drug diffusion through the 
skin, using two compartment cell diffusion. Several types of diffusion cell are available, 
and the most commonly used cell type is the Franz type diffusion cell (Franz, 1975). The 
Franz cell apparatus used in testing with human skin more closely resembles a topical 
administration to human skin (Koch et al., 1987). Nevertheless, the data and the results 
obtained from the preclinical study, especially in transdermal drug delivery, may not be 
interpreted to represent in vivo experiments. The skin obtained may lose its integrity, the 
barrier may disrupt, and blood supply and metabolic enzymes may not available. In 
addition, human skin is not always available or not in sufficient quantity. While using 
animal skin may be possible, the animal model is different to human skin.  
To obtain clinical information about a drug in the skin, relevant in vivo methods must be 
applied, especially in a pharmacokinetic study. Many techniques are available for direct 
assessment of pharmacokinetic profiles in local tissue such as tape stripping (TS) or 
dermatopharmacokinetic (DPK) (Pershing et al., 1994, Schwarb et al., 1999, Weigmann 
et al., 1999b, Weigmann et al., 1999a), microdialysis (MD) (Muller et al., 1995, 
Lorentzen et al., 1996, Fang et al., 1999), or combined microdialysis with other 
techniques, such as positron emission tomography (PET) (Langer et al., 2005). 
Microdialysis can be used to evaluate electroporation and transcutaneous sampling (ETS) 
(Sammeta et al., 2009). Other techniques such as magnetic resonance imaging, skin 
biopsies, skin blister fluid sampling, confocal microscopy, pharmacodynamic methods 
and suction blisters to assess skin drug levels following systemic administration, have 
been explored for measuring bioavailability of topical drug products (Shah, 2001). 
Until now the clinical experience in the application of microdialysis and tape stripping 
has been limited, with little clinical information on the appropriate methods for the 
measurement of highly lipid soluble and protein bound drugs. Tetracaine is a highly 
lipophilic and protein bound compound that penetrates the skin and is available in the 
local tissue for several hours. Thus TS and MD methods were used to determine the 
Comparison of TS, MD, and systemic measurement for PK study 
 
Page 202 of 334 
concentration of tetracaine and its metabolite in the different compartments rather than 
plasma. Both techniques were compared with the conventional systemic method. 
4.2 Microdialysis 
Microdialysis (MD) is a relatively non-invasive technique, used in clinical and preclinical 
studies including pathophysiology, pharmacology, and physiology. MD is applied for 
continuous sampling of endogenous and exogenous substances in the extra cellular fluid 
(ECF) of the tissue at normal conditions. Also MD can be used to deliver a drug to 
specific target tissues (Hocht et al., 2007). Microdialysis was developed in 1958 (Kalant, 
1958), when Kalant  modified the dialysis procedure of Axelrod and Zaffaroni (Axelrod 
and Zaffaroni, 1954). It was used in neuroscience early on in the 1960s, when scientists 
were trying to correlate between neurochemistry and behaviour (Groth, 1996). In 1966, 
Bito et al. (Bito et al., 1966) illustrated that a semi permeable membrane can be used to 
sample the amino acids and electrolytes in animal brains. The results of using MD in 
animals encouraged researchers to use it in humans. In 1987, MD was used to understand 
the characterization of the intracellular space, by measuring glucose concentrations 
(Lonnroth et al., 1987). Successful results supported the introduction of MD in other 
experiments, such as: 
 The evaluation and interpretation of a drug’s concentration and its 
metabolites, and the investigation of physiological function in the human 
body, induced by chemicals (Schmelz et al., 1997, Clough, 1999, Morgan 
et al., 2006). 
  The investigation of physiological function in animals (Ungerstedt et al., 
2009, Zhu et al., 2009, Wang et al., 2009). 
 Using MD for the measurement of the neurotransmitters GABA and 
glutamate in rat following stimulation with potassium (Buck et al., 2009). 
  Using MD to evaluate preferred alternative drug route of administration 
(Feng et al., 2009). 
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  Using MD for the measurement of drug distribution (Chang et al., 2009).  
 In an in vivo study, a MD sampling method was connected directly to 
chromatography techniques (Johansen et al., 1997), for continuous analysis 
of the pharmacokinetic time profile of unbound baicalin in rat blood and 
brain (Huang et al., 2008). 
MD is a simple technique to obtain tissue drug concentrations. For this reason it is 
increasingly being used in drug development and research. The system can be used in 
vitro and in vivo for the measurement of drug and/or metabolite concentrations in tissues 
and organs. This can give useful information to investigate tissue penetration of drugs 
into a variety of tissues (Chang et al., 2009, Hegemann et al., 1995a, Boelsma et al., 
2000b), to identify that adequate drug concentrations are obtained (Feng et al., 2009, 
Muller et al., 1995), to investigate the physiological function such as neurotransmitters 
(Buck et al., 2009), and to deliver drugs to target organs or tissues (Hocht et al., 2007). 
Compared with intramuscular (IM) and subcutaneous injections, MD causes minimum 
pain and is easy to perform. MD has several research benefits, starting with continuous 
sampling, cost-benefit, time, and precise data. To date the MD technique has been used in 
three possible ways, as an alternative to blood sampling, to collect organ specific data, or 
as a combination of both ways. 
MD can be used in different organs and tissues, hence, different types of MD probes are 
available for use, including concentric, linear, loop, and side by side (Johansen et al., 
1997, Garrisona et al., 2002 , Klimowicz et al., 2004). All catheter probes except linear 
have a concentric design. Figure 4.1 shows the concentric probe connected to a MD 
apparatus pump, which was used in this study. The MD apparatus pumps the perfused 
fluid into the dialysis tube where the exchange of molecules takes place between the 
extracellular fluid and the Ringer solution, similar to the blood elements exchange 
(Figure 4.2). MD catheters have been used to examine different human organs, including 
adipose tissue, brain, breast, bone, lung, gastrointestinal tract, heart, muscle, and 
subcutaneous tissue. However, the most common organ is the skin, with the most 
frequently used probe being the linear probe due to its simplicity and low cost 
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(Kreilgaard, 2002). The probe is implanted either in the dermis or in the subcutis 
(Anderson, 2006), in parallel. MD has been shown to give a proven estimate of the skin 
penetration of a substance (Hegemann et al., 1995b, Muller et al., 1997, Benfeldt et al., 
1999, Barbour et al., 2009). Boelsma et al. (Boelsma et al., 2000a) have shown that 
methyl nicotinate can be detected after 1 minute exposure to a concentration of 25 mM, 
with an increase in the level when the concentration and/or when the application time was 
increased. Another study showed the benefit of MD to investigate the use of 
microemulsion formulations in dermal drug delivery (Kreilgaard, 2001). A recent study 
investigated the response to in vivo cytokines generation following an intradermal 
injection of an allergen (Geraldine et al., 2007). Some other studies used MD to 
administer a drug singly and in a combination for a continuous dose (Morgan et al., 
2006). 
4.2.1 The principle of microdialysis  
The basic principle of MD has been extensively reviewed, and described in detail 
(Kreilgaard, 2002, Muller, 2002, Joukhadar and Muller, 2005, Chaurasia et al., 2007, 
Schmidt et al., 2008). In brief, the principle of MD is to implant a tubular semipermeable 
dialysis membrane “hollow fibre” into the tissue, which mimics the passive function and 
movement of molecules into and out of a capillary blood vessel, into a living tissue, 
similar to that used in an artificial kidney (Anderson, 2006) (Figure 4.2). The hollow 
fibre is typically 0.2–0.6 mm in diameter, and about 8μm thick. The membrane is made 
with a very fragile fibre which can easily be damaged. The possibility that a MD probe 
can be assembled with a puncture needle before insertion of the introducer to the skin has 
been discussed (Anderson, 2006). 
The tubular semipermeable dialysis membrane is connected to a MD pump (a precise 
syringe drive pump) and constantly perfused with tissue compatible sterile buffer similar 
to the physiological fluid (the perfusate), at flow rate between 0.1–5 µL/minute (Figure 
4.1). Now that the probe is implanted into the tissue, the perfusate diffuses into and out of 
the semipermeable dialysis membrane to equilibrate with the ECF of the tissue 
surrounding the membrane. The probe functions as an artificial membrane in the skin. 
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Molecules diffuse across the membrane from the tissue to the probe and vice versa 
according to Fick's law of simple diffusion. The exchange of substances occurs due to the 
concentration gradients, a process called passive diffusion, in this process the degree of 
equilibration is subject to Fick’s second law of diffusion (Stahle, 2000). 
 
Figure 4.1 Diagram showing the microdialysis catheter with two ends (inlet and outlet) 
and in the circle the permeable membrane. 
 
Figure 4.2 Diagram to show the perfusion of fluid through the microdialysis catheter 
into extracellular fluid compared to the mechanism occurring during blood 
elements exchange (CMA). 
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The sample (the dialysate) is collected over time, and stored at –20°C to analyze later for 
endogenous or exogenous substances. The dialysate contains only unbound molecules. 
Thus highly lipophilic and protein bound molecules are not detected. 
4.3 Tape stripping 
Effective drug therapy requires that the active agent should be delivered to the site of 
action in adequate and sufficient concentrations, with few side effects. Bioavailability 
(BA) is defined in the FDA CFR 320.1 (a), as the rate and extent to which the active 
ingredient or active moiety is absorbed from a drug product and becomes available at the 
site of action (FDA, 2008). Thus measuring drug concentration including the metabolites 
can help to monitor a drug’s therapeutic level. Many in vivo methods for measuring 
dermal absorption of drugs are invasive or not feasible (Herkenne et al., 2008), such as a 
venous cannula inserted into a vein to withdraw blood, where complications may arise in 
the vein as a result of the cannulation procedure. Complications include haematoma, 
infiltration (drug not reaching the vein), embolism (occurs when air enters the blood 
vessel), phlebitis (results from an inflammation of the vein). Other methods need ethical 
consideration, and are costly. These methods include microdialysis and the skin blister. 
Some methods are slow, such as collection of urine samples over long periods of time. 
Thus, there is a significant need for the development of a method to determine drug 
concentrations locally. 
Tape stripping (TS) of the outermost skin layer, the stratum corneum (SC), is a fast and 
relatively non-invasive technique to measure a drug absorbed into the skin (Tokumura et 
al., 1999, Reddy et al., 2002, Herkenne et al., 2007). TS is usually performed by placing 
an adhesive tape strip onto the skin surface. Gentle pressure is applied to ensure a good 
contact and subsequently the tape is removed by a quick upward movement. The 
procedure was proposed as dermatopharmacokinetics (DPK) in 1998 in the FDA draft 
guidance, although, it was withdrawn in 2001 for drugs not targeting the SC. Later, the 
FDA carried out an investigation to develop a new technique and reinstated DPK in 
bioequivalence and bioavailability studies of transdermal drugs (FDA, 2002) for a 
disrupted SC. The SC may be disrupted by dermal disease, physical and mechanical 
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problems. DPK is relatively painless, given that only dead cells (corneocytes) in the 
outermost layers in the skin are removed. 
The technique supports the development of transdermal drug therapy. However, it is 
required that the drug must be delivered into the rate-limiting barrier of skin, the SC. In 
skin stripping studies, an area of skin is exposed to a substance for a period of time and 
then cleaned of drug residue. The FDA guidance suggests that 12 strips be applied to the 
area exposed, and they be removed in a sequenced manner to maintain the substance 
concentration versus time profile. The FDA realized that discarding the first two strips, to 
clean the residue of the drug, may cause a variable estimate. However, 90% of the drug is 
found in the first 10 tape strips (Benfeldt et al., 2007), and the quantity steadily decreases 
with deeper layers (Caron et al., 1990). Thus, using a cotton pad to clean the residue, and 
then applying 11 strips and discarding the first TS may give a good result. 
The determination of the concentration of a chemical in TS is performed in conjunction 
with a validated bioanalytical assay for the measurement of substances, such as HPLC 
(Shah et al., 1991), and CE. Tape stripping has been verified as producing a superior and 
reproducible result in SC harvesting in various studies such as, anti acne (Pershing et al., 
2003), dermatologic corticosteroid products (Pershing et al., 2002a), antifungal (Pershing 
et al., 2002b), and antipsoriasis drugs (Umemura et al., 2008), using the human volar 
forearm. The results obtained from these studies, can be used to approximate 
permeability coefficients and partition coefficients. 
The current study was performed to quantify the amount of tetracaine delivered through 
the SC into healthy human skin by tape stripping. 
4.4 Ametop 
Ametop gel is a tetracaine based formulation. It consists of 4% tetracaine base in a 
white/yellow semitransparent gel. Tetracaine has a short onset of action and long duration 
of action, and has become a superior alternative to other local anaesthetics. Similar to 
EMLA cream, Ametop is a topical drug used for dermal anaesthesia especially in 
children undergoing invasive operations. Several clinical studies were performed to 
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compare EMLA and Ametop, and they have concluded that Ametop has a rapid onset of 
action of 30–45 minutes, and has a longer duration of local anaesthesia, with less 
methemoglobinemia (Bishai et al., 1999, Shah et al., 2008). The application of Ametop 
for 30 minutes was clinically equivalent to a 1 hour application of EMLA cream (Bishai 
et al., 1999, Choy et al., 1999). The short onset of action of Ametop is an advantage 
especially in busy clinics and wards, by offering time and cost benefits. 
The use of topical anaesthetics has increased in recent decades. Most biochemical and 
pharmacological effects of drugs take place in tissues or cells, especially locally acting 
drugs which are most closely applied to the site of action. Thus assessing tissue 
concentration is meaningful and useful for drug pharmacology studies. 
Ametop is a local anaesthetic applied to skin, and its concentration is high in local tissue 
compared to plasma. At this time, MD and TS are available to provide information from 
the extracellular space and outermost layer of the skin, respectively. Thus, using skin 
samples is more meaningful than using blood samples, especially when the systemic 
concentration of tetracaine is low or nil. Many studies did not detect tetracaine, and only 
detected the metabolite 4-butyaminobenzoic acid (BABA) even in analyzed plasma 
directly after taking blood (Kudo et al., 2001). Tetracaine is mainly hydrolyzed either in 
plasma by pseudocholinesterase and/or by esterase in the liver resulting in breakdown of 
tetracaine into its metabolite (BABA). 
The mechanism of action of Ametop is dependent on a phase change in the formulation. 
Tetracaine forms a meta stable hydrate in the presence of water, resulting in a reduction 
in the melting point from 42 to 29°C (Dennis et al., 2004). Also tetracaine has higher 
lipid solubility compared to lidocaine and prilocaine. When tetracaine is applied locally, 
it melts at skin temperature and forms an oily solution, which facilitates its penetration 
through the lipid layer. Tetracaine exerts its effect by reversibly blocking the nerve ends 
close to the site of application, preventing impulses for both conduction and generation. 
This results in temporary loss of sensation, ‘‘numbness’’, in the local tissue due to the 
reduction in sodium ion permeability through the channel in the cell membrane, from the 
intracellular storage of the cell, by competing with calcium, causing an inhibition of 
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depolarisation. The dermis has nociceptive input which is blocked by the local 
anaesthetics (Shah et al., 2008). 
4.5 Objective 
The main objective of this study was to determine the best approach to the 
pharmacokinetic measurement of topical products. Skin stripping with adhesive tape 
(TS), microdialysis (MD) fluid, and plasma samples were compared, using the PK 
analysis of tetracaine and its metabolite (BABA).  
4.6 Study approval 
The study protocol was approved by the East London and The City Health Authority 
Research Ethics Committee, reference number 3 of 05/Q0605/98, dated 15th February 
2008. Written informed consent was obtained from all healthy volunteers enrolled in the 
study.  
4.7 Materials and methods 
4.7.1 Treatment 
Ametop gel (containing 4% w/w tetracaine) was supplied in a 1.5 g tube and stored in a 
refrigerator until the study day for each volunteer (one mL of Ametop gel). This is 
required by the manufacturer and the characteristics of storage stability. 
4.7.2 Apparatus 
CMA 60 MD catheters were used together with CMA 107 MD pumps supplied by CMA 
microdialysis Ltd. (Sweden) for the MD study. Adhesive tape for the TS study was 
TESA 4204 PV5 supplied by TESA UK Ltd. 
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4.7.3 Perfusion fluid 
Perfusion fluid was an isotonic sterile perfusion fluid with osmolality of 290 mosm/kg, 
and pH 6. The perfusion fluid contents were Na+ 147mmol/L , K+ 4 mmol/L, Ca 2 + 2.3 
mmol/L, and Cl- 156 mmol/L. 
4.7.4 Subjects 
Twelve healthy men and women were recruited by advertisement to staff and students of 
Queen Mary, University of London, Barts and the London NHS Trust, and to the general 
community, as approved by a Central Office for Research Ethics Committee (COREC). 
4.7.5 Study design 
The study involved a single dose with two visits, pharmacokinetic study for MD and 
systemic measurement in one visit, and skin stripping in the second visit in healthy 
volunteers with a minimum of 1-week gap in between. The study lasted for a maximum 
of 6 hours for each visit.  
4.7.6 Screening evaluation 
Prospective subjects attending the study site had a screening visit within 4 weeks of study 
commencement. In this visit the nature of the study, the procedures, and the risks were 
fully explained. Before any screening procedures occurred they signed an informed 
consent form in which they acknowledged that they were willing to be enrolled and 
would follow all the study protocols. Subjects participating in this study were screened 
for the inclusion and exclusion criteria referred to appendix 6. This included a medical 
history, health questionnaires, physical examination (age, blood pressure, heart rate, 
height, sex, and weight), concomitant medication, and urine tests, a urine specimen was 
obtained for drug screening, and a pregnancy test for females. The volunteers were fully 
informed of the nature of the pharmacokinetic study at this time. The subjects were 
permitted to join the study if they passed the screening. 
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4.7.7 Study procedure and protocol 
Subjects entering the study unit for initiation of the study, had blood pressure and heart 
rate checked. All hairs were removed from the volar forearm on both hands using a razor. 
The sites were thoroughly cleaned with water and wiped dry with a towel. The arms were 
checked for cuts or abrasions which would invalidate the study. The subject layed supine 
on a bed and one arm was cannulated with a 20G cannula for collection of serial blood 
samples. The first blood sample (5mL) was drawn immediately after canulation for a 
baseline reading. On the contralateral arm from the venous sampling, a circular area of 10 
cm2 was marked with a pen in the centre of the volar forearm using a template for the 
treatment application.  
4.7.8 DMD probe implantation 
The MD guide cannula was inserted in the dermis (subcutaneously) at about 1 cm below 
the marked area. Probe implantation was performed without anaesthesia under sterile 
conditions by a physician using a puncture needle before inserting the introducer. The 
MD probe was inserted through the tip of cannula and the needle then pull back, leaving 
the probe implant, about 3 cm long in the dermis (subcutaneous) below the marked area. 
The inlet and outlet tubing was attached to the skin using self adhesive fabric tape. The 
inlet tubing was connected to the MD pump and the outlet tubing was connected to the 
microvial. 
Upon successful MD probe implantation, the subject was allowed to recover for 60 
minutes to diminish skin reactions (i.e. increase in skin blood flow and histamine release) 
(Anderson et al., 1994) before the onset of the experiment. The perfusion fluid was 
perfused for 20 min at a flow rate of 1.0 µL/min and a 5 mL venous blood was collected 
for a baseline sample. Twenty minutes after collection of the MD sample, Ametop gel 
was applied to the skin at the marked area and occluded with a dressing for the period of 
1 hour. Then, the residual drug was removed and the skin cleared with tissue. Dialysate 
sampling was commenced for 4 h replacing the micro vial every 20 min. Venous samples 
were collected at 0, 20, 40 minutes, 1, 1.5, 2, 2.5, 3, 3.5, and 4 h post dose. Both venous 
and MD samples were stored at –20°C until further analysis by a validated liquid 
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chromatography-mass spectrometry (LC-MS/MS) method with adequate sensitivity and 
accuracy to measure a low concentration of drugs in plasma, and the low volume of 
sample in MD.  
After completion of all of the above procedures, both the MD and intravenous catheter 
were removed and the subject was discharged. The subject had a minimum of a 1-week 
washout period for the TS study.  
4.7.8.1 Implantation of the catheter 
A 30 mm length specific catheter with a dialysing membrane was used for MD in the 
subcutaneous tissue. The probe had diffusion characteristics that permitted exchange of 
substances in the ECF. The inlet tubing was connected to the pump and the outlet tubing 
ended in a needle fixed into a microvial holder and the microvial to collect the sample. 
The microvial was changed every 20 minutes during the study, and then stored at -20° C 
until the analysis. The catheter was pre-loaded into a unique parallel slit cannula 
introducer that allowed easy insertion into the tissue. 
Prior to catheter implantation into the subcutaneous tissue, the membrane was pre-wetted 
(without removing the protection tube surrounding the catheter), and checked for its 
validity using a MD pump to flush the catheter with sterile perfusion fluid. This was to 
prevent any damage and/or tissue blockage to the probe membrane during the time of 
insertion into the subcutaneous tissue. 
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Figure 4.3 Volar forearm picture of a healthy volunteer from the microdialysis clinical 
study, showing an implanted microdialysis catheter, connected at the outlet 
with microdialysis pump and at the inlet with a microvial holder and 
microvial. 
4.7.9 Tape stripping procedure 
A total of nine rectangular sites (sites 1–9), each 6 cm2 (2 cm x 3 cm) of skin surface area 
were demarcated on the ventral forearm using a template. The treated area (sites 2–8) was 
at the central volar forearm which was 3cm above the wrist and 3cm below the 
antecubital fossa. Site 1, a minimum of 3cm above the antecubital fossa, served as a 
control (0 h sampling). The treatment was 1mL Ametop, applied on all of the 8 
application sites by using a 2.5 mL syringe followed by an occlusive dressing. Ametop 
was distributed across the treated area using a metal spatula, and to maintain treatment in 
its place, subjects were asked to keep their hand in a horizontal position. All the 9 sites 
represented the uptake and the elimination phase. TS was performed at 0, 15, 30, 45 
minutes and 1 hour for the uptake phase (sites 1, 2, 3, 4, and 5) and 1.5, 2, 3, and 4 hours 
for the elimination phase (sites 6, 7, 8, and 9). 
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Figure 4.4 Treatment and tape stripping application area on the volar forearm 
(modified from Barts medical image library at Queen Mary). 
4.7.9.1 Removal of the residual products and application of tape to the 
skin 
The SC harvesting was performed directly on site 1 before Ametop gel application. 
Before SC harvesting from the treated skin sites, the residual product was removed from 
the skin surface using 3 independent dry cotton pads. The residual product was removed 
at 15, 30, 45 min from sites 2, 3, and 4. For sites 5 to 9, the residual product was removed 
at 1 hour. After product removal from the skin, the first adhesive tape was applied and 
briskly rubbed with blunt ended forceps to harvest the SC. The tape was removed using 
the forceps. The first adhesive tape was discarded due to the potential contamination 
from the residual product not removed with dry cotton wool. The remaining 10 adhesive 
tapes were applied sequentially using the same procedure described above. All the tapes 
were placed in polypropylene tubes and kept frozen at –20° C until further analysis for 
the tetracaine content. The product application and SC harvesting were performed by a 
single person to minimize variability. The forceps used for the application and removal of 
the tape were wiped with 70% isopropyl alcohol between skin sites to avoid 
contamination. A pin prick test was performed at the strip site to determine the degree of 
numbness. 
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4.7.9.2 Pin prick procedure 
In the skin stripping study, the degree of anaesthesia was assessed using a pinprick 
technique prior to the stratum corneum harvesting at 15 minutes, 30 minutes, 45 minutes, 
1h, 1.5h, 2h, 3h, and 4h. The pin prick test was repeated on subjects prior to skin 
stripping procedures on each site of the study. 
Pinprick testing was performed by using a safety pin, which was inserted through a 
rubber stopper with a mass of 30g. The apparatus was lowered down perpendicularly on 
the skin and rested gently on the skin surface. The 30g stimulus was to ensure the 
pressure was always the same for every pinprick and did not penetrate the skin (Bucalo et 
al., 1998). Pain scores after the pinprick test were recorded using a verbal rating score 
(VRS) and visual analogue score (VAS). In the VRS assessment, the volunteers were 
asked the following questions: How strong was the pain of the procedure?, and were 
provided with a choice of four categories: 1) no pain; 2) minimal sensation; 3) moderate 
pain; and 4) sharp pain. The volunteer selected one answer for each time point by circling 
the number. In the VAS assessment, a 100 mm horizontal line with endpoints that were 
anchored by descriptors ‘no pain’ and ‘sharp pain’ was shown. For each time point, the 
volunteer was asked ‘What did the procedure feel like?’ and then was requested to make 
a vertical line across the tramline which represented the intensity or unpleasantness of 
their pain from the procedure. Values were measured in millimetres from the left of the 
tramline.  
4.8 Analytical methods 
Plasma and MD samples were analyzed for tetracaine and BABA concentrations by a 
LC-MS-MS method. This highly sensitive method was used so that the expected low 
concentrations of tetracaine and BABA in plasma and the concentrations in the small 
volume of MD samples (20 µL) could be measured.  
In contrast, tape samples contained an expected high amount of tetracaine, so that 
analysis could be performed by different separation techniques with UV detection. Thus 
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two different chromatography techniques with UV detection have been used and 
validated for the analysis of tetracaine. The first was rapid and simple CE (Al-Otaibi et 
al., 2009), and the second was HPLC. In addition a simple and rapid CE method was 
developed to detect the BABA concentration in the tape samples. These methods were 
discussed in detail in Chapter 3. 
4.8.1 LC-MS-MS method for the analysis of plasma and MD samples 
4.8.1.1 Chemicals 
Chemicals are referred to in chapter 3, except clobazam, and bupivacaine hydrochloride 
were supplied by Sigma Aldrich Company, Poole, UK. 
4.8.1.2 Instruments 
Solvent delivery was achieved using an Agilent 1100 pump. Sample injection was 
performed using an Agilent 1100 autosampler, and an Agilent 1100 column oven was 
used to control the column temperature. 
Detection was by Applied Biosystems Sciex API 4000 mass spectrometer.   
4.8.1.3 Chromatographic system 
A Sciex API 4000 triple quadrupole mass spectrometer equipped with a heated-ion spray 
(heated electro-spray ionisation, ESI) was used to introduce the sample into the mass 
spectrometer. 
Plasma sample 
A 50 mm x 4.6 mm Hypersil 3µ C18-BDS column (Hichrom, Reading, UK) was used, 
and maintained at 50°C. The mobile phase was 35% acetonitrile: 65% aqueous 0.1% 
formic acid, pumped at 800 µL/minute. The sample was injected in a volume of 25 µL to 
the mass spectrometer. 
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Dialysate 
A 100 mm x 4.6 mm Supelcosil 5 µ Silica LC-SI column was used. The mobile phase 
was 25% acetonitrile: 75% 0.1% aqueous formic acid, and pumped at 1000 µL/minute. 
The sample was injected in a volume of 25 µL to the mass spectrometer. 
4.8.2 Assay procedures 
4.8.2.1 Calibrators and quality control samples for MD 
4.8.2.1.1 Tetracaine and BABA calibrator 
A combined stock solution containing tetracaine, BABA was prepared by pipetting 1 mL 
of combined solution (5mg/mL) into a 100 mL volumetric flask and making up to the 
mark with 50% methanol in de-ionized water to produce a sub-stock. 
4.8.2.1.2 Tetracaine and BABA quality 
A combined stock solution containing tetracaine, BABA was prepared by pipetting 1 mL 
of combined solution (5mg/mL) into a 100 mL volumetric flask and making up to the 
mark with 50% methanol in de-ionized water to produce a sub-stock. 
4.8.2.1.3 Internal standard 
Bupivacaine with final concentration of 100 µg/L was used as I.S. for tetracaine, and 
clobazam with final concentration of 100 µg/L was used as I.S. for BABA. 
4.8.2.1.4 Ringer solution aliquots 
Calibrator 
1 mL of the stock solution was pipetted into a 50 mL volumetric flask and made up to the 
mark with Ringer solution to produce a sub-stock (cal1). Then working calibration 
solutions were prepared by diluting the sub stock (cal 1) with Ringer solution as tabulated 
in Table 4.1. 
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Table 4.1 Calibration solution preparations from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/L) 
Volume of 
sub stock (mL)
8  10 12.50 0.125  
7 10 25.00 0.250 
6 10 50.00 0.500 
5 10 100.0 1.000 
4 10 200.0 2.000  
3 10 400.0 4.000  
2 10 600.0 6.000  
      Cal 1 = Sub stock  1000.0  
The calibration solutions were stored at approximately 4ºC. 
Calibrator 1 and calibrator 8 were used as upper limit of quantitation (ULOQ), and lower 
limit of quantitation (LLOQ). 
4.8.2.1.5 Quality control (QC) samples 
0.5 mL of the stock solution was pipetted into a 50 mL volumetric flask and made up to 
the mark with Ringer solution to produce a sub-stock (cal1). Then working calibration 
solutions were prepared by diluting the sub stock (cal 1) with Ringer solution as tabulated 
in Table 4.2. 
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Table 4.2 Quality control preparations from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/L) 
Volume of 
sub stock (mL)
1 (low) 10 50.0 1  
2 (medium) 10 500.0 10  
      Cal 1 = Sub stock  500.0  
 
4.8.2.2 Calibrators and quality control samples for plasma 
4.8.2.2.1 Tetracaine and BABA calibrator 
A combined stock solution containing tetracaine, BABA was prepared by pipetting 1 mL 
of combined solution (0.5mg/mL) into a 100 mL volumetric flask and making up to the 
mark with 50% methanol in de-ionized water to produce a sub-stock. 
4.8.2.2.2 Tetracaine and BABA quality control 
A combined stock solution containing tetracaine, BABA was prepared by pipetting 1 mL 
of combined solution (0.5mg/mL) into a 100 mL volumetric flask and making up to the 
mark with 50% methanol in de-ionized water to produce a sub-stock. 
4.8.2.2.3 Internal standard 
Bupivacaine with final concentration of 100 µg/L was used as I.S. for tetracaine, and 
clobazam with final concentration of 100 µg/L was used as I.S. for BABA. 
4.8.2.2.4 Calibrator samples 
1 mL of the stock solution was pipetted into a 50 mL volumetric flask and made up to the 
mark with 50% acetonitril to produce a sub-stock (cal1). Then working calibration 
solutions were prepared by diluting the sub stock (cal 1) with 50% acetonitril as tabulated 
in Table 4.3.  
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Table 4.3 Calibration solution preparations from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/L) 
Volume of 
sub stock (mL)
7 10 0.50 0.05 
6 10 1.00 0.10 
5 10 5.0 0.50 
4 10 10.0 1.00  
3 10 25.0 2.50  
2 10 50.0 5.00  
      Cal 1 = Sub stock  100.0  
The calibration solutions were stored at approximately 4ºC. 
Calibrator 1 and calibrator 8 were used as upper limit of quantitation (ULOQ), and lower 
limit of quantitation (LLOQ). 
4.8.2.2.5 Quality control (QC) samples 
0.5 mL of the stock solution was pipetted into a 50 mL volumetric flask and made up to 
the mark with 50% acetonitril to produce a sub-stock (cal1). Then working calibration 
solutions were prepared by diluting the sub stock (cal 1) with 50% acetonitril as tabulated 
in Table 4.4.  
Table 4.4 Quality control preparations from Sub stock (Cal1). 
Cal 
No. 
Total 
Volume (mL)
Assay conc 
(µg/L) 
Volume of 
sub stock (mL)
1 (low) 10 12.5 2.5  
2 (medium) 10 40.0 8.0 
      Cal 1 = Sub stock  50.0  
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4.8.2.3 Extraction 
A simple liquid-liquid extraction was used for plasma samples. 
Dialysate mixture 
10 µL dialysate were transferred to a tube containing 100 µg/L clobazam, and 100 µg/L 
bupivacaine in 1mL of 50% methanol, and then mixed before injection. 
Plasma extraction 
100 µL plasma samples were transferred to a tube, to which was added 500 µL 
acetonitrile and 25 µL internal standard. The contents were mixed and centrifuged at 
13684 g (Relative Centrifugal Force (RCF)) for 5 minutes at room temperature. The 
clean sample in the top layer was then taken and injected. 
4.9 Results 
Twelve healthy volunteers, 6 males and 6 females (Table 4.5) were recruited and 
successfully completed the study according to the protocol of the tetracaine study, with 
no side effects/events observed during or after the study. All of the samples obtained 
from the TS study were successfully analyzed by two validated techniques CE-UV, and 
HPLC-UV. The two methods have been compared and tested by Bland Altman to assess 
the percentage error of the difference. Both tests were shown to have an acceptable 
difference. In addition, tape samples have been analyzed for BABA in another CE-UV 
method. The results showed no BABA was detected in the samples. All of these methods 
have been described in detail in Chapter 3. In contrast, MD and plasma samples were 
analyzed by a LC-MS-MS method to detect tetracaine and BABA. The LLOQ was set at 
5.0, and 12.5µg/L for plasma analysis, and microdialysis sample, respectively. The 
separation was 1.0, and 1.9 minutes for BABA and tetracaine, respectively. The data 
analysis shows a quantified BABA concentration in both MD and plasma, although 
tetracaine was detected but not quantified in MD samples. 
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Table 4.5 Demographic data for 12 subjects in tetracaine pharmacokinetic study. 
Subject Age 
(years) 
Sex 
 
Height 
(cm) 
Weight 
(kg) 
Body mass 
(kg/m2) 
S01 26 F 166 56 20 
S02 22 M 171 57 19 
S03 34 M 174 78 26 
S04 40 M 168 65 23 
S05 29 F 157 55 22 
S06 28 M 170 59 20 
S07 28 F 160 47 18 
S08 23 F 169 56 20 
S09 24 F 165 58 21 
S10 24 M 174 71 23 
S11 31 M 171 76 26 
S12 21 F 158 74 30 
The analyzed data obtained from TS, MD, and plasma have been plotted against time 
profiles, tetracaine concentration versus time shown in Figure 4.5 for TS, and BABA 
concentration versus time in Figure 4.6 and Figure 4.7, for MD and plasma, respectively. 
In MD two subjects were not included in the results due to failed canulations. Figure 4.8 
shows the plots of TS, MD, and plasma profiles on a log scale. The plots and data 
obtained demonstrated that the Cmax concentration of tetracaine was 3 times higher in the 
SC compared to BABA concentrations in the extracellular dialysate and 10 times higher 
in plasma. Tetracaine was detected in the SC at 15 minutes after the application of 
Ametop, but was not detected in either MD or plasma samples. However, BABA was 
detected at 15 minutes for the dialysate, and 40 minutes for plasma samples. 
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Figure 4.5 Mean tetracaine (nM) versus time (minutes) in tape samples following a 
1mL dose of Ametop gel (4% w/w tetracaine), linear concentration axis (n 
=12, Error Bars= 95% CI). 
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Figure 4.6 Mean BABA concentration (nM) versus time (minutes) in MD samples 
following a 1mL dose of Ametop gel (4% w/w tetracaine), linear 
concentration axis (n =10, Error Bars= 95% CI). 
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Figure 4.7 Mean BABA concentration (nM) versus time (minutes) in plasma samples 
following a 1mL dose of Ametop gel (4% w/w tetracaine), linear 
concentration axis (n =12, Error Bars= 95% CI). 
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Figure 4.8 Mean tetracaine concentration (nM) in tape samples, and BABA 
concentration (nM) in MD and plasma, versus time (minutes) following a 
1mL dose of Ametop gel 4%, logarithmic axis (n =10, Error Bars= 95% CI). 
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In addition, the data were analyzed for pharmacokinetic parameters of tetracaine and 
BABA. Table 4.6 and Table 4.7 show the higher AUC and Cmax for tetracaine in TS 
compared to BABA in MD and plasma (Mean AUC0-4h: 88582 nM.min, 55594 and 
13208 nM.min: Mean Cmax (0–4h), 850 nM, 459, 110 nM, respectively). 
Tetracaine was detected in TS samples reaching the maximum concentration faster than 
BABA in dialysate and plasma samples. Wilcoxon’s Signed Rank Test, showed a 
significant statistical difference (p= 0.002) between TS tmax and plasma tmax, and the 
median tmax was higher in plasma (IQR -52.5 min, CI -105, and -30) compared with tape 
samples. However, the tmax for MD cannot be predicted as the concentration of BABA 
was endlessly increasing to the last dose time points of sampling (240 minutes).  
Table 4.8 show the tmax of plasma and TS samples. The mean t1/2 of BABA in plasma was 
106 minutes with the CV% 45% (Table 4.9). 
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Table 4.6 Tetracaine AUC0-4h, data obtained from TS, and BABA from MD, and 
plasma. 
Subject TS MD Plasma 
(nM.min) (nM.min) (nM.min) 
1 60412 25232 14300 
2 108703 12378 27576 
3 77323 16285 10331 
4 104382 124963 17250 
5 75094 92512 10536 
6 123283 41682 22794 
7 58969 12481 1614 
8 81534 NA 16005 
9 101624 14789 885 
10 80046 124331 13402 
11 95990 91296 13395 
12 79730 41615 6427 
 n = 12 n = 11 n = 12 
Mean 87258 54324 12876 
SD 19639 45171 7805 
CV % 23% 83% 61% 
 n = 10 n = 10 n = 10 
Mean 88582 55594 13208 
SD 21436 47406 8284 
CV% 24% 85% 63% 
NA: not available, n: sample number, TS: tape stripping, MD: microdialysis, nM: nano 
molar, SD: standard deviation, CV: coefficient of variation. 
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Table 4.7 Tetracaine Cmax (0–4h), data obtained from TS, and BABA from MD, and 
plasma. 
Subjects TS MD Plasma 
(nM) (nM) (nM) 
1 427 255 111 
2 1030 88 205 
3 761 109 90 
4 868 894 194 
5 803 914 85 
6 840 458 183 
7 355 107 22 
8 618 NA 114 
9 1075 112 15 
10 724 869 106 
11 1622 792 93 
12 1223 288 83 
 n = 12 n = 11 n = 12 
Mean 862 444 108 
SD 346 353 61 
CV% 40% 80% 56% 
 n = 10 n = 10 n = 10 
Mean 850 459 110 
SD 354 368 66 
CV% 42% 80% 60% 
NA: not available, n: sample number, TS: tape stripping, MD: microdialysis, nM: nano 
molar, SD: standard deviation, CV: coefficient of variation. 
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Table 4.8 Tetracaine tmax (0–4 h), data obtained from TS, and BABA from 
plasma. 
Subjects 
TS Plasma 
(minutes) (minutes) 
1 60 60 
2 30 120 
3 60 90 
4 45 90 
5 60 90 
6 60 90 
7 45 240 
8 60 120 
9 60 240 
10 45 120 
11 60 120 
12 60 90 
Mean 54 122.4 
SD 10.2 57.6 
CV% 19% 47% 
TS: tape stripping, SD: standard deviation, CV: coefficient of 
variation. 
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Table 4.9 BABA t1/2, data obtained from plasma. 
Subjects 
Plasma t1/2 
(minutes) 
1 115 
2 65 
3 81 
4 53 
5 133 
6 76 
7 NA 
8 208 
9 NA 
10 87 
11 132 
12 NA 
Mean 106 
SD 48 
CV% 45% 
NA: not available, SD: standard 
deviation, CV: coefficient of variation. 
4.9.1 Least square regression 
The t1/2 of tetracaine and BABA could not be analyzed from TS and microdialysis 
samples, respectively (Figure 2.9and Figure 2.10). 
Equation 4.1 was fitted to the data using non linear least square regression. The sum of 
squares between the measured values (yi) and the fitted values (ŷi) (Equation 4.2) was 
minimised using the Solver add-in of the Microsoft Excel 2007 program. 
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Ct ൌ C0ሺeെλt െ eെka tሻ
 
Equation 4.1 Non linear least square regression. 
C0 = hypothetical concentration at time node (intercept). 
Ct = concentration at t time. 
λ = elimination (slop). 
Ka = absorption (slop). 
෍ሺyi െ ŷiሻ2
 
Equation 4.2 The sum of squares between the measured values (yi) and the fitted values 
(ŷi). 
yi = measured concentration value. 
ŷi = fitted concentration value. 
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Figure 4.9 BABA concentration (obtained from one subject) with time profile 
(minutes) in MD samples after application of 1 mL Ametop gel (4% w/w 
tetracaine) blue line (raw data), red line (fitted data) unresolved. 
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Figure 4.10  Tetracaine concentration (obtained from one subject) with time profile 
(minutes) in tape samples after application of 1 mL Ametop gel (4% w/w 
tetracaine) blue line (raw data), red line (fitted data) unresolved. 
In addition, the AUC and Cmax values demonstrated that the TS study showed low 
variability compared to plasma and most variability for MD (CV%; AUC0-4h, 24, 63, and 
85%: Cmax (0–4h), 42, 60, 80%, respectively). Figure 4.11 and Figure 4.12 show the plot 
of Test for Equal Variances (Bartlett’s and Levene’s test) for AUC and Cmax from TS, 
plasma and MD studies. The wider CI can be seen clearly in MD compared to plasma, 
and the smaller CI in TS for both pharmacokinetic parameters, AUC, and Cmax (Bartlett’s 
test, p= 0.004 for AUC; and Levene’s test, p=0.042, and 0.028, respectively). 
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Figure 4.11 Plot of Test for Equal Variance for AUC, with 95% Confidence Interval for 
tape stripping (TS), plasma and microdialysis (MD). 
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Figure 4.12 Plot of Test for Equal Variance for Cmax, with 95% Confidence Interval 
for tape stripping (TS), plasma and microdialysis (MD). 
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4.9.2 Correlation between TS, plasma and MD 
Tetracaine was only quantified in samples obtained by TS with a Cmax concentration 3 
times higher and 10 times higher compared to the metabolite (BABA) concentrations in 
extracellular dialysate and plasma, respectively. The three measurements differed 
significantly in the AUC, and also the tmax and Cmax values. A matrix plot for the AUC 
and Cmax (Figure 4.13 and Figure 4.14) showed no correlation between the three 
measurements. An additional test, Pearson Correlation Coefficient was used for further 
investigation to determine if any correlation existed. However, the results showed there 
was no correlation between the three methods for all three PK parameters (Table 4.10). 
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Figure 4.13 Matrix plot of AUC for tape stripping (TS), microdialysis (MD) and plasma. 
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Figure 4.14 Matrix plot of Cmax for tape stripping (TS), microdialysis (MD) and plasma. 
Table 4.10 Pearson correlation coefficient of AUC, Cmax and tmax, between TS, MD and 
plasma methods of skin study. 
 TS MD 
AUC Cmax tmax AUC Cmax tmax 
MD r 0.106 0.289     
P 0.772 0.418     
Plasma r 0.567 0.140 -0.182 0.150 0.243  
P 0.088 0.700 0.571 0.679 0.498  
r =Pearson correlation coefficient 
P value > 0.05 = no significant correlation 
4.9.3 Pin prick test 
VRS and VAS scores were tested by pin prick test, and plotted in Figure 4.15 and Figure 
4.16, respectively. The results showed that lowest VRS was reached at 90 minutes and 
lasted until 180 minutes post dose (mean, VRS; 1 unit), while for VAS the least pain was 
felt at 120 minutes post-dose (VAS; 19 mm). The assessments demonstrated a good 
relationship with the SC tetracaine level in TS (mean tmax; 52 minutes) and local tissue 
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BABA concentrations in plasma (mean tmax; 122 minutes). The average BABA level in 
MD also correlated well with VRS and VAS. Figure 4.17 and Figure 4.18 show a decline 
in BABA level at point 240 minutes at the same time as there is an increase in both VRS 
and VAS. The same result was noted in plasma and TS. 
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Figure 4.15 Pin prick test showing the mean VRS pain score with time profile (minutes) 
(n=12, Error Bars= 95% CI). 
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Figure 4.16 Pin prick test show the mean VAS pain score with time profile (minutes) 
(n=12, Error Bars= 95% CI). 
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Figure 4.17 Pain visual rating score (VRS), with TS tetracaine, plasma and MD BABA 
profiles, (n=10, Error Bars= 95% CI). 
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Figure 4.18 Pain visual analogue score (VAS), with TS tetracaine, plasma and MD 
BABA profiles, (n=10, Error Bars= 95% CI). 
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4.10 Discussion 
Topical application of drugs has an advantage over other routes in its ability to manage 
specific problems. However, appropriate pharmacokinetic measurement of topical 
administered drugs is still under investigation. Local anaesthetics of an ester type, such as 
tetracaine and procaine, are mainly hydrolyzed in plasma by pseudocholinesterase and 
esterase in the liver, resulting in possible toxicity. Thus, in the measurement of drugs 
their metabolites must also be analyzed in plasma (FDA, 2001a), and in the dermis for 
successfully conducted clinical studies. 
The most popular methods used to assess drug pharmacokinetics in human skin are tape 
stripping and microdialysis (Herkenne et al., 2008). The reasons for not using other 
methods such as skin biopsies, and skin blister fluid sampling are due to the ethical 
considerations, costs and the lack of reproducibility (Muller et al., 1995), which have 
limited the application and practice of these methods in clinical drug development. 
However more practice and comparison between these methods may helpful in providing 
useful information and critical ideas for the application of these methods in the local 
tissue or compartment, and to assess the pharmacokinetic profile of the drugs. 
In this study, three different types of sample have been collected for the measurement of 
tetracaine and its metabolite by developed novel methods. The samples were 
conventional plasma, stratum corneum tape stripping, and dialysate extracellular fluid, 
after the application of 1 mL of Ametop gel onto the patient’s volar surface of the 
forearm. Nevertheless, the use of MD is limited for several reasons. MD requires very 
sensitive bioanalytical assays or appropriate assays (Muller et al., 1996, Benfeldt and 
Groth, 1998), to detect each soluble molecule in the extracellular fluid (ECF) (Muller, 
2002). MD needs a skilled person for the insertion of the probe into local tissue to 
minimize variability between individuals. The recovery of large molecules, highly 
protein bound or a lipophilic drug in the skin is another challenge in MD (Benfeldt and 
Groth, 1998). In this study, tetracaine, used as a local anaesthetic was the drug 
investigated. The topically applied tetracaine is highly lipid soluble and protein bound. 
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The plasma protein binding is about 75.6% (EMEA, 1997). The LC-MS-MS was a highly 
sensitive method suitable for the analysis of tetracaine and its metabolite from plasma 
and microdialysis samples. The separation mode used was referred to as a HILIC system 
(Hydrophilic Interaction Chromatography or Hydrophilic Interaction Liquid 
Chromatography). Both plasma and dialysate contained quantified tetracaine metabolite 
(BABA), although tetracaine was detected in some dialysate samples, but not quantified. 
The high concentration of tetracaine in tape samples was expected. Hence, an appropriate 
method has been employed in the development and validation of a rapid and simple CE-
UV method (Al-Otaibi et al., 2009). The CE-UV has been compared with a developed 
and validated HPLC-UV. Both methods were equally valid for the measurement of 
tetracaine accurately and reproducibly from patients tape samples. In addition, a simple 
and rapid CE-UV method was developed and used to analyze BABA in patient tape 
samples, but none was detected. Refer to chapter 3 for more detail of CE-UV and HPLC-
UV methods. 
The analysis of dialysate appears to be simple and quicker than plasma, and did not 
require a complex extraction from an endogenous compound, such as lipid and protein 
which may interfere with the analyte peak. Thus, the dialysate sample can be introduced 
to the analytical system directly (Davies et al., 2000, Bagger and Bechgaard, 2004, 
Huang et al., 2008). Nevertheless, the presence of salts in the dialysate is a challenge due 
to the high ionic strength which may clog the ionization source causing background noise 
(Davies et al., 2000), and may cause deterioration of the analyte peak. Several methods 
can be used to resolve the problem by use of off line solid phase extraction prior to 
injection (Prokai et al., 1998), and desalting the sample with de-ionized water. In this 
study, samples were analysed without any problem. 
All sample matrixes obtained from 12 healthy volunteers have been successfully 
measured by the analytical methods. The study proved that tetracaine, as a local 
anaesthetic agent, was absorbed, distributed, and its action occurs in the local tissue, 
particularly the epidermis including the stratum corneum, the dermis, and subcutaneous 
tissue. All pharmacokinetic parameters including AUC, Cmax, tmax, and t1/2 were measured 
for BABA. It was not possible to calculate the t1/2 in TS samples, due to the presence of a 
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two compartment model which can be seen clearly in most patient samples (Appendix 22 
and Appendix 23), where the concentration declined after reaching tmax and then 
increased again. The same also occurred in the dialysate sample, the AUC and Cmax were 
the only pharmacokinetic parameters measured, due to a continuous increase in the 
concentration of the metabolite BABA. The continuous increase in the BABA 
concentration in the dialysate sample correlated with the lowest scores from 90 to 180 
minutes for VAS and VRS pain score measurements in this study. The elevated drug 
concentrations observed between 60 and 240 minutes correlated with the local 
anaesthetic effect of Ametop. Microdialysis is considered to provide information on drug 
kinetics in the receptor sites beyond the stratum corneum (Muller et al., 1997). 
The absorption of tetracaine into the systemic circulation was low and required a longer 
time to achieve the maximal concentration of its metabolite. In plasma BABA Cmax was 
110 nM and tmax was 122 minutes compared with the TS concentration of tetracaine Cmax 
850 nM and tmax 54 minutes. BABA concentrations started to decline in the systemic 
circulation 100 minutes after the application of the dose. This was due to the elimination 
process of the tetracaine metabolite. The lag time and t1/2 observed for BABA from 
patient plasma samples were 54 minutes and 105 minutes, respectively. The low Cmax and 
AUC values, with the longer tmax obtained in plasma showed that dermatological drug 
products, such as local anaesthetics, have limited systemic absorption. 
The high variability of Cmax and AUC in MD compared to plasma and TS may be 
attributed to the implantation depth, as the same subjects were used for all methods. In 
addition, the amount of lipid tissue is likely to cause interpatient variability (Lorentzen et 
al., 1996). 
Although tetracaine was stable in tape stripping samples, it was hydrolyzed into BABA 
quickly and completely in all patients’ plasma samples, and almost completely in the 
dialysate samples. The hydrolysis of tetracaine to its major metabolite was due to the 
presence of pseudocholinesterase and esterase in the plasma and liver, respectively. The 
stability of tetracaine and procaine were studied in chapter 3, and it was shown that 
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tetracaine was hydrolysed/broken down into its major metabolite BABA at 37 °C body 
temperature and at a pH of 7.8, close to blood pH of 7.4.  
TS and MD have been proven to be effective with an excellent rank-order in 
bioequivalence of topical products (Benfeldt et al., 2007). The tissue concentration of 
topical drugs obtained by MD is much more precise than plasma estimation (Muller et 
al., 1995). MD provides a reliable pharmacokinetic model to estimate cutaneous in vivo 
penetration on a routine basis (Kreilgaard, 2001). In this study, TS and MD have been 
more relevant for assessing the pharmacokinetics of topical anaesthetics products. 
In comparison to TS, MD is more invasive. A few challenges are associated with the MD 
technique, such as when it is used for sampling very lipophilic or very highly protein 
bound molecules (Benfeldt and Groth, 1998), and it requires a trained person to minimize 
variability in the study results.  
4.11 Conclusions 
Topical tetracaine was safe and decreased pain in the healthy subjects. The study results 
demonstrated that skin stripping with adhesive tape and MD were useful methods of 
pharmacokinetic assessment of topical drugs. However, in comparison with plasma, skin 
stripping with adhesive tape was less and microdialysis was more variable. Nevertheless 
both methods measured local drug concentrations and thus may be more relevant 
methods of measurement for assessing the pharmacokinetics of drugs such as local 
anaesthetics. A few challenges need to be resolved with the MD technique, such as its 
high variability, and low reproducibility. 
Thus, more studies concerning the consistency of TS and MD are needed to consider the 
ideal pharmacokinetic measurement for transdermal drug delivery. 
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Chapter 5 General discussion 
This thesis mainly describes pharmacokinetic studies performed in healthy human 
volunteers. The projects included the study of diazepam delivery through the skin with a 
liquid formulated to promote absorption, developing and validating methods to anlayze 
drugs obtained from skin samples, and appropriate methods to measure and assess the 
transdermal delivery of drugs. The aims of this thesis as listed in the objectives (1.10, 
page 66) in Chapter 1 were achieved with varying degrees of success and there is a need 
for further studies. 
1. The TDS® system has been combined with diazepam, in a phase I 
pharmacokinetic study to compare TDS® diazepam with Diastat® in 12 healthy 
adult subjects.  
The stability and quality control of Diastat® and TDS® diazepam were analyzed by a new 
HPLC-UV assay. The results showed that for Diastat® the mean weight of the rectal 
diazepam gel was 2.13 g and it contained an average dose of 9.84 mg diazepam with a 
CV of 2%. In the TDS® diazepam, five sprays, 1 mL, gave a mean weight of diazepam of 
10.17 mg with a CV of 1%. Diazepam in the plasma samples was assayed by a newly 
developed HPLC-MS method to obtain the necessary high sensitivity. The developed 
method successfully analyzed all samples in this study without any problems. 
The transdermal delivery of diazepam was studied in vivo by Schwarz (Schwarz et al., 
1995). They showed that by using submicron emulsions, diazepam was effective and the 
concentrations achieved were equivalent to the parental delivery. In the present study, 
diazepam was successfully delivered by the TDS® system. It had good safety and 
tolerability. However, the TDS® diazepam was not bioequivalent to the existing rectal 
diazepam (Diastat®) and the mean ratios of TDS® diazepam/Diastat® for diazepam and 
desmethyldiazepam were 11.6 and 47.4%, respectively. The low concentration of 
diazepam was mainly due to the barrier layer of the stratum corneum. Diazepam is a 
lipophilic drug and accumulates in the lipid tissue. Although, desmethyldiazepam was 
present in all subjects in the TDS® group, diazepam was not detected in subject number 
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S05, and was delayed in subject number S08. This is may have been due to the 
metabolism of diazepam in the skin. Additionally, the presence of desmethyldiazepam 
concentration in the first time point of the TDS® system suggests that the washout period 
between treatments was insufficient to allow for the long half life of desmethyldiazepam. 
Any future study needs to allow a longer time to clear desmethyldiazepam.  
Benzodiazepines are the treatment of choice for the management of acute seizures. These 
types of drugs are active against many types of seizure, have a rapid onset of action, and 
have been well studied (Martindale, 1996a). Although, the rectal route of administration 
is not liked by the patients, their family, and the clinicians, it is difficult and hazardous to 
administer the drug by IV and IM injections, or orally when the patient is actively 
convulsing. In this study, diazepam was successfully delivered through the skin into the 
systemic circulation by the TDS® system. Although not bioequivalent to rectal 
administration, the route was safe and tolerated by all the volunteers, and devoid of any 
risk that may affect safety and compliance by the other routes of administration such as 
IV, IM and oral. 
Drug therapy, linked with pharmacokinetics provides useful information to select the 
optimum dosage regimen that gives an optimum therapeutic effect. Therapeutic range is 
the concentration of drug that exerts maximum effect with minimum side effects. The 
presence of the active metabolites and/or stereoisomers or toxicity is not defined. Thus, it 
is possible to identify the correlation between drug concentrations and the drug effect, by 
the measurement of plasma drug concentrations.  
The plasma concentration of diazepam needed to stop convulsions is not well established, 
although a range of 150–350 µg/L has been suggested (Agurell et al., 1975), which was 
supported by Knudsen with a range 200–300 µg/L (Knudsen, 1977). In our study, the 
plasma diazepam concentrations were within or slightly above the suggested diazepam 
concentration range (199–379 µg/L) in 11 out of 12 subjects in the rectal diazepam study, 
but not following the TDS® diazepam (7–67 µg/L). The anticonvulsive range was 
maintained for 1–5 hours in rectal diazepam group. The wide plasma concentration range 
observed in this study was due to the high variability in the metabolism of diazepam, and 
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the differences in the body lipid contents and protein binding affinity between subjects. 
The pharmacokinetic variability between subjects has been observed in previous studies 
(Greenblatt et al., 1989, Ogutu et al., 2002). The pharmacokinetics and skin metabolism 
of diazepam obtained from this study should be used for further development of the 
TDS® system and diazepam skin delivery, to make this route viable to the patients. 
2. Different bioanalytical methods have been explored in this thesis for the analysis 
of diazepam in the two dosage forms and in plasma, and tetracaine in different 
biological matrixes, including their metabolites. The methods have been chosen to 
be sensitive, selective, accurate, precise, reproducible, and stable.  
Two new short end (reversed) capillary electrophoresis (CE) with ultra violet (UV) 
detection methods have been developed, and used to analyze tetracaine and BABA in the 
tape samples obtained from the TS study. Since, the tape samples contained only 
tetracaine, the first method was optimized and validated for this purpose (Al-Otaibi et al., 
2009). In addition, a high performance liquid chromatography (HPLC) with UV detection 
method was also developed and validated to investigate the quantitative performance 
compared to the developed CE, in analyzing tetracaine in skin using tape samples 
obtained from healthy volunteers given tetracaine as part of pharmacokinetic drug 
studies. In the comparison between the two methods, the accuracy and selectivity of both 
methods allowed the measurement of tetracaine in all samples obtained from a skin tape 
stripping study in healthy subjects, referred to in Chapter 4. The separation was fast for 
both methods, especially for short end direction (reversed) CE. Although the imprecision 
was higher, the lower cost and volume of solvent used and faster running time made CE 
preferable over HPLC for this kind of study. This finding agreed with previous results 
(Clohs and McErlane, 2003, Aurora Prado et al., 2005, Muscarella et al., 2005, Carlucci 
et al., 2007, Kowalski and Plenis, 2007, Kocevar et al., 2008). The benefit of a fast 
analytical method satisfied the high demand for analysis of samples in busy 
pharmaceutical companies, and laboratories. Although, BABA was not assayed in tape 
samples, the stability of tetracaine and procaine has been studied by the second CE-UV 
method in a pH media of 7.8 close to blood pH of 7.4. 
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3. The correlation of tetracaine measurements have been explored between methods 
applied for the pharmacokinetic profiles of transdermal drugs by skin tape 
stripping, microdialysis, and conventional systemic measurement in blood. The 
results obtained from this study would be appropriate for pharmacokinetic, 
toxicokinetic, and forensic measurements of topically applied drugs. 
Ametop gel was available to target local tissue for an anaesthetic effect. The conventional 
pharmacokinetic assessment of a drug in plasma may not be an appropriate method for a 
topical drug. The drug concentration locally may be higher than the drug concentration in 
plasma due to many factors including drug metabolism in plasma. Thus, tetracaine and 
BABA were assayed by three different pharmacokinetic measurements. The study was 
conducted in 12 healthy volunteers and performed for the measurement of tetracaine and 
its metabolite (BABA) in plasma, MD, and TS samples. Ametop gel was used as a model 
local anaesthetic, applied on the forearm. The analyzed samples were successfully 
assayed without any problem. For TS both methods of CE-UV (Al-Otaibi et al., 2009) 
and HPLC were used; dialysate and plasma samples were analyzed by a developed LC-
MS-MS method. The results showed that tape harvesting of the stratum corneum in TS 
and dialysate samples in MD methods were more reliable than the systemic plasma 
measurements, in the assessment of the pharmacokinetics of transdermally delivered 
drugs such as a local anaesthetics. Although tetracaine was not found in plasma or the 
dialysate samples, the concentration of BABA was log linearly related to the anaesthetic 
effect of Ametop gel in the dialysate. Microdialysis is considered to provide information 
on drug kinetics in the receptor phases beyond the stratum corneum (Muller et al., 1997). 
This finding demonstrated that BABA is an important metabolite/breakdown compound 
of tetracaine that needs to be assayed if tetracaine is given to subjects. 
Drugs can interact with protein (s) in blood plasma and elsewhere resulting in variation 
of drug-protein binding. High affinity binding of molecules to protein results in low 
levels of free drug that can reach the target sites, and therefore there is less therapeutic 
effect. The most abundant human blood proteins are albumin, lipoprotein, and 
glycoprotein. In drugs that are highly plasma protein bound (> 95%) such as diazepam 
and desmethyldiazepam, the free unbound drugs are less than 1.5 and 3% (average), 
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respectively (Allen and Greenblatt, 1981). Thus a small change in protein binding can 
increase the free unbound drug, that is responsible for the pharmacological action, which 
affects drug elimination and pharmacokinetics, and toxicity is likely to occur.  
In the TDS® diazepam study, the elimination half life of diazepam was 85 hours after 
rectal administration, but could not be measured for TDS® diazepam. This is may have 
been due to the accumulation of diazepam in the lipid tissue of the skin. In addition, the 
half life of desmethyldiazepam could not be measured in both dosage forms. The 
presence of desmethyldiazepam in 5 subjects in the TDS® diazepam group at the zero 
time point confirmed that desmethyldiazepam has a half life of more than 14 days.  
Tetracaine is a highly protein bound and lipophilic drug. The plasma protein binding of 
tetracaine is about 75.6% (EMEA, 1997). The measurement of highly protein bound and 
lipophilic drugs are difficult in MD (Benfeldt and Groth, 1998). Tetracaine was not 
measured in MD samples due to its protein binding, accumulation in the lipid tissue, and 
possibly metabolism in the skin. 
Protein binding may also be saturable, resulting in a rise of unbound drug proportional to 
an increase in drug concentration. Other factors that may affect protein binding include 
drug-drug interactions, the drug has a high binding affinity to plasma protein, which may 
displace the bound drug and increase its unbound fraction. Drug protein binding is 
usually reversible, and only unbound drug undergoes metabolism. The drug may 
dissociate from the protein, thus free drug is released and metabolized. The metabolism 
of drug facilitates drug elimination, and tends to keep plasma drug concentrations in 
equilibrium. 
5.1 Clinical trials and their regulations 
Clinical trials (CTs) are research studies conducted for drugs or appliances to observe 
their effects on numbers of subjects to attain useful information on safety and efficacy. In 
Britain, it was recognized that there was a need for a Clinical Trials Committee after the 
development of insulin in 1920s, which led to the creation of the Medical Research 
Council in 1931 (Valier and Timmermann, 2008). The Medical Research Council 
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together with medical manufacturers designed guidelines on the appropriate conduct of 
clinical trials. Consequent needs and the success of clinical trials created the Tuberculosis 
Chemotherapy Trials Committee, which led to the organization of the world’s first 
randomized controlled clinical trial in 1946 by a British research team using streptomycin 
for the treatment of tuberculosis (Yoshioka, 1998, Valier and Timmermann, 2008). The 
subsequent medical interventions led to the establishment of the Nuremberg Code in 
1947, and ethics in medical research adapted that in the Declaration of Helsinki in 1964. 
The Declaration of Helsinki has been implemented for use in medical ethics to afford 
directives for the medical researcher in the conduct of clinical trials involving human 
subjects. The amendment and changes to the Declaration of Helsinki has forced many 
countries to adopt further regulations in their medical research, including good clinical 
practice (GCP), and good laboratory practice (GLP). 
The European Clinical Trials Directive (2001/20/EC) came into effect in the United 
Kingdom in May 2004 via the Medicines for Human Use (Clinical Trials) Regulations 
2004. The clinical trial regulations control research conduct in Clinical Trials of 
Investigational Medicinal Products (CTIMPs). Health authorities and organisations such 
as the NHS support and maintain systems that are suitable so that CTIMPs can be 
directed and performed in accordance with clinical trials regulations and the research 
governance framework. The outcome is to facilitate and simplity the application process 
for clinical drug research and to improve research studies. 
In addition, there is considerable importance placed on the regulations including the 
protection of the research subject, by improving the previous standard regulatory and 
ethics inspections of all drug research that is required for commercial drug research.  
The Medicines for Human Use Act authorized the Amendment of the Regulations of 
2004 and were passed in Parliament on July 2006, and came into effect on August 2006. 
This regulation implemented the EU Directive (2005/28/EC) on GCP, the arrangement of 
fees/expenses, informing the licensing authority of any breach in the system including 
GCP, protocols, and any warning notices. 
In order to apply for clinical drug research, the CTIMPs require; 
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1) A registration with an available regulatory agency, such as the Medicines and 
Healthcare Products Regulatory Agency (MHRA), in the UK. MHRA is the authorized 
national agency responsible for this.  
2) Ethical consideration and approval is provided by a research ethics committee (REC), 
on behalf of the Central Office for Research Ethics Committees (COREC).  
3) The research study requires funding and support usually by a sponsor with legal 
responsibility such as the institute, or the pharmaceutical company, to ensure that the trial 
is conducted in accordance with The Medicines for Human Use legislation. 
Additional to the above requirements: 
4) Maintenance of documents and archiving of the study is also important. 
Further amendments and additional changes in the regulations have led to the delay of 
many clinical trials. The number of drug research papers in anaesthetic drugs mainly in 
post marketing (phase IV) drug developments declined by 15 and 29% in Europe and in 
the United Kingdom, respectively, within 3 years following the introduction of the 
European Clinical Trials Directive (Walker et al., 2009). The decline observed in 
European anaesthetic development was due to the high financial demand and complex 
paper work required by ethics committees, which forced local hospitals and other medical 
institutions to conduct fewer clinical trials. However, large organizations, such as 
pharmaceutical companies, may prefer to conduct their clinical trials in less regulated 
countries. 
However, there was a delay for a least 1 year in the diazepam study so that it would 
comply with these regulations. The Medicines for Human Use (Clinical Trials) 
Regulations 2004 and the Medicines for Human Use (Clinical Trials) Amendment 
Regulations 2006 were referred to as the Clinical Trials Regulations in this thesis.  
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5.2 Appropriate transdermal monitoring and drug analysis 
Drugs have different receptor sites that may interact and/or bind with a specific target 
protein. Thus, once a drug is absorbed from the site of the application it may be affected 
by many factors such as first pass metabolism as in oral dosage form, or the thickness of 
the stratum corneum such as in transdermal drug delivery, before the drug is distributed 
to the site of action. A drug must reach its therapeutic concentration to exert its effect by 
interacting with the receptor. Thus a drug should be measured near its receptor or target 
site. The benefit of this is to evaluate the drug concentration that can give the optimum 
therapeutic effect, with the least side effects.  
Most drug measurements are usually determined in blood plasma or serum as the total 
unbound protein concentration. Other biological matrixes can be useful in the 
measurement of a drug such as saliva, urine, and extracellular fluid samples. The plasma 
drug concentration is well understood, and the drug concentration is in equilibrium within 
the body. A drug may metabolise or bind to a protein in plasma, thus the measurement of 
a drug must include as many metabolites as possible. 
Topically applied drugs, such as local anaesthetics, target receptors which are located in 
skin tissue especially at the site of application. Thus, the measurement of drug 
concentration in local tissue is vital for locally applied medication rather than assessing 
the drug concentration in plasma. The first method of evaluation of topically applied 
drugs was the use of Franz cell apparatus for transdermal drug delivery. The method has 
been used for the study of cutaneous drug diffusion (Koch et al., 1987), by using animal 
skin, human skin, or artificial membranes. Although, the method has been used for many 
years, this in vitro model has several limitations. These include the absence of drug 
elimination, skin metabolising enzymes, blood vessels, and the integrity of the skin. 
Therefore, this method determines percutaneous absorption instead of cutaneous 
bioavailability of the topically applied drug. 
Recently, researchers in the field recognized that to obtain clinically relevant information 
about the measurement of a local drug in the local tissue in vivo pharmacokinetics must 
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be applied. Therefore, many techniques/methods have been established and evaluated 
including tape stripping (TS), microdialysis (MD), and skin biopsies. From these 
methods, MD and TS are commonly used in transdermal drug delivery due to their 
consistency. 
The tape stripping (TS) method is relatively simple and showed good reproducibility 
when applied and used as a pharmacokinetic method for transdermal drugs. In this thesis, 
TS was reproducible with less variability compared to plasma and microdialysis (MD). It 
has been confirmed in previous studies that TS is the method of choice for the 
measurement of bioequivalence (Shah et al., 1998), and bioavailability (Weigmann et al., 
1999b) of a topically applied drug. The TS method is useful to quantify metabolic 
enzymes in the skin such as the esterase enzyme in the stratum corneum (Beisson et al., 
2001).  
In plasma, only BABA was found because tetracaine was broken down. This breakdown 
could have been due to esterases in blood or may simply have been due to the pH of 
blood. The latter is more likely, since tetracaine is stable when in contact with the stratum 
corneum, although it known that the stratum corneum contains esterases (Beisson et al., 
2001). In disodium tetraborate buffer at pH 7.8, tetracaine is rapidly broken down to 
BABA, and a similar breakdown has been noted for procaine (Iglesias-Martinez et al., 
2006). Further studies are needed to confirm this finding. 
Tape stripping of the outer skin layer, the stratum corneum, and assessment of the 
extracellular fluid are among the most prevalent and reliable methods to use for the 
measurement of drug concentrations in transdermal drug delivery. Although, the methods 
have been extended, a few challenges still need to be addressed before they can be 
regarded as generally applicable routine techniques for cutaneous drug delivery 
assessments. 
The tape stripping (TS) method is applied with the standard practice of repeated 
application and removal of adhesive tape on the epidermis. The tape sample contains 
stratum corneum which contains an amount of applied drug. Although, TS is not difficult 
to perform, many intrinsic and extrinsic factors need to be investigated. It has even been 
General Discussion 
 
Page 251 of 334 
suggested that the amount of drug recovered by the tape is influenced by seasons of the 
year (Tokumura et al., 1999), and the site of application (Tokumura et al., 1999, Loffler 
et al., 2004). To minimize the seasonal time and the site of application in TS method, the 
study was performed in the autumn, and at one site of application (e.g. the forearm). 
Additionally, the inter-individual variability was difficult to minimize in this study, such 
as the amount of stratum corneum (SC) in the tape sample, which is affected by many 
factors such as SC thickness, amount of cells, the composition of the lipid layer, age, 
gender and race of the patient (Lademann et al., 2009). Further investigations are needed 
to address some question about these factors. 
Extrinsic factors that may affect the amount of SC include the type of the tape, the 
pressure and time the tape was applied for prior to tape stripping, the applied force for 
removal from the skin surface, and the nature of the topically applied drug and its 
formulation (Lademann et al., 2009). The high surface area of the tape sample compared 
to the amount of drug dispersed may result in the loss of compound by evaporation, if a 
volatile drug is being studied. In such cases, the analysis of tape samples should be 
performed immediately after the removal of the adhesive tape from the skin. 
Alternatively, the tape sample can be transferred to dry ice instantaneously after removal 
from the skin surface. 
Normally, TS studies require consistent practice in order to minimize any within and 
between variability between individuals. The type of the tape used is considered 
important for good stripping and results. In the TS study, the composition of the adhesive 
part was uniformly distributed and did not contain any empty spaces. Prior to the study, 
the tape was tested to prevent any reaction with the subject’s skin that might occur, such 
as hypersensitivity. A constant tape size was used for all subjects and application areas. 
Additionally, the pressure applied was another challenge in the TS procedure. Some 
workers have used a rollers, or constant weight, to apply uniform pressure to the skin 
(Lademann et al., 2009). Although it has not been described in previous studies, in this 
study, a spatula was used by just one person to give a constant pressure and minimize 
individual inter-variability. 
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Another factor that may affect results is the speed of removal of the tape. It has not been 
standardized, but high speed may decrease the amount of stratum corneum harvested and 
vice versa for low speed (Loffler et al., 2004). Usually constant and rapid speeds are 
needed, which have been performed in this TS study. Weighing the tape prior to and after 
tape stripping was often used to measure the amount of SC removed (Weigmann et al., 
1999a). It is not without error, as it is based on the assumption that sebum, the drug, and 
interstitial fluid may increase the weight. Other methods, such as measurement of protein 
content in the corneocytes (the major component of the SC) to determine the amount of 
SC, and using microscopy to determine the amount of SC, are among the more time 
consuming processes (Lademann et al., 2009). Additionally, transepidermal water loss 
(TEWL) may be used but this can also be affected by environmental factors, the topically 
applied drug, and interstitial fluid (Lademann et al., 2009). 
MD is well established for the assessment of topically applied drugs. However, many 
limiting factors can affect drug concentrations in MD samples. The most important factor 
is the low recovery of molecules, particularly those with a large molecular weight (Groth, 
1996, Clough, 2005), such as insulin (Jansson et al., 1993, Rosdahl et al., 2000), highly 
lipid soluble drugs (Groth, 1996, Clough, 2005), highly protein bound drugs (Clough, 
2005), a low concentration gradient, and molecular charged drugs. Tetracaine is a highly 
lipophilic and protein bound drug. In this study, tetracaine was applied for 1 hour to the 
same site for all volunteers to minimize variability. Tetracaine was not measured in the 
dialysate because of its lipid solubility and protein binding. However, the water soluble 
metabolite of tetracaine (BABA) was measured. The flow rate and duration (Clough, 
2005) which may affect drug concentration in the dialysate, were minimized by using a 
constant flow rate of 1 µL per minute, and for a fixed duration of time for all subjects. 
Additionally, the length of the dialysis membrane was kept constant using the same type 
of probe catheter. The implantation depth can affect drug concentration. Although, it was 
done for all subjects by the same physician, it was difficult to eliminate inter-individual 
variability. The dialysis membrane is affected by factors including; the probe location 
(Clough, 2005), probe membrane permeability, probe area, and perfusion fluid properties 
(Chaurasia, 1999, Ettinger et al., 2001). These factors were minimized in this study by 
implanting the catheter in the same site on the forearm, and as mentioned before with 
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same catheter type, and the use of Ringer solution similar to the physiological fluid. The 
small volume and low concentrations of drug in the dialysate sample may limit MD 
usage, which requires highly sensitive techniques for analysis (Benfeldt and Groth, 
1998). In this study, LC-MS-MS was needed to analyze the plasma and dialysate 
samples. 
These problems with MD have contributed to a high variability in the pharmacokinetic 
parameters. The large variability can be seen between individuals, compared to within 
individuals. The high intra-individual variability may be contributed to the implantation 
depth of the probe, and/or probe to probe variability (Ettinger et al., 2001). Since, 
tetracaine is a highly lipid soluble and highly protein bound drug. The variability in this 
study may have come from the inter-individual variability in the lipid layer of the skin, 
protein binding, and the probe implantation depth.  Standard procedures for the use of 
MD should be available to overcome some errors, such as the insertion of the probe, by 
using ultrasonography to evaluate the depth of probe (Klimowicz et al., 2007), which 
must be performed by trained physician. 
5.3 Transdermal drug delivery: progress and problems 
Transdermal drug delivery is an alternative drug administration choice. The human skin 
is a readily accessible surface for drug delivery. Michaels and colleagues determined that 
the ideal diffusion coefficient of drugs in the stratum corneum results in significant 
permeability of some drugs (Michaels et al., 1975). However, to consider the cutaneous 
route as viable, a sufficient amount of drug delivery is required. Poor absorption is due to 
the protective barrier of the SC in the skin, limiting local drug application. Many methods 
have been tested to facilitate the delivery of molecules through the skin and the only 
limitation was the success to which a drug can reach its site of action in sufficient 
quantity. This was implemented in the development of the first patch, and was approved 
in 1979 to deliver scopolamine for the prevention of motion of sickness (Shaw and 
Chandrasekaran, 1978).  
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Currently, transdermal drug delivery methods are available as topically applied creams, 
ointments, patches, and gels. The drug targets local tissue or other organs through the 
systemic circulation, avoiding factors that may affect drug bioavailability by the oral 
route, such as hepatic first-past effect, dose missing, and food-drug interaction. Another 
advantage for the transdermal delivery of drugs is that treatment can be interrupted or 
eliminated when necessary (Godwin and Michniak, 1999). Patient compliance can be 
improved, which is especially notable in patches that require only once weekly 
application e.g. the once a week transdermal estradiol adhesive patch appears to be an 
acceptable means of hormone replacement therapy compared to the twice a week patch 
(Harrison et al., 1997). 
Since some drugs have poor penetration through the SC, a chemical enhancer may be 
used. However, drug absorption in the skin may be limited, and there is need for a potent 
transdermal delivery system. There appear to be promising transdermal delivery systems 
available, but they are still under investigation such as liposomal, iontophoresis, 
magnetophoresis, sonophoresis (phonophoresis).  
Liposomes, are small vesicles composed of phospholipids, which when dispersed in an 
aqueous phase (hydration) form bilayer membranes in the shape of a sphere (Yarosh, 
2001). Liposome structures consist of amphiphiles characterized by a hydrophilic (head), 
and hydrophobic (tail) (Yarosh, 2001). The hydrophilic groups align toward the aqueous, 
and the hydrophobic tails point to the inner lamellae. Liposomes were introduced in 
1980, and used for topical drug delivery (Mezei and Gulasekharam, 1980, Mezei and 
Gulasekharam, 1982, Moghimi and Patel, 1993). Drug delivery into and through the skin 
depends upon the type and composition of liposomes. The liposome encapsulation of a 
drug can increase drug permeation across the skin, and prolong the local anaesthetic 
effect of tetracaine compared with EMLA cream (Fisher et al., 1998). The benefits are to 
control drug concentration in the systemic circulation, to avoid a drug’s adverse effects 
and toxicity, or to target local tissue with drugs such as local anaesthetics. Several 
methods with liposomes have been tested to determine outcomes. For example, the 
penetration of carboxyfluorescein through the skin was inversely related to the particle 
size of the liposomes used (Verma et al., 2003). The delivery of clindamycin phosphate 
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through the skin was increased when an electrical charge was applied to the liposomes 
(Shanmugam et al., 2009). In addition, the presence of a chemical enhancer such as 
ethanol containing vesicles called ethosomes has been investigated. The ethosomal 
system considerably enhanced the skin permeation of minoxidil in vitro, testosterone 
from an ethosomal patch in vivo and in vitro (Touitou et al., 2000), and in vitro and in 
vivo studies have demonstrated the penetration of finasteride through the skin by 
liposomes and niosomes (Tabbakhian et al., 2006). 
Nevertheless, the main progress in transdermal delivery systems can be demonstrated by 
the application of a small electric potential to the skin so that charged drug molecules can 
penetrate into the skin more readily. The penetration is due to electrophoresis, electro-
osmosis, and the amount of transported molecules is dependent on the quantity of charge 
penetrated (Kaliaa et al., 2004). The method of iontophoresis uses a small amount of 
electric current to drive polar and neutral molecules through the skin (Banga et al., 1999, 
Denet et al., 2003). It has been used to deliver drugs through the skin such as diclofenac 
(Fang et al., 1999), piroxicam (Curdya et al., 2001) and sumatriptan (Patel et al., 2007). 
In addition, iontophoresis can be combined with a chemical penetration enhancer, 
resulting in a synergistic effect. For example, iontophoresis with geraniol was effective in 
transporting diclofenac in vivo (Kigasawa et al., 2009). Electroporation, similar to 
iontophoresis, uses high voltage treatment for a short time to provide short pulses of 
current to induce transient pores in the skin. The pores are responsible for ion and 
molecular transport, and each pore can transport many ions and molecules (Weaver et al., 
1999). Methotrexate was successfully delivered through isolated porcine skin by the 
combination of electroporation, iontophoresis, lipid enhancers, and local hyperthermia 
(Wong et al., 2005). Magnetophoresis is a method of drug delivery, using a magnetic 
field to transport a drug through the skin. The influence of magnetic field strength was 
determined, and it was shown that by increasing the magnetic field, the diffusion flux of 
the drug was increased (Murthy, 1999). Additionally, sonophoresis uses ultrasound 
energy to transport a drug through the skin. Although, the mechanism is not clear, 
mechanical cavitations, and thermal effects may be the method of drug transportation 
(James et al., 1993, Escobar-Chávez et al., 2009). Also, the use of low level ultrasound 
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waves can be useful for increasing the permeability of human skin, including the high 
molecular weight drugs such as insulin (Mitragotri et al., 1995). 
5.4 Conclusions 
The development of new/existing drugs is fundamental for the management/treatment of 
disease and can increase the quality of life (well being) of individuals. The process 
includes discovery of a new entity, modification of an existing product such as 
improvement of drug structure, dosage form, and formulation. Progress in transdermal 
drug delivery offers advantages over other routes of drug delivery. Nevertheless, the 
limiting barrier of the stratum corneum requires an effective transdermal drug delivery 
system and an appropriate method of drug measurement in the skin. 
The TDS® delivery system has been developed to offer a new method of transporting a 
drug molecule into and through the skin, providing advantages over other routes or 
delivery systems. The TDS® preparation was shown to deliver diazepam systemically 
through human skin in this project. This study demonstrated that the TDS® delivery 
system could be combined with a drug to form a powerful transdermal drug delivery 
system. Further development of the TDS® preparation is required to deliver drugs 
through the skin in sufficient amounts for a therapeutic effect. 
The development of an analytical method for pharmacokinetic and pharmacodynamic 
studies requires sensitive, selective, accurate, precise, reproducible and stable methods. 
Rapid and simple methods should be available in clinical studies because of increasing 
numbers of samples to assay. The development of capillary electrophoresis (CE) and high 
performance liquid chromatography (HPLC) methods using UV detection were 
successfully used in the analysis of tetracaine. Although, the imprecision was higher, the 
lower cost and volume of solvent used and a faster running time made CE preferable over 
HPLC for this kind of study. 
For most drugs, the pharmacokinetics are characterized by systemic measurement of 
plasma concentrations. However, to be effective, local anaesthetics need to maintain high 
concentrations in the local tissues. In vivo methods to determine the best approach to 
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study the pharmacokinetics of tetracaine following topical administration and to compare 
the drug concentration measurements using skin stripping with adhesive tape (TS), in 
microdialysis (MD) fluid, and in plasma were investigated. The study results 
demonstrated that skin stripping with adhesive tape and MD were useful methods for the 
pharmacokinetic assessment of topical drugs. Both methods measured local drug 
concentrations and these may be more relevant measurements for assessing the 
pharmacokinetics of drugs such as local anaesthetics. However, a standard protocol for 
TS and MD is required for their validity in the application and the assessment of topically 
applied drugs, which can fully satisfy the criteria of the regulatory authorities. 
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Appendix 1 Ethics approval letter for TDS® diazepam. 
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Appendix 2 Ethics approval letter for pharmacokinetic study of dermatopharmacokinetics. 
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Appendix 3 Informed consent form (sample). 
 
WRITTEN CONSENT FORM: REC Number: 05/Q0605/98  Ver. 3.1
 
Title of research proposal: Study of a combined percutaneous local anaesthetics: Evaluation by 
systemic measurement, skin stripping and microdialysis. 
 
Name of Patient / Volunteer (Block Capitals): 
 
Address: 
 
 
The study organisers have invited me to take part in this research.            
I understand what is in the leaflet about the research.  
I have a copy of the Patient’s Information leaflet version 5.1 to keep. 
I have had the chance to talk and ask questions about the study.     
know what my part will be in the study and I know how long it will take.   
     
I have been told about any special drugs, operations, tests or other checks I might be given.  I 
know how the study may affect me. I have been told if there are possible risks. 
I understand that I should not take part in more than one study at a time. I know that the  
local North East London and City Health Authority Research Ethics Committee 
Has seen and agreed to this study. 
I understand that personal information is strictly confidential:  I know the only people who may 
see information about my part in the study are the research team or an official representative 
of the organisation which funded the research. 
      
I freely consent to be a subject in the study. No-one has put pressure on me. 
   
I know that I can stop taking part in the study at any time. 
     
I know that if there are any problems, I can contact:        
Prof. Atholl Johnston    Dr Arthur T. Tucker 
 
Department of Clinical Pharmacology,  The Ernest Cooke Clinical Microvascular Unit, 
William Harvey Research Institute, 4th Floor Dominion House, 
Charterhouse Square,    St. Bartholomew’s Hospital, 
London. EC1M 6BQ.    London. EC1A 7BE. 
 
Tel. No: (020) 78823414    (020) 76018498 
Patient’s / Volunteer’s  Signature:  .................................................. Date: ............................................... 
The following should be signed by the Clinician/Investigator responsible for obtaining consent 
As the Clinician / Investigator responsible for this research or a designated deputy, I confirm that I have 
explained to the patient / volunteer named above the nature and purpose of the research to be undertaken. 
Investigator’s Name seeking consent: ........................................................ 
Investigator’s Signature: ........................................................ Date: ....................................... 
Patient Information Sheet, Ametop Version 5.1 (13/04/07)  
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Appendix 4 Patient information sheet (sample). 
 
Study of a combined percutaneous local anaesthetics: Evaluation by systemic 
measurement, skin stripping and microdialysis. 
 
Lay title: “Study of skin anaesthetic drug delivery-Ametop” 
 
Study no. :05/LA 003/01 
 
Invitation to participate in a Research Project 
 
We invite you to take part in a research project, which we think may be important. The
information, which follows, tells you about it. It is important that you understand what is in this
leaflet. It says what will happen if you take part and what the risks might be. Try to make sure
you know what will happen to you if you decide to take part. Whether or not you do take part
in the study is entirely your choice. Please ask any questions you want to know about the
research and we will try our best to answer them. 
 
 
Why have we approached you? 
Procedures which involve insertion of needles through the skin are commonly perceived as
painful and may lead to apprehension and anxiety, especially in children. Bad experiences
with needles can often lead to problems with future procedures. The introductions of
anaesthetic creams, which are applied on the skin have been a great help. However, current
anaesthetic creams are slow to have an effect (30 minutes to 1½ hours) and this may lead to
difficulties in organising clinics, wards and operating theatre routines around their application
time. A local anaesthetic cream with a more rapid effect would be an important development
both for the patient and for the smooth running of hospital procedures. 
 
 
 
Lidocaine has been used for many years as a local anaesthetic. Normally it takes a very long
time to penetrate skin and hence it is mainly given by injection. In this study, we will mix the
nitric oxide system with lidocaine, apply it onto your skin, and carry out a series of studies
called “pharmacokinetics” in order to measure the effectiveness of the system. We believe
that the nitric oxide produced by this system may increase the speed of penetration of
lidocaine and produce a more rapid anaesthesia. We will compare this new drug mixture with
EMLA cream, and Ametop gel. EMLA cream, and Ametop gel are a local anaesthetic skin
cream currently used for skin anaesthesia in the venepuncture and minor procedure. We
have been completed this study with EMLA, now want to continue with Ametop which is a
local anaesthetic gel. 
 
Most drug content studies in the body are normally done by the measurement of blood.
However, measurement of a drug in the blood is not always useful for evaluating skin-based
medications (especially local skin anaesthetics). Anaesthetics designed to target the local
skin to which they are applied do not readily diffuse into the rest of the body and the blood
system. For this reason normal methods of drug measurement using blood samples have
proved unhelpful.  
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In this study, we will therefore measure the amount of drug in the surface layers of the skin
using adhesive tape and a needle procedure, called microdialysis This will allow us to
carefully compare the drug levels in the blood with the drug levels in the skin at any
moment in time. We will then be able to decide which of the methods is most effective. 
 
Microdialysis is a technique which allows measurement of the amount of the test drug in
the skin itself and involves placing a special needle (or cannula) under the skin for the
duration of the study. This is a safe procedure, but you may feel some transient discomfort
when the needle is inserted. Skin samples are taken with normal everyday sticky tape by
applying and then removing the tape. This results in removal of those outermost layers of
the surface of skin which are normally shed into clothing during the course of the day.
Both methods will allow measurement of the varying amount of drug in the skin during the
study period.  
 
The main purpose of this study is to find the best technique for measuring the dose and
effectiveness of skin based drug delivery. The results from this study will, however, also be
of indirect benefit as they may lead to improvements in anaesthetic delivery systems for
clinical use. 
 
What would I do in the study, if I took part? 
If you agree to take part, we will take a detailed medical and a physical examination,
including blood pressure, pulse rate and rhythm. Signs of drug and alcohol abuse will also
be checked. We will treat all the drug screening results as confidential and the
results will not be used for any purpose other than inclusion or exclusion from this
study. 
 
The study involves two visits with a minimum of one-week gap in between. The study will
last for the maximum of six hours for every visit. 
 
Visit 1: Microdialysis and systemic measurement  
 
Upon entry to the study ward for the initiation of the study, we will check your blood
pressure and heart rate. The hairs from forearm on both of your arms will be removed by
using a shaver and thoroughly cleaned with water and wiped dry with a towel. Your arms
will be checked for cuts or scrapes which could complicate the study. You will be asked to
lay down on a bed and we will start by inserting a small cannula (a small tube, same size
as a blood test needle) into a vein in your arm. By using the cannula we will be able to take
regular small blood samples during the study without having to insert a blood test needle
each time. 
 
On your other arm, a circular area of 10 cm2 will be marked with a pen in the centre of the
forearm. The microdialysis guide needle will be inserted in the just under the skin about 1
cm from the marked area. The microdialysis probe will be inserted through the tip of
needle, which is then removed, leaving the probe (about 3 cm long) below the marked
area. Inlet and outlet tubing will be attached to the sampling probe and secured to the skin
using adhesive tape. The inlet tube will be connected to the microdialysis pump and the
outlet tubing connected to a small collection pot. You will have to carry the pump (about
the size of a mobile phone) with you during the study.  This pump moves a special liquid
through the probe in order to measure the drug concentration in the skin. Please take care
of it. These are safe procedures, but you may feel some discomfort when the needles are
inserted, which should quickly fade
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After the microdialysis probe implantation, you wi ll be allowed to rest for 60 minutes to
allow the skin to recover before the start of the measurements. For 20 min a special fluid
will be pumped through the microdialysis probe and collected for later testing. This fluid is
very safe, used frequently in research and, in fact, you will not even notice this pumping
through implant. A five-millilitre blood sample (about a teaspoon full) will also be collected
from the needle in your other arm. After these measurements, the test drug ( Ametop gel)
will be applied to the skin at the marked area and covered with a dressing for 1 hour. After
one hour, the remaining drug will be removed and your skin gently cleaned. The special
fluid will be passed through the microdialysis probe and collected for 4 hours after the drug
is applied. Five millilitre blood samples (about a teaspoon full) will be collected at 20 and
40 minutes and at 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours after applying the drug. 
 
 
At the end of the study day, we will remove the small cannula and the microdialysis probe
from your arms and put on a dressing before you leave to prevent bleeding. 
 
One week later you will come again for tape stripping study. 
 
Visit 2: Tape stripping study 
In this study, we will measure the amount of the drugs, which enter the outermost layers of
skin (known as the “stratum corneum”). We will mark nine 2 x 3 cm rectangular sites (sites
1-9), on your forearms which is used for microdialysis study, with a pen. Site 1, positioned
3 cm above the elbow will be served as a control (no drug). One gram of  Ametop gel will
be applied on all the sites 2 to 9. We will remove the cream from the application site at 15,
30, 45 min., and 1h. We will perform the tape strip at 0, 15, 30, 45 min., 1, 1.5, 2, 3, and 4
h. Before performing the tape strip, we will measure the effectiveness of the anaesthetic by
assessing your abilty to perceive a small pinprick in the areas of the drug application on
your skin. We will ask you about any sensation you feel by touching your skin with the
needle (without puncturing it) and ask you a few questions about what you felt. 
 
 
 If you have any medical problems or have to take any medicines, e.g. a course of
antibiotics, during the two weeks before the study or during the time immediately
afterwards it is important that you let us know as soon as possible. 
 
If you have any problems after the study you should contact Dr Art Tucker (020) 7601
8498 or Professor Atholl Johnston in the Clinical Pharmacology Department (020) 7882
3413. Outside working hours you can contact us via the hospital switchboard. 
 
The study has been seen and approved by the local East London and City Authority
Research Ethics committee. Any personal information will remain strictly confidential. 
 
If you agree to join the study we will notify your GP that you are taking part. 
 
If you feel any discomfort during the investigations, you must say so and we will
stop the tests at any time. 
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Will this study help me? 
This study may not benefit to you directly.  It may, however, lead to the development of
more effective skin anaesthesia. 
 
 
Will I be paid? 
For attending the Screening session we wi ll compensate you with £10-00. At the end of
the study we will be pleased to pay you £85-00for your time, commitment to the study and
expenses (a total maximum payment of £95-00). 
 
 
Could I come to any harm if I take part in the study? 
The doses of the drugs have been chosen so that it should cause an effect only on the
skin of your hands and not the rest of your body.  
Ametop gel is a local anesthetic(tetracaine), it is safe and widly used for many years and is
used at a very low concentration to reduce the pain prior to venepuncture or venous
cannulation 
 
There are very few risks involved in inserting a needle into a vein in the hand for venous
sampling and subcutaneous tissue for microdialysis probe implantation and sampling. You
may feel transient pain when the needle is placed under the skin which is similar to having
a blood test. You may also experience discomfort and there may be a small bruise around
the area which may last for a couple of days.  
 
If you feel unacceptable discomfort or for any reason you do not wish to continue, than we
will stop the test immediately. 
 
 
Are there any factors which would exclude me from taking part in the research?
(and which are not known by the investigators) e.g. Pregnancy or other
medications. 
 
We need to know whether you are taking any medication or if you have had any reactions
to drugs in the past as this may also exclude you from the study. 
 
There may be a risk that taking part in this trial might harm an unborn child and therefore
pregnant women will not be included in this study. If you think that there is any chance that
you might be pregnant, please inform the investigator and, with your consent, a pregnancy
test will be performed.  
 
You should not take part in this study if you are already involved in any other study. 
 
You will also not be able to take part in the study if you are taking drugs of abuse, either
short or long term. 
 
 
How will confidentiality be protected? 
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All the information obtained about you in the course of the study is confidential and will be 
kept in a locked room. Only the investigators will have access to the data.   
 
The investigators performing the study will have access to the data collected in this study. 
Official representatives of the Drug Regulatory Authorities may at some stage in the future 
request access to the data collected in this study. You will not be identifiable in any publication 
arising from the study. 
 
If you would like more information about the study or are worried about any aspect of it please 
feel free to contact: 
 
Dr Arthur Tucker   
Ernest Cooke Clinical Microvascular Unit, 
4th floor, Dominion House, 
St Bartholomew’s Hospital, 
London EC1A 7BE. 
Tel No. (020) 7601 8498 
 
Mr Faisal Al-Otaibi 
Clinical Pharmacology, 
William Harvey Research Institute, 
Charterhouse Square, 
London EC1M 6BQ. 
Tel No. (020) 7882 3413 
 
You don’t have to join the study. You are free to decide not to be in this trial or to drop out at 
any time. 
 
 
What happens if you are worried or if there is an emergency? 
You will always be able to contact an investigator to discuss your concerns and/or to get help 
 
Name:  Prof. Atholl Johnston 
Post:   Professor of Clinical Pharmacology 
Address:  Department of Clinical Pharmacology, Charterhouse Square, London.  
Telephone/Fax: (020) 7882 3413 
 
 
What happens if something goes wrong? 
We believe that this study is basically safe and do not expect you to suffer any harm or injury 
because of your participation in it. However, we carry insurance to make sure that if your 
health does suffer as a result of your being in the study, then you will be compensated. In 
such a situation, you will not have to prove that the harm or injury, which affects you, is 
anyone’s fault. If you are not happy with any proposed compensation, you may have to 
pursue your claim through legal action.  
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Appendix 5 inclusion and exclusion criteria for the volunteers (Chapter 2). 
 
Inclusion criteria 
1. Male and female Caucasian subjects are between 18 and 50 years of age, inclusive.  
2. The subject is willing and able to read and understand the Subject Information Sheet 
and provide written informed consent.  
3. The subject has a body mass index (BMI) within 18–35 kg/m2.  
4. The subject is in good health as determined by medical history and physical 
examination. 
5. Female subjects must be practicing an acceptable method of birth control. Acceptable 
methods of birth control include hormonal contraceptives or double-barrier methods 
(condom or diaphragm with a spermicidal agent or IUD).  If practising an acceptable method 
of birth control, a negative urine pregnancy test must be obtained at screening and on each 
Treatment Day.  
6. The subject is a non-smoker.  
7. The subject must agree to comply with the placement of an indwelling catheter on 
two occasions and the drawing of blood samples for the pharmacokinetic assessments during 
the study. 
8. The subject is willing and able to comply with all testing and requirements defined in 
the protocol.  
9. The subject is willing and able to return to the study site for all visits. 
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Exclusion criteria 
Subjects meeting any of the following criteria will be excluded from entry into the study: 
1. The subject has any relevant deviations from normal in physical examination (including 
any skin condition that in the investigator’s judgment may affect the transdermal 
absorption of diazepam), electrocardiogram (ECG), or clinical laboratory tests, as 
evaluated by the investigator.   
2. The subject has had a clinically significant illness within 30 days preceding entry into 
this study.  
3. The subject has a history of significant neurological, hepatic, renal, endocrine, 
cardiovascular, gastrointestinal, pulmonary, or metabolic disease. 
4. The subject has a known allergy or history of hypersensitivity to diazepam or similar 
compounds.    
5. The subject has used any prescription medication within 14 days or over-the-counter 
(OTC) medication or alcohol within 48 hours of dosing or intends to use any 
prescription or OTC medication during the study that may interfere with the evaluation 
of study medication (excluding oral contraceptives). 
6. Subject is pregnant or breast-feeding.   
7. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) 
weeks of the study, and their haemoglobin concentration and haematocrit have not 
returned to within 5% of normal.  
8. The subject has a history of substance abuse or a current positive urine drug screen or 
urine alcohol test. 
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9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks 
per week for males, or more than 14 standard drinks per week for females). 
10. Subjects who have received an investigational drug or have used an investigational 
device in the 30 days prior to study entry. 
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Appendix 6 inclusion and exclusion criteria for the volunteers (Chapter 4). 
 
Inclusion criteria 
In order to be eligible to enter the study, volunteers must meet the following criteria: 
1  Male and female aged between 18 and 45 years of age. 
2  Free of significant abnormal findings as determined by medical history, urinalysis 
(including specific gravity), and vital signs (sitting blood pressure, sitting pulse rate, 
within 1 week of commencement of the study.  
3. BMI between 18 and 30 
4 No history or signs of drug abuse (including alcohol), licit or illicit.  
5 Agrees not to use any medications (prescribed or over-the-counter including herbal 
remedies, but excluding oral contraceptives) judged to be clinically significant by the 
Principal Investigator during the seven (7) days preceding the study, and during the 
course of the study. 
6 Not pregnant and is using an acceptable form of contraception, or judged unable to 
become pregnant (for females), and willing to take precautions to prevent pregnancy 
with their partner (for males) until completion of the study. 
7 Able to understand and sign the written Informed Consent Form. 
8 Able and willing to follow the Protocol requirements. 
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Exclusion criteria 
Volunteers will not be admitted to the study if they meet any of the following exclusion 
criteria: 
1 Any significant history of allergy and/or sensitivity to any of the contents of study drugs. 
2 A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure >160 or <80 
mmHg and/or a sitting diastolic pressure of >100 or <60 mmHg. 
3 Any significant illness during the four (4) weeks preceding the screening period of the 
study. 
4 Any contraindication to blood sampling. 
5 Any contraindication to local anaesthetics administration. 
6 Positive urine drug screen or indication 
7 Is currently breast feeding. 
8 Positive screening Pregnancy test (females only). 
9 Participation in any clinical study during the 8 weeks proceeding the dosing period of 
the study 
10 Donation of blood during the eight (8) weeks proceeding the screening period of the 
study or during the investigation. 
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Appendix 7 Certificate of analysis of diazepam-D5, and metabolites-D5 (Chapter 2) 
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Appendix 8 Delegation Log (sample). 
 
 
 
 
All those involved in the above study must read the protocol (and the amendment if applicable) and understand their role as outlined in protocol 
   Key for list of duty categories: 
1. Obtaining informed  
2. Physical Exam/ Clinical Evaluations 
3. Source document entry (ie. Medical notes) 
4. CRF completion / data entry 
5. Resolving data queries  
6. Review & reporting adverse event & SAE 
 
7. Medical prescriptions 
8. Drug accountability 
9. Maintaining investigator file 
10. Archiving 
Other duties specific to above study please specify below 
11. Principle Investigator 
12. Study Support
Name (print) Job title Signature Sign initial 
List duty 
categories 
PI signature 
and date 
Date of 
leaving the 
team (if appl.) 
       
       
       
       
       
       
       
       
Study title: 
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Appendix 9 Screening Log (sample). 
 
 
 
 
 
 
Date  Patient Initials Date of birth Hospital Number Sex 
Enrolled  
( yes or no) 
 
Reason for exclusion 
       
       
       
       
       
       
       
       
       
Study title: 
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Appendix 10 Enrolment Log (sample). 
 
 
 
 
 
 
Subjects ID 
code 
Subject 
initials 
Date of 
birth 
Date of 
consent 
Date of 
randomization 
Date of 
withdrawal 
 
Date 
completed 
       
       
       
       
       
       
       
       
       
       
Study title: 
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Appendix 11 Plasma diazepam concentration following rectal administration for 12 subjects (Chapter 2). 
 
Time Subject / Concentration (µg/L) 
(h) S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 Average 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.25 266.9 367.4 120.8 215.4 174.1 201.0 250.7 118.1 169.1 60.4 210.3 162.4 193.1 
0.5 308.7 234.2 230.6 309.7 198.7 349.2 254.3 207.9 359.2 132.7 268.8 294.3 262.4 
0.75 246.4 242.8 286.8 252.6 156.1 333.0 250.1 323.4 303.1 138.3 297.8 346.8 264.8 
1 240.1 375.4 173.5 192.3 161.5 297.9 233.3 343.3 301.4 129.2 272.5 378.7 258.3 
1.5 210.9 190.9 133.3 126.3 133.1 215.6 151.1 294.3 217.7 108.2 223.8 324.7 194.2 
2 177.8 235.2 86.7 109.5 123.2 178.9 130.5 222.1 152.8 82.0 178.3 253.2 160.9 
2.5 138.6 126.5 92.8 89.2 111.8 150.2 132.2 222.4 132.7 63.4 138.9 230.6 135.8 
3 125.5 102.8 78.4 87.9 109.9 141.5 115.0 183.6 121.9 66.2 118.6 200.9 121.0 
4 109.0 87.7 97.8 79.1 102.2 126.5 121.9 179.6 120.2 56.3 88.1 176.2 112.1 
5 102.1 82.4 96.9 75.8 100.5 133.1 113.0 154.6 109.6 44.8 95.4 139.4 104.0 
6 108.2 79.0 85.2 81.6 99.7 141.1 102.7 124.8 108.2 38.0 83.8 124.7 98.1 
8 67.4 59.7 73.2 73.7 93.0 129.2 104.7 83.7 89.9 48.0 83.6 109.4 84.6 
10 78.6 83.9 75.9 69.5 84.0 114.7 72.1 84.0 93.0 34.0 65.9 96.2 79.3 
12 61.2 49.1 73.3 67.5 73.4 110.2 79.9 93.8 75.2 36.6 61.4 66.3 70.7 
24 52.0 75.2 94.3 63.0 69.9 83.6 64.1 49.1 57.8 23.2 60.5 72.1 63.7 
32 61.4 49.4 70.2 48.0 57.7 72.0 45.7 41.9 30.0 15.3 45.5 47.5 48.7 
48 48.4 45.8 68.9 0.0 44.5 50.0 51.7 32.3 33.9 7.8 38.0 26.4 40.7 
72 35.8 36.1 48.7 0.0 36.9 30.2 33.8 25.2 43.3 5.1 24.6 22.0 31.1 
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Appendix 12 Plasma diazepam concentration following TDS® administration for 12 subjects (Chapter 2). 
 
Time Subject / Concentration (µg/L) 
(h) S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 Average 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
0.25 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
0.75 7.3 0.0 11.8 0.0 0.0 14.1 0.0 0.0 0.0 5.1 5.2 0.0 3.6 
1 8.9 0.0 12.9 0.0 0.0 19.4 0.0 9.5 5.6 12.5 9.3 11.9 7.5 
1.5 21.3 7.5 29.7 0.0 6.0 26.5 0.0 35.6 14.2 13.0 31.3 36.8 18.5 
2 29.9 10.2 33.8 0.0 14.3 22.7 0.0 58.9 21.8 17.0 59.2 47.7 26.3 
2.5 36.3 15.2 30.4 0.0 17.5 14.4 0.0 63.2 23.6 14.4 66.8 45.5 27.3 
3 37.0 15.8 29.2 0.0 20.9 16.0 0.0 63.4 20.8 12.6 57.4 53.1 27.2 
4 25.9 21.0 30.5 0.0 19.2 16.4 0.0 47.3 16.9 9.5 46.0 37.5 22.5 
5 27.0 17.4 27.5 0.0 15.5 18.0 0.0 36.7 18.0 8.6 32.7 35.4 19.7 
6 21.9 16.2 24.2 0.0 16.9 19.5 0.0 30.8 15.6 9.5 26.1 31.6 17.7 
8 20.3 18.0 24.0 0.0 14.1 13.8 0.0 29.1 17.7 11.6 25.9 34.0 17.4 
10 14.2 19.0 26.7 0.0 14.2 19.1 0.0 28.5 17.3 12.4 26.4 30.6 17.4 
12 12.4 17.3 27.3 0.0 27.6 16.9 0.0 30.8 20.6 10.9 21.7 31.7 18.1 
24 18.6 19.4 27.8 0.0 16.3 12.7 7.3 34.0 22.8 14.0 29.9 32.4 19.6 
32 16.4 15.7 23.8 0.0 26.9 5.5 7.2 34.0 20.9 11.6 19.7 33.1 17.9 
48 18.1 14.5 21.8 0.0 26.4 0.0 6.8 19.7 16.0 8.9 18.7 20.7 14.3 
72 12.9 12.1 19.4 0.0 20.8 0.0 7.1 9.0 10.0 0.0 14.6 10.1 9.7 
Final 5.2 5.3 5.2 0.0 12.9 0.0 0.0 0.0 6.8 0.0 0.0 0.0 3.0 
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Appendix 13 Plasma desmethyldiazepam concentration following rectal administration for 12 subjects (Chapter 2). 
 
Time Subject / Concentration (µg/L) 
(h) S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 Average 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 
0.25 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 
0.5 0.0 5.0 0.0 6.8 0.0 11.1 0.0 0.0 6.0 0.0 6.9 5.2 6.8 
0.75 0.0 5.7 0.0 8.7 0.0 14.8 6.6 5.5 6.9 0.0 8.5 8.7 8.2 
1 0.0 10.4 0.0 8.2 0.0 19.4 7.7 7.1 7.9 5.8 8.9 9.6 9.4 
1.5 5.9 8.5 0.0 8.8 5.1 19.6 8.4 10.0 9.6 9.3 10.9 12.8 10.3 
2 7.1 12.3 0.0 8.9 6.0 20.4 9.8 13.3 9.8 8.6 13.1 13.5 11.6 
2.5 6.1 7.8 6.0 8.5 6.4 19.8 10.6 15.7 10.3 9.3 12.4 13.8 11.0 
3 7.9 7.8 5.1 9.9 6.7 22.2 11.1 15.2 10.5 10.7 13.4 14.5 11.6 
4 8.4 8.5 7.2 9.8 8.1 22.6 13.0 18.0 12.8 11.6 13.5 18.9 13.1 
5 8.9 9.4 8.4 9.8 8.7 25.2 14.8 19.0 12.1 10.7 15.9 19.3 13.9 
6 11.9 10.1 9.0 11.9 11.2 31.2 15.5 17.9 13.4 10.7 16.0 19.2 15.1 
8 9 9.4 8.8 12.9 12.8 34.4 19.5 15.5 13.5 15.2 19.8 21.9 16.7 
10 12.4 14.0 11.0 13.9 14.1 36.6 18.7 17.9 17.0 14.6 18.8 24.5 18.3 
12 10.6 9.9 11.7 17.1 14.2 38.5 19.3 21.2 14.8 16.6 19.3 18.3 18.3 
24 14.5 20.3 28.3 23.7 23.0 52.1 29.9 24.4 24.2 20.7 30.4 32.5 28.1 
32 24.4 17.3 25.8 23.3 25.9 54.0 30.0 27.3 18.4 19.1 29.5 32.2 27.5 
48 25.2 22.0 35.9 0.0 30.7 57.6 37.7 30.4 26.7 20.0 36.4 28.8 32.6 
72 27.6 22.9 38.7 0.0 41.1 54.2 41.0 31.8 37.6 16.8 34.7 27.2 34.6 
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Appendix 14 Plasma diazepam concentration following TDS® administration for 12 subjects (Chapter 2). 
 
Time Subject / Concentration (µg/L) 
(h) S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 Average 
0 0.0 7.7 0.0 0.0 0.0 0.0 9.3 13.9 7.9 0.0 5.0 0.0 10.5 
0.25 9.9 8.2 19.9 0.0 0.0 0.0 10.8 12.4 8.2 0.0 5.5 0.0 10.6 
0.5 9.4 7.6 19.7 0.0 5.5 0.0 9.5 11.9 8.6 0.0 5.5 0.0 11.3 
0.75 11.6 10.2 18.5 0.0 5.4 0.0 9.5 11.3 10.0 0.0 5.2 0.0 11.4 
1 10.3 8.1 19.7 0.0 5.0 0.0 10.1 12.5 10.3 0.0 0.0 0.0 12.4 
1.5 11.4 9.3 19.0 0.0 6.1 0.0 11.6 12.6 10.7 0.0 6.0 0.0 11.9 
2 11.1 7.3 19.6 0.0 5.1 0.0 10.6 11.5 10.8 0.0 6.6 0.0 11.9 
2.5 11.1 8.2 18.2 0.0 5.7 0.0 10.8 12.4 11.6 0.0 7.6 0.0 12.2 
3 11.6 9.5 18.7 0.0 5.7 5.0 10.8 13.7 10.6 0.0 7.1 0.0 11.8 
4 11.2 11.0 19.6 0.0 6.3 5.4 10.2 16.6 10.4 0.0 8.2 0.0 12.2 
5 12.0 8.8 19.0 0.0 5.5 6.8 10.4 15.5 11.2 0.0 7.9 0.0 13.0 
6 10.8 9.4 18.2 0.0 6.0 6.3 9.1 14.5 10.5 0.0 7.5 5.3 11.9 
8 11.3 9.5 18.1 0.0 5.7 6.1 10.5 14.2 11.6 0.0 9.8 6.9 12.5 
10 7.3 11.3 19.9 0.0 5.9 10.3 8.8 16.3 11.1 0.0 10.5 6.7 12.6 
12 8.0 9.0 19.4 0.0 11.6 13.1 9.5 18.2 11.6 0.0 9.9 7.3 13.1 
24 11.4 10.2 21.7 5.1 11.8 15.2 9.4 20.9 14.3 6.5 13.8 10.3 13.6 
32 12.3 10.7 22.5 6.8 15.7 13.4 10.6 25.4 15.6 8.1 12.9 12.6 15.2 
48 14.4 12.3 21.6 0.0 17.3 5.8 10.4 23.2 14.6 8.7 16.5 15.1 15.5 
72 15.0 13.5 25.5 0.0 19.7 0.0 10.1 18.5 15.0 7.8 17.7 14.0 13.3 
Final 9.6 9.2 13.4 0.0 13.0 0.0 8.2 8.2 13.4 0.0 12.1 8.0 11.3 
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Appendix 15 Plasma tetracaine metabolite (p-butyl amino-benzoic acid) concentration for 12 subjects (Chapter 4). 
 
Time Subject / Concentration (µg/L) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
20 0 0 0 0 0 0 0 0 0 0 0 NA 0 
40 6 2.2 0.6 NA 0 14.3 0 NA NA 0 0 NA 2.9 
60 21.5 15.5 13.5 16.7 1.4 33 0 0 0 1.6 8.2 NA 10.1 
90 19.7 29.6 17.3 37.5 16.5 35.4 0 11.6 0 12.3 16.8 16 17.7 
120 14.6 39.7 11.5 21.1 15.7 24.4 1 22.1 0 20.5 17.9 15 16.9 
150 11.8 33.6 9.6 13.9 11.7 17.7 1.6 22 0.7 18 15.7 10.4 13.9 
180 10.4 26.6 7.6 11.1 9.4 15.1 2.4 20.1 1.3 15.4 13 NA 12.0 
210 9.4 23.7 6.4 9.8 9.2 11.8 3.3 19.1 2.3 12.2 10.6 NA 10.7 
240 8.6 20.1 5 7.6 8.4 10.8 4.2 16.4 2.8 13.2 10.9 NA 9.8 
 
NA: not available. 
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Appendix 16 Tetracaine metabolite (p-butyl amino-benzoic acid) concentration from dialysate fluid for 12 subjects (Chapter 4). 
 
Time Subject / Concentration (µg/L) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0 0 0 0 0 0 0 0 NA 0 0 0 47.6 4.3 
20 0 0 0 0 0 0 0 NA 0 0 0 17.7 1.6 
40 0 6.1 6.6 0 0 0 0 NA 0 0 0 17.7 2.8 
60 4.4 9.1 6 28.6 0 0 8 NA 0 32.6 0 25.9 10.4 
80 15.6 16.6 11.5 103.0 7.6 9.9 19.9 NA 13.6 108.6 31.3 30.2 33.4 
100 24.3 17.0 18.1 146.3 41.6 12.3 18.5 NA 16.8 151.4 71.0 28.6 49.6 
120 21.1 16.3 14.9 172.8 90.3 25.3 20.6 NA 13.2 168.0 127.9 34.4 64.1 
140 23.3 11.8 12.7 150.1 118.5 47.6 7.3 NA 17.0 145.5 118.6 39.2 62.9 
160 36.7 6.3 16.3 148.0 151.2 49.1 12.2 NA 16.4 147.1 126.5 33.9 67.6 
180 28.5 8.9 21.0 150.3 176.6 66.8 9.3 NA 17.7 124.3 96.7 35.7 66.9 
200 28.45 10.5 20.6 116.9 120.6 88.5 9.6 NA 21.7 131.7 153.1 40.7 67.5 
220 37 12.7 19.8 139.2 132.6 74.7 12.1 NA 16.9 135.8 122.5 46.5 68.2 
240 49.3 8.7 19.7 104.5 109.8 57.1 6.2 NA 19.2 112.7 69.1 55.6 55.6 
 
NA: not available. 
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Appendix 17 Tetracaine amount from tape stripping harvesting sample analyzed by CE method for 12 subjects (Chapter 4). 
 
Time Subject / Concentration (µg/L) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
15.0 36.3 215.4 61.3 95.2 61.3 104.2 50.6 70.4 28.9 62.7 139.0 32.9 95.9 
30.0 43.6 309.7 115.6 135.5 88.5 93.4 40.4 73.2 117.5 115.0 210.3 76.1 124.6 
45.0 48.9 252.6 122.3 261.0 80.7 141.3 106.9 106.3 205.8 217.9 160.8 104.3 145.9 
60.0 128.5 192.3 228.7 258.0 241.6 252.6 101.2 186.0 323.3 194.6 487.9 367.7 178.6 
90.0 88.6 126.3 87.1 93.8 112.9 118.2 62.1 108.1 139.0 113.8 89.0 67.3 131.2 
120.0 78.3 109.5 60.5 118.2 79.3 131.8 63.2 104.6 144.2 58.3 44.4 99.0 131.6 
180.0 88.6 89.2 85.1 114.8 86.3 173.9 84.2 93.6 79.1 95.2 57.3 58.5 107.4 
240.0 61.7 87.9 106.0 106.5 52.0 213.5 91.2 100.9 86.9 67.2 71.3 84.2 114.5 
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Appendix 18 Tetracaine amount from tape stripping harvesting sample analyzed by HPLC method for 12 subjects (Chapter 3). 
 
Time Subject / Concentration (µg/L) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
15.0 33.5 27.5 57.5 94.0 65.7 94.2 47.2 75.6 48.9 70.4 146.6 31.1 91.5 
30.0 43.7 119.5 130.6 155.0 93.4 103.7 38.9 81.0 96.6 119.4 211.5 87.0 141.2 
45.0 46.4 221.1 135.1 278.2 89.3 143.1 100.2 118.3 114.6 226.9 185.8 93.8 158.9 
60.0 127.9 297.8 240.6 284.0 254.9 214.4 93.7 200.0 143.0 190.2 448.3 343.1 191.2 
90.0 97.4 130.5 99.8 88.3 NA 114.7 60.6 114.4 93.7 119.4 92.3 62.8 148.5 
120.0 76.2 133.4 59.0 138.2 88.8 129.0 57.7 109.5 94.9 63.9 42.1 109.4 144.9 
180.0 83.1 74.7 100.9 111.9 94.4 160.4 78.4 99.0 72.2 102.0 53.1 67.8 119.5 
240.0 57.0 83.1 120.8 123.5 58.4 186.2 84.6 NA 100.2 73.7 74.2 94.2 109.2 
 
NA: not available. 
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Appendix 19 VRS scores by pin prick test following the application of 1mL tetracaine gel to 12 subjects (Chapter 4). 
 
Time Subject / VRS Score (Category 1-4) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0.0 3.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 2.0 3.0 4.0 2.8 
15.0 1.0 1.0 1.0 1.0 2.0 2.0 2.0 2.0 2.0 2.0 1.0 3.0 1.7 
30.0 1.0 1.0 1.0 1.0 1.0 1.0 2.0 2.0 1.0 1.0 1.0 2.0 1.3 
45.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 2.0 2.0 1.0 1.0 1.0 1.2 
60.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
90.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
120.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
180.0 3.0 1.0 2.0 2.0 1.0 3.0 1.0 1.0 1.0 1.0 1.0 1.0 1.5 
240.0 3.0 2.0 2.0 2.0 3.0 3.0 3.0 3.0 3.0 2.0 3.0 4.0 2.8 
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Appendix 20 VAS scores by pin prick test following the application of 1mL tetracaine gel to 12 subjects (Chapter 4). 
 
Time Subject / VAS Score (0-100 mm) 
(min) S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 Average 
0.0 60.0 20.0 35.0 24.5 49.5 77.0 28.5 83.0 63.0 28.5 63.5 90.5 51.9 
15.0 5.0 4.5 0.0 0.0 36.5 35.5 23.0 35.0 22.0 28.5 0.0 50.0 20.0 
30.0 1.5 2.0 0.0 0.0 10.0 0.0 19.0 24.0 0.0 7.5 0.0 13.5 6.5 
45.0 3.0 2.5 0.0 0.0 0.0 0.0 0.0 27.0 27.0 0.0 0.0 0.0 5.0 
60.0 4.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 
90.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 
120.0 2.5 1.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 
180.0 62.5 2.5 10.0 14.0 5.5 61.5 0.0 0.0 1.0 0.0 0.0 4.5 13.5 
240.0 60.0 20.0 35.0 24.5 49.5 77.0 28.5 83.0 63.0 28.5 63.5 90.5 51.9 
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Appendix 21 Patients plasma diazepam and desmethyldiazepam concentrations 
(Chapter 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20.A Plasma diazepam (subjects S02–S04) versus time following 10 mg 
rectal (filled red circles) and TDS® diazepam (filled blue squares), 
linear concentration axis, and logarithmic concentration axis. 
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Figure 20.B Plasma diazepam (subjects S05–S07) versus time following 10 mg 
rectal (filled red circles) and TDS® diazepam (filled blue squares), 
linear concentration axis, and logarithmic concentration axis. 
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Figure 20.C Plasma diazepam (subjects S08–S10) versus time following 10 mg 
rectal (filled red circles) and TDS® diazepam (filled blue squares), 
linear concentration axis, and logarithmic concentration axis.  
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Figure 20.D Plasma diazepam (subjects S11–S13) versus time following 10 mg 
rectal (filled red circles) and TDS® diazepam (filled blue squares), 
linear concentration axis, and logarithmic concentration axis.  
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Figure 20.E Plasma desmethyldiazepam (subjects S02–S04) versus time following 
10 mg rectal (filled red circles) and TDS® diazepam (filled blue 
squares), linear concentration axis, and logarithmic concentration axis.  
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Figure 20.F Plasma desmethyldiazepam (subjects S05–S07) versus time following 
10 mg rectal (filled red circles) and TDS® diazepam (filled blue 
squares), linear concentration axis, and logarithmic concentration axis.  
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Figure 20.G Plasma desmethyldiazepam (subjects S08–S10) versus time following 
10 mg rectal (filled red circles) and TDS® diazepam (filled blue 
squares), linear concentration axis, and logarithmic concentration axis.  
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Figure 20.H Plasma desmethyldiazepam (subjects S11–S13) versus time following 
10 mg rectal (filled red circles) and TDS® diazepam (filled blue 
squares), linear concentration axis, and logarithmic concentration axis.  
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Appendix 22 Volunteers tetracaine concentration with time profile in tape samples 
(Chapter 4). 
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Figure 21.A Tetracaine concentration (obtained from subjects S01–S06) with time 
profiles in tape samples after application of 1 mL Ametop gel (4% w/w 
tetracaine) blue line (raw data), red line (fitted data) unresolved. 
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Figure 21.B Tetracaine concentration (obtained from subjects S07–S12) with time 
profiles in tape samples after application of 1 mL Ametop gel (4% w/w 
tetracaine) blue line (raw data), red line (fitted data) unresolved. 
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Appendix 23 Volunteers BABA concentration with time profile in microdialysis 
sample (Chapter 4). 
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Figure 22.A  BABA concentration (obtained from subjects S01–S06) with time 
profiles in microdilaysis samples after application of 1 mL Ametop gel 
(4% w/w tetracaine) blue line (raw data), red line (fitted data) 
unresolved. 
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Figure 22.B BABA concentration (obtained from subjects S07–S12) with time 
profiles in microdilaysis samples after application of 1 mL Ametop gel 
(4% w/w tetracaine) blue line (raw data), red line (fitted data) 
unresolved. 
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Appendix 24 Volunteers plasma BABA concentration (Chapter 4). 
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Figure 23.A Plasma BABA concentration (obtained from subject S01–S06) with 
time profile after application of 1 mL Ametop gel (4% w/w tetracaine) 
blue line (raw data), red line (fitted data) unresolved. 
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Figure 23.B Plasma BABA concentration (obtained from subjects S07–S12) with 
time profiles after application of 1 mL Ametop gel (4% w/w 
tetracaine) blue line (raw data), red line (fitted data) unresolved. 
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Rapid analysis of tetracaine for a tape stripping pharmacokinetic studyF. Al-Otaibi,a* A. T. Tucker,a,b A. Johnstona and D. Perrettc 
ABSTRACT: A rapid and simple short-end (reverse) capillary zone electrophoresis method was developed and validated for
the separation and quantification of tetracaine in skin using tape samples. The separation was performed in a 485 mm (400 mm
to window) × 50 mm internal diameter fused silica capillary using a background electrolyte of phosphoric acid–Tris pH2.5 at
–25 kV. The extraction of tetracaine from tape samples was achieved using methanol diluted to 50% with water before injection.
Procaine was the internal standard. The migration times for procaine and tetracaine were 1.25 and 1.36 min, respectively. The
limit of quantification for tetracaine was 50 mg, with a signal-to-noise ratio greater than 10. The calibration curve was linear
from 50 to 1200 mg with r2 greater than 0.99. The CV for both within- and between-assay imprecision and the percentage
inaccuracy for the quality control samples including lower and upper limits of quantitation were <12.1% and <11%, respec-
tively. The absolute mean recovery of tetracaine was >97%. The accuracy and selectivity of this method allowed the rapid
measurement of tetracaine in tape samples obtained from a skin tape stripping study of local anaesthetics in healthy subjects.
Copyright © 2008 John Wiley & Sons, Ltd.
Keywords: capillary electrophoresis; short-end injection; tape stripping; local anaesthetics
Introduction
Local anaesthetics can be classified according to their chemical
structure into amide or ester groups. Tetracaine (amethocaine,
2-dimethylaminoethyl 4-butylamino-benzoate) was developed
in the early 1990s and is a potent local anaesthetic belonging to
the amino ester class (Fig. 1). It is used for topical anaesthesia,
ophthalmology, antiprurit, spinal anaesthesia and as a nerve block.
Also tetracaine has been incorporated into a mucosa adhesive
polymer film to relieve the pain of oral lesions resulting from
radiation and antineoplastic therapy.
Tetracaine hydrochloride can be found in solutions, creams,
gels and as the base in ointments. The topical anaesthetic action
of tetracaine is more prolonged than the mixture of lidocaine
and prilocaine known as EMLA cream (Martindale, 1996). It also
appears to have a more rapid onset of action, i.e. 30–45 min,
than EMLA cream, without any risk of methemoglobinaemia. In
addition, it causes local vasodilatation, which may be an advan-
tage when used prior to central venous catheter placement, and
where obtaining i.v. access or blood is difficult, especially in the
newborn.
Most biochemical and pharmacological effects take place in
the local tissue and most drugs exert their effect in target tissue
or cells, especially local drugs, which are closer to the site of action.
Thus assessing tissue concentration is both meaningful and useful
for drug pharmacology studies. Ametop is a local anaesthetic
applied to skin; its concentration is high in local tissue compared
with plasma. At present, microdialysis and tape stripping are
available to provide analytical data concerning drug levels in the
extracellular space and outermost layer of the skin, respectively.
Tape stripping of the outermost skin layer, the stratum corneum
(SC), is a fast and relatively noninvasive technique to measure
drug absorbed into the skin (Stinchcomb et al., 1999, Christophe
et al., 2007), usually performed by placing an adhesive tape strip
onto the skin surface, after removing the residue of the drugs
followed by gentle pressure to ensure a good contact and sub-
sequent removal by a sharp upward movement. The procedure
is relatively painless, given that only dead cells (corneocytes) in
the outer most layers in the skin are removed.
The determination of tetracaine in biological samples has
been performed mainly in plasma. Several methods are avail-
able, such as high-performance liquid chromatography (HPLC),
(Menon and Norris, 1981; Yang et al., 1984; Mazumdar et al., 1991),
nevertheless human plasma contains proteins and endogenous
compounds that may interfere with the chromatographic
system. There are several reported ways to extract tetracaine
from plasma, e.g. organic extraction or solid-phase extraction,
but these are time-consuming. Thus the use of coupled column
(RAM-columns) or micellar liquid chromatography (MLC) as
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alternative methods has been proposed (Gilabert et al., 2001). In
addition gas chromatography–mass spectrometry (GC-MS) (Hino
et al., 2000; Yukiko et al., 2002), direct ultraviolet spectrophotom-
etry and colourimetry (Robert and Albert, 2006) can also be used.
Capillary electrophoresis (CE) is an alternative to the chromato-
graphic techniques in drug analysis. It was developed in the
1980s and expanded in the 1990s, and it has become a comple-
mentary separation technique that can separate a variety of
compounds with separations being based on differences in elec-
trophoretic mobility. CE with UV detection is a simple and fast
way to determine local anaesthetics in tape-stripping pharma-
cokinetic studies since high sensitivity is not usually required
to detect the drug levels involved, and it has a cost benefit com-
pared with MS detection.
The purpose of this study was to develop and validate a fast,
high-throughput but simple CE method using a short-end injec-
tion approach. This method was used to determine tetracaine
in skin using tape samples from volunteers given Ametop gel as
a part of pharmacokinetic drug delivery study.
Experimental
Chemicals
Tetracaine hydrochloride (HCl; lot no. 065k1501; 99.9% purity)
for calibrator and control sample preparation and procaine hydro-
chloride (HCl; lot no. 114k0569; 100% purity) for use as internal
standard were obtained from Sigma Aldrich (Poole, UK).
HPLC-grade solvents were obtained from Rathburn Chemicals
Ltd (Walkerburn, UK). All other AnalaR grade reagents were
obtained from Merck (BDH) Ltd (Poole, UK).
CE Instrumentation
The analysis and separations were carried out on an Agilent
3DCE G1600AX capillary electropherograph controlled by 3D-CE
Chemstation Rev. B.02.01[244] (Agilent, West Lothian, UK). Fused
silica capillaries, 485 mm total length with a window at 85 mm
from one end × 50 μm i.d. (Composite Metal Services, Ilkley, UK)
were conditioned on first use by flushing with 1 M NaOH (BDH,
Poole, UK) at >950 mbar, 40°C, for 20 min. Pre-conditioning on
injection was a 3 min flush with 0.1 M NaOH (BDH, Poole, UK),
then a 3 min flush with background electrolyte (BGE). In the final
separation a potential of –25 kV was employed. The capillary
was thermostated at 25.0°C. The injections of the samples into
the system were carried out hydrodynamically for 10 s at −50 mbar.
Detection was by photodiode array over 195–360 nm, but 315 nm
with bandwidth 10 nm was used for quantitation since 315 nm is
the λmax for tetracaine. The run time was 2 min. Both BGE vials were
replenished every 12 injections. All samples and standards in the
auto-sampler were kept at ambient temperature.
Experimental Design
Background electrolyte. As the aqueous background electrolyte
0.1 M Tris–phosphate at pH 2.5 was used. The buffer was prepared
by diluting 20 mL phosphoric acid (0.5 M) to 80 mL with deionized
water followed by adding 15 mL of 0.5 M Tris to obtain a solution
at pH 2.5. This solution was made up to 100 mL with deionized
water. Then the pH was checked and adjusted if necessary.
Calibrators and quality control samples. Stock solutions for
tetracaine (5 mg/mL) were prepared in 50% methanol–water and
for procaine 300 μg/mL in water (internal standard, IS). All stock
solutions were stored at –20ºC. All calibrators and quality control
samples were prepared by appropriate dilution of the stock.
Calibrations were nominally 50, 200, 400, 600, 800, 1000 and 1200μg
tetracaine; 50 and 1200 μg were the lower limit of quantity
(LLOQ) and the upper limit of quantity (ULOQ), respectively, plus
1500 μg IS, and quality controls were nominally 100, 250,
1000 μg tetracaine plus 1500 μg IS.
Preparation of tape sample and extraction. For the purpose of
validation and assay calibration, a length of self-adhesive poly-
propylene tape (Tesa 404 PV5, Beiersdorf, Hamburg Germany)
was cut into 10 samples, each approximately 3 × 2 cm. A 100 μL
volume of standard or quality control solution was placed onto
the adhesive part of the tape. The solution was distributed appro-
ximately evenly over the tape. The sample was left to dry at
room temperature, which required approximately 30 min. The
samples then were transferred into a 10 mL polypropylene tube
and stored frozen at –20°C until analysis.
Extraction procedure. A 5 mL aliquot of methanol was dispensed
into each tube containing standard/QC tape or samples. The
contents were mixed for 45 min with a shaker. A 5 mL aliquot of
solution of 300 μg/mL procaine (InternalStandard.) in water was
added to the tube to make 50% methanol–water solution. The
contents was mixed again using a shaker for further 15 min. A
200 μL aliquot of the solution was transferred into a 250 μL
auto-injector vial for CE analysis.
Method Development
Optimization of buffer pH. The role of the pH of 0.1 M Tris-
phosphate BGE was studied over the range 2–3.5. pH 2.5 was the
optimum with respect to the resolution of tetracaine and procaine.
Optimization of temperature. Various temperatures were stud-
ied, 15, 20, 25 and 30°C, and 25°C was found to be optimum.
Optimization of buffer concentration. Different buffer concen-
trations at constant pH in the range 0.05–0.2 were investigated
Figure 1. Chemical structures of tetracaine and procaine.
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and 0.1 M was the optimum buffer concentration with respect to
peak resolution and current.
Optimization of voltage. A voltage of −25 kV gave the best
separation with respect to analysis time and gave only a moder-
ate current, typically 50–70 μA.
Optimization of injection time. Injections time were studied
from 1 to 65 s, and 10 s was optimum for both resolution and
sensitivity.
Calculating inaccuracy and imprecision. Inaccuracy was tested
by the determination of low, medium and high quality control
samples, together with the LLOQ and ULOQ samples. Each con-
trol sample contained tetracaine. The nominal values for the low,
medium and high control samples were 100, 250 and 1000 μg,
respectively. The nominal values for the ULOQ and LLOQ were
the same nominal concentration as the highest and the lowest
calibration standards, respectively.
Assay imprecision was measured both within-batch and
between-batch by the analysis of three control samples, the
LLOQ and the ULOQ. Within-batch and between-batch impreci-
sion were calculated by the nested analysis of variance (ANOVA)
using internationally agreed methods (ISO 5725:1994).
Validation Procedures and Results
Specificity. Six samples of blank tape and six samples of tape
place with tetracaine were prepared and carried through the
extraction. The concentration of tetracaine used was 5 μg/mL
LLOQ and the internal standard was 150 μg/mL. No significant
interfering peaks were found at the migration time of tetracaine
or procaine. The signal-to-noise ratios at the LLOQ for both
drugs were greater than 10. Figure 2 shows the electrophero-
gram obtained from blank tape spiked with 50 μg tetracaine
with added intenal standard of 1500 μg procaine while Figures 3
and 4 show the electropherograms of Ametop gel solution and
one of the tape samples from the study, respectively.
Calibration curve/linearity. Calibrations were nominally 50, 200,
400, 600, 800, 1000 and 1200 μg tetracaine plus 1500 μg procaine
(internal standard). Seven batches of calibration curve were plotted
using the area ratio of tetracaine to internal standard vs known
concentration of tetracaine. All the results were calculated using
a y = ax + b linear regression (Table 1). The regression coefficients
for all the calibration curves obtained were greater than 0.99.
Inaccuracy. The within- and between-assay and the total varia-
bility obtained from the ANOVA are summarized in Table 2. The
percentage inaccuracy for all the quality control samples includ-
ing LLOQ and ULOQ was below 11%.
Within-assay reproducibility. For within-batch and between-
batch imprecision the LLOQ and ULOQ and the three control
samples were each assayed six times in three separate assays.
Each assay had an individual calibration curve. The coefficient of
variation (CV) for imprecision for all the quality control samples
including LLOQ and ULOQ was below 2.5%.
Between assay repeatability. For each of the three assays
mentioned above, the mean concentration for each assay was
used to calculate the between-assay reproducibility. The CV for
imprecision for all the quality control samples including LLOQ
and ULOQ was below 12.1%.
Stability. Samples were stable at room temperature for 24 h
and for at least 3 weeks when stored at –20ºC.
Figure 2. Electropherogram obtained from extracted tape sample
spiked with 50 μg tetracaine and added internal standard of 1500 μg
procaine. Displayed at 315 nm.
Figure 3. Electropherogram obtained from Ametop gel solution con-
taining 50 μg tetracaine and added internal standard of 1500 μg pro-
caine. Displayed at 315 nm.
Figure 4. Electropherogram obtained from tape sample at 4 h post dose
with added internal standard of 1500 μg procaine. Displayed at 315 nm.
Table 1. Calibration line parameters for 5 separate runs 
Batch Slope (A) Intercept (B) r2
1 0.0194 −0.0192 0.9992
2 0.0195  0.0099 0.9993
3 0.0194  0.0155 0.9986
4 0.0191  0.0070 0.9998
5 0.0198  0.0041 0.9997
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Recovery. Absolute recovery of tetracaine was determined using
tape samples doped with tetracaine at the same nominal con-
centration as the quality control samples. Peak area measurements
from extracted samples were compared with the peak areas
from direct solvent injection of the test compounds. Mean and
standard deviation were calculated from at least six measure-
ments at each level. Two samples of solution and six samples of
tapes loaded with 50, 100, 200, 400, 600, 800, 1000 and 1200 μg
of tetracaine were used, and 1500μg procaine as internal standard.
The absolute mean recovery of tetracaine ranged from 97 to 104%.
Discussion
Bioanalysis of biological fluids for the quantitative determina-
tion of drugs and their metabolites plays a significant role in the
evaluation and interpretation of bioequivalence, pharmacoki-
netics and toxicokinetics studies. The huge number of samples
and the quality of these studies, which is directly reflected by
the results obtained, require the development of rapid and
simple analytical methods. Thus the validation of the present
methods employed the latest guidance and principles of valida-
tion approved (FDA, 2001).
In this study we have developed a very short end direction
(reverse) CE method. Applying a short end direction (reverse) by
negative voltage resulted in tetracaine and procaine being fully
separated. The short migration times obtained for procaine
(1.25 min) and tetracaine (1.36 min) are an advantage of CE com-
pared with the 5 min retention time for tetracaine using HPLC
(Mazumdar et al., 1991). All the validation results meet the inter-
national requirements as outlined by the FDA’s 2001 bioanalyti-
cal method validation guidelines (FDA, 2001). In an attempt to
reduce the migration time even further, the capillary length was
shortened to 35 cm from the original 48.5 cm, but this resulted
in tetracaine and procaine not being fully separated and the run
time was only reduced by about 30 s. The purpose of this work
was to develop a fast and simple CE method that was fully
validated. This method is currently being used to determine
tetracaine in skin using tape samples from healthy volunteers given
tetracaine as a part of a pharmacokinetic drug delivery study.
Conclusions
A simple and rapid short end direction (reverse) method to
determine tetracaine in skin using tape samples has been devel-
oped and validated for the separation and quantification using
capillary zone electrophoresis with UV detection. The method
was successfully used to analyse hundreds of tape samples from
a tape stripping study.
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